ࡱ>  bjbj }  ###8[#k('''!")! 5!r*i# "!##''N000# ''0#00B'{#.UfϷd0>.&>>ˠ=!Z!@0!4 "=!=!=!0=!=!=!####>=!=!=!=!=!=!=!=!=! :  Division of Medical Services Pharmacy Unit P.O. Box 1437, Slot S-415 Little Rock, AR 72203-1437 501-683-4120 Fax: 501-683-4124MEMORANDUM TO: Arkansas Medicaid Prescribers and Interested Parties FROM: Suzette Bridges, P.D., Division of Medical Services Pharmacy Program DATE: December 8, 2010 SUBJ: AR Medicaid DUR Board edits approved at the OCTOBER 20, 2010 meeting: Clinical edits through Manual Review PA Process added to: C-II stimulant use in ADULTS age 18 yrs and older; Suboxone or Subutex edits revised; Fenofibrate & Fenofibric Acid products; Millipred (prednisolone) 5 mg tablets and tablet dose packs; CiproDex Otic Susp (ciprofloxacin/dexamethasone), Cipro HC Otic Susp (ciprofloxacin/HC), Trioxin Otic susp (chloroxylenol/benzoc/HC), Cortisporin-TC Ear susp (Neomy sulf/colist sul/HC/thonz), Cortamox lotion (HC/pramoxine HCl/chloroxylenol), Coly-mycin S Ear Drops (neomy sulf/colist sul/HC/thonz), and Acetasol HC ear drops; Clinical edits added or revised through point-of-sale (POS) edit system: topical steroid agents; topical antifungal agents; Pulmozyme (dornase alfa) inhalation solution; TOBI (tobramycin) inhalation solution; Restasis (cyclosporine) .05% Eye Emulsion, Lacrisert (hydroxyproply cellulose) 5 mg eye insert; Vectical (calcitriol) ointment, Tazorac (tazarotene) gel/cream, Dovonex (calcipotriene) cream; Protopic (tacrolimus), Elidel (pimecrolimus), Testosterone replacement products (Androgel Androderm, Testim, testosterone injection); Valcyte (valganciclovir) oral solution; topical products for treating rosacea; topical products for treating seborrheic dermatitis; Humira (adalimumab) injection; ICD9 code list used to identify COPD patients in Medicaid history for PA criteria revised; Cumulative Quantity Edits: Drugs in the Medicaid system that currently have a daily dose limit will have a cumulative quantity edit added; Non-FDA approved drugs removed from coverage: topical Urea, Salicylic Acid, Urea/Salicylic Acid, and urea/lactic acid/salicylic acid, urea/hyaluronate sodium, urea/lactic acid/zinc undecylenate, salicylic acid/ammon lact/aloe, lactic acid products; topical sulfacetamide sodium products, and selenium sulfide 2.25% shampoo; FreshKote Eye Drops The Arkansas Medicaid Drug Utilization Review (DUR) Board voted to implement the following point of sale (POS) or manual review approval criteria using clinical edits, age edits, and or quantity/dose edits for the drugs listed below. Specific criteria for the point of sale (POS) clinical edits can be viewed on the Medicaid website at HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf"https://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf; specific claim edits such as quantity edits, dose edits, age edits, or gender edits can be viewed on the Medicaid website at HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls"https://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls. The following edits will be effective January 18, 2011, unless otherwise stated. C-II Stimulants (methylphenidate, dexmethylphenidate, amphetamine salts, lisdexamfetamine, or dextroamphetamine or methamphetamine products) used in ADULT (AGE 18 YRS OR OLDER): Providers requesting a Prior Authorization (PA) for a C-II stimulant should contact the Evidence-based Prescription Drug Program PA Call Center Toll Free 1-866-250-2518 or Local 501-526-4200 or Fax 501-526-4188. Please include any supporting documentation for the request with the fax, and include recipient ID number, recipient name, and Medicaid Provider ID with your request. In addition to the criteria listed below, the DUR Boards recommendation included that the Prior Authorization (PA) criteria for amphetamine agents will require that physicians adhere to the requirements of Arkansas Medical Board Regulation No. 7, which governs the prescribing of amphetamines. CLINICAL EDITS: Narcolepsy: SmartPA point of sale (POS) approval for a C-II stimulant for an adult age 18 years or older will require a diagnosis code for narcolepsy in Medicaid history in previous two (2) years. Narcolepsy diagnosis ICD-9 code(s) not found in AR Medicaid claims history will require a manual review process. The prescriber may fax documentation that supports diagnosis of narcolepsy, such as sleep study data, prior to Prior Authorization (PA) approval. All other uses of a C-II stimulant agent(s) for an ADULT recipient age 18 years or greater will require a manual review process prior to Prior Authorization (PA) approval. Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD): Review of written documentation to substantiate the ADD/ADHD diagnosis is required prior to Prior Authorization (PA) approval. Written documentation shall include description of signs, symptoms, and behaviors that substantiate the diagnosis of ADD/ADHD while excluding other plausible causes, such as bipolar disorder, hypothyroidism, depression, anxiety disorders, etc. The documentation can include mental status evaluation or chart notes, psychological history, computerized or other standardized test results, etc. Patients currently receiving C-II stimulant for ADD/ADHD: Review of written documentation to substantiate ADD/ADHD diagnosis is required as noted above. A short-term prior approval Prior Authorization (PA), e.g., one month, may be approved to allow prescriber time to submit the ADD/ADHD documentation. Additional time may be allowed if testing cannot be performed and ADD/ADHD documentation submitted within the first month; New start requests for ADD/ADHD: Review of written documentation to substantiate ADD/ADHD diagnosis is required as noted above. Drug treatment is considered the first-line treatment for adults with ADD/ADHD diagnosis with either moderate or severe levels of impairment. Atomoxetine, a non-stimulant medication, will be required for all adult new starts, unless prescriber can provide documentation that the medication would be contraindicated for the patient. The onset of action for Atomoxetine is longer than that of C-II stimulant medications and must be taken into account in order to give an adequate trial of the medication. Patients over 70 kg should be titrated to an optimum therapeutic target dose of 80 mg, or up to a maximum dose of 100 mg, for at least a 4-week trial. ADD/ADHD with co-morbid conditions of bipolar disorder or schizophrenia: Review of written documentation to substantiate ADD/ADHD diagnosis is required as noted above. Patient adherence to appropriate medication therapy for the co-morbid conditions will be required and reviewed in the manual review process, or the prescriber must provide adequate documentation as to why the co-morbid condition(s) is no longer being treated. Off-label use of C-II stimulants as adjunct therapy for refractory unipolar depression in absence of ADD/ADHD diagnosis: Documentation must be submitted for review of off-label request that must include data on trials and failures of appropriate medications at optimum therapeutic dose for a minimum of four (4) weeks each of at least two (2) different medications for treating unipolar depression. Compliance with current antidepressant medication therapy indicated for or recognized to treat unipolar depression is required for Prior Authorization (PA) approval and will be noted in the review process. Off-label use of C-II stimulants as adjunct therapy for refractory bipolar depression in absence of ADD/ADHD diagnosis: Documentation must be submitted for review of off-label request that must include data on trials and failures of appropriate medications at optimum therapeutic dose for a minimum of four (4) weeks each of at least two (2) different mood-stabilizers (e.g., lamotrigine or divalproex sodium), lithium, or other medications indicated for or recognized to treat bipolar depression. Compliance with current antidepressant medication therapy indicated for or recognized to treat bipolar depression is required for Prior Authorization (PA) approval and will be noted in the review process. In the absence of an ADD/ADHD diagnosis, requests will be denied for the following: Adjunct or monotherapy for schizophrenia; Adjunct or monotherapy for bipolar mania; Adjunct or monotherapy for anxiety disorders; Monotherapy for refractory unipolar depression; Monotherapy for refractory bipolar depression; The inferred change in therapy edit that allowed Therapeutic Duplication (TD) with overlapping days supply once per 93 days between short-acting agents or between long-acting agents will be removed from the point of sale (POS) approval criteria for the adult population age 18 and older. Focalin immediate release tablets will be included with the Therapeutic Duplication (TD) edits with the other short-acting immediate release C-II stimulant formulations for all Medicaid beneficiaries. A Therapeutic Duplication (TD) point of sale (POS) denial edit will be added to the C-II stimulant criteria for all Medicaid beneficiaries and will reject an incoming C-II stimulant claim if there is either Provigil (modafinil) or Nuvigil (armodafinil) in history with overlapping days supply to the incoming claim. Suboxone (buprenorphine/naloxone) and Subutex (buprenorphine) SL tablets or SL film: Prior Authorization (PA) will be changed from a point of sale (POS) approval to a manual review process. The manual review process will be required for all requests for buprenorphine/naloxone SL tablet or SL film and buprenorphine SL tablets used for an Office-based Opioid Dependence Pharmacotherapy treatment program. The Suboxone statement of medical necessity form will be posted on the Medicaid website in the Prescription Drug Program section under Prescription Drug PA forms at these locations:  HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.doc" https://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.doc  HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.pdf" https://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.pdf The medical necessity request must be completed for all new and all continuation therapy requests. Prescribers must also fax in one of the following to signify the prescriber has completed the appropriate training for an Office-based Opioid Dependence Pharmacotherapy program: a copy of the X-DEA NUMBER certificate showing DW30 or DW100, or a copy of the Substance Abuse and Mental Health Services Administration (SAMHSA) letter of approval. The information can be faxed to the Medicaid Pharmacy Program office fax number: 501-683-4124. Fenofibrate and fenofibric acid products: Even though fenofibrate is available in multiple strengths, pharmacokinetic data has indicated that most of them achieve equivalent plasma concentrations. Fenofibrate 54 mg, 67 mg and 160 mg, as well as gemfibrozil, will pay at point of sale (POS) with no Prior Authorization (PA) criteria required. All other strengths of fenofibrate, fenofibric acid products, and Triglide 160 mg, (fenofibrate nanocrystalllized) will require manual Prior Authorization (PA) review. Millipred (prednisolone) 5 mg tablets and 5 mg dose pack (21 and 48 tablet dose packs): Prednisolone sodium phosphate 15 mg/5 ml solution, prednisone tablets and prednisone dose packs, and methylprednisolone tablets and methylprednisolone dose packs are available without prior approval required. Millipred (prednisolone) 5 mg tablets and 5 mg dose pack (21 and 48 tablet dose packs) will require manual review for all requests. Ear preparations: anti-infective, antibiotic, anti-inflammatory, local anesthetics. The chart below lists the ear preparations that will require Prior Authorization (PA) through manual review. For your convenience, the ear drops that do not require Prior Authorization (PA) are also listed. In addition, DERMOTIC OIL (fluocinolone acetonide) 0.01% EAR DROPS, will be limited to one 20 ml bottle per prescription. Label NameGeneric NameEdit statusLabel NameGeneric NameEdit statusCIPROFLOXACIN 0.3% EYE DROPS 1 2 CIPROFLOXACIN, 2.5 ml, 5 ml, 10 mlNO PAACETASOL HC EAR DROPSACETIC ACID/HYDROCORTISONEManual Review PASULF-PRED 10-0.25% EYE DROPS1 2SULF-PRED 10-0.25% EYE DROPS 5 ml, 10 mlNO PACIPRODEX OTIC SUSPENSIONCIPROFLOXACIN HCL/DEXAMETHManual Review PASULF-PRED 10-0.23% EYE DROPS1 2SULF-PRED 10-0.23% EYE DROPS 5 ml, 10 mlNO PACIPRO HC OTIC SUSPENSIONCIPROFLOXACIN HCL/HCManual Review PASULFACETAMIDE 10% EYE DROPS1 2 SULFACETAMIDE 10% EYE DROPS 5 ml, 10 mlNO PATRIOXIN OTIC SUSPENSIONCHLOROXYLENOL/BENZOC/HYDROCORTManual Review PAOFLOXACIN 0.3% EAR DROPSOFLOXACIN, 5 ml, 10 mlNO PACORTISPORIN-TC EAR SUSPNEOMY SULF/COLIST SUL/HC/THONZManual Review PARE PRAMOXINE-HC OTIC DROPSHC/PRAMOX HCL/CL-XYLENOL/WATERNO PACORTAMOX LOTIONHC/PRAMOXINE HCL/CHLOROXYLENOLManual Review PAANTIPYRINE-BENZOCAINE EAR DROPANTIPYRINE/BENZOCAINE/GLYCERIN, 10 ml or 15 mlNO PACOLY-MYCIN S EAR DROPSNEOMY SULF/COLIST SUL/HC/THONZManual Review PANEOMYCIN-POLYMYXIN-HC EAR SOLNNEOMY SULF/POLYMYX B SULF/HCNO PA NEOMYCIN-POLYMIXIN-HC EAR SUSPNEOMY SULF/POLYMYX B SULF/HCNO PAPRAMOTIC EAR DROPSCHLOROXYLENOL/PRAMOXINE HCLNO PACHLOROXYLENOL-PRAMOXINE HCLCHLOROXYLENOL/PRAMOXINE HCLNO PAACETIC ACID 2% EAR SOLUTIONACETIC ACIDNO PARE BENZOTIC 20% OTIC DROPSBENZOCAINENO PARE CHLORPHENYLCAINE OTIC DROPSPHENYLEPHRINE/ANTIPY/B-CAINENO PADERMOTIC OIL 0.01% EAR DROPSFLUOCINOLONE ACETONIDE OILNO PA 1Charnock, D., (1997). Early postoperative otorrhea after tympanostomy tube placement: a comparison of topical ophthalmic and otic drops. ENT: Ear, Nose & Throat Journal; 76, (12), pp. 871-872. 2 Wintermeyer, S., Hart, Nahata, M. (1997). Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. Otolaryngol Head Neck Surg; 116, p.451.) Topical antifungal creams, solutions, lotions and shampoos: The approval criteria for topical antifungal agents have been revised. In order to obtain a product that requires a Prior Authorization (PA), the requirement of a trial of at least two different products in the previous 45 days has been modified to a trial of at least two different products containing different drug entities in the previous 45 days. The list of topical antifungal agents are noted below: Label NameGeneric NameStatusCiclopirox 0.77% cream Ciclopirox olamine 0.77% cream No PACiclopirox 0.77% topical suspensionCiclopirox olamine 0.77% topical suspensionNo PAClotrimazole 1% creamClotrimazole 1% cream (OTC or Rx)No PAClotrimazole 1% solution Clotrimazole 1% solutionNo PAEconazole 1% creamEconazole nitrate 1% creamNo PAKetoconazole 2% cream Ketoconazole 2% creamNo PAKetoconazole 2% Shampoo Ketoconazole 2% shampooNo PAErtaczo 2% cream Sertaconazole nitrate 2% creamPAExelderm 1% cream Sulconazole nitrate 1% creamPAExelderm 1% solution Sulconazole nitrate 1% solutionPALoprox 0.77% gel Ciclopirox 0.77% gelPALoprox 1% Shampoo Ciclopirox 1% shampooPAMentax 1% creamButenafine HCl 1% creamPANaftin 1% CreamNaftifine HCl 1% CreamPANaftin 1% Pump CreamNaftifine HCl 1% CreamPANaftin 1% Gel Naftifine HCl 1% gelPAOxistat 1% cream Oxiconazole nitrate 1% creamPAOxistat 1% lotion Oxiconazole nitrate 1% lotionPA Topical corticosteroid agents: The approval criteria for topical corticosteroid agents have been revised. In order to obtain a product that requires a Prior Authorization (PA), the requirement of a trial of at least two different products in the previous 60 days has been modified to a trial of at least two different agents containing a different drug entity within the same potency category that do not require Prior Authorization (PA). The complete list of topical corticosteroids and potency categories is located on the Medicaid website at this location: HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf"https://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf. In addition, Capex (fluocinolone acetonide) shampoo, Clobex (clobetasol propionate) 0.05% shampoo, and Derma-Smoothe/FS (fluocinolone acetonide) Body Oil, in each respective potency category, have been added to the list that will require a trial of at least two different drug entities in previous 45 days before Prior Authorization (PA) approval. Derma-Smoothe/FS Scalp Oil with shower cap kit will require manual review. Quantity edits to topical corticosteroid agents will be added as follows: Products that do not require Prior Authorization (PA): limit up to maximum of 200 gm or 240 gm per prescription, depending on manufacturers package size; Products that require Prior Authorization (PA): limit of one bottle/tube/can per prescription. Pulmozyme (Dornase Alfa) Inhalation Solution: Daily administration of Pulmozyme (dornase alpha) Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. Point of sale (POS) approval criterion includes the following: Diagnosis of Cystic Fibrosis in Medicaid history in previous 2 yrs. TOBI (tobramycin) Inhalation Solution: TOBI is indicated for the management of cystic fibrosis patients with P. aeruginosa. The recommended dose of TOBI is 300 mg twice daily in repeated cycles of 28 days on drug, followed by 28 days off drug. The 300 mg dose of TOBI is the same for patients regardless of age or weight. Quantity limits have been implemented for TOBI that support the FDA approved dosing cycle. Point of sale (POS) approval criterion include the following: Diagnosis of Cystic Fibrosis in Medicaid history in previous 2 yrs. COPD: The ICD-9 diagnosis codes used to identify a COPD (Chronic Obstructive Pulmonary Disease) patient as related to point of sale (POS) approval criteria for the clinical edit system have been revised. The two codes that will be used to identify a COPD patient are 492 Emphysema and 496 Chronic airway obstruction, not elsewhere classified. Lacrisert (hydroxypropyl cellulose) 5 mg Eye Insert and Restasis (cyclosporine) 0.05% Eye Emulsion (30 ml and 60 ml bottle): The point of sale (POS) approval criteria will require one of the following diagnosis codes associated with dry eye (see chart) in Medicaid history in previous 2 years. In addition, a Therapeutic Duplication (TD) will be added to both agents to prevent overlapping days supply between the two agents. ICD-9-CM CODES ASSOCIATED WITH DRY EYEDiagnosisCodeKeratoconjunctivitis sicca, non-Sjgren's syndrome370.33Keratoconjunctivitis, exposure370.34Xerosis372.53Tear film insufficiency, unspecified (Dry eye syndrome)375.15Keratoconjunctivitis sicca, Sjgren's syndrome710.2 The AR Medicaid Pharmacy Program will only reimburse for covered outpatient drugs that have been approved for safety and effectiveness as a prescription drug by the Food and Drug Administration (FDA) under section 505 of the Federal Food, Drug, and Cosmetic Act. In addition, the AR Medicaid Pharmacy Program will only reimburse for NDCs for covered outpatient drugs for which the manufacturer has entered into and has in effect a federal rebate agreement with Centers for Medicare & Medicaid Services (CMS) as required by the Social Security Act 1927. It has been determined that the following products currently listed in the Medicaid Pharmacy Program system have not been approved by the FDA as a prescription drug and have been moved to non-covered status. Topical products used as keratolytic agent: Urea, Salicylic Acid, Urea/Salicylic Acid, and urea/lactic acid/salicylic acid, urea/hyaluronate sodium, urea/lactic acid/zinc undecylenate, salicylic acid/amon lact/aloe, lactic acid, have not been approved by the FDA as prescription drugs and have been moved to non-covered status effective Oct. 25 and Oct 27, 2010. Carmol HC 1% cream (hydrocortisone acetate/urea) is an FDA approved drug and is a covered outpatient drug in the Medicaid Pharmacy Program. Topical products used for seborrheic dermatitis or rosacea: Topical sulfacetamide sodium products and selenium sulfide 2.25% shampoo currently listed in the Medicaid Pharmacy Program system have not been approved by the FDA as prescription drugs and will be moved to non-covered status. Seborrheic Dermatitis treatments: Selenium Sulfide 2.5% shampoo is FDA approved as a prescription drug and will remain as a covered product with AR Medicaid Pharmacy Program. If new FDA-approved agents used for seborrheic dermatitis come to market, they will require prior approval criterion as noted below: Trial of two fills of selenium sulfide 2.5% shampoo in the previous 27-60 days before a claim for a product requiring Prior Authorization (PA) will pay at point of sale (POS). Rosacea treatments: Finacea (azelaic acid) 15% Gel, Metrogel (metronidazole) 1%, Noritate (metronidazole) 1% cream for treatment of rosacea are FDA approved prescription drugs and will require prior approval. Metronidazole 0.75% cream, gel, or lotion, are FDA approved prescription drugs and will not require prior approval. Point of sale (POS) approval criteria for Finacea 15% Gel, Metrogel 1%, Noritate 1% cream are as follows: Diagnosis of rosacea in Medicaid history in previous 2 yrs; AND Trial of two fills of generic metronidazole 0.75% cream, gel, or lotion, in the previous 27-60 days before a claim for Finacea15% gel, Metrogel 1%, or Noritate 1% cream will pay at point of sale (POS); AND Point of Sale (POS) denial criteria will reject any of the above claims if there is a diagnosis of acne vulgaris in Medicaid history in previous 60 days. Condoms will be moved to non-covered status. Ahist (clorpheniramine tannate) 12 mg tablet: Ahist 12 mg tablet is not an FDA approved prescription drug. This product has been moved to non-covered status in AR Medicaid Pharmacy Program, effective Nov. 3, 2010. FreshKote Eye Drop: FreshKote Eye Drop is not an FDA approved prescription drug and has been moved to non-covered status, effective Aug. 17, 2010. Vectical (calcitriol) ointment; Dovonex (calcipotriene) 0.005% cream/ointment/scalp solution; Sorilux"! (calcipotriene) Foam 0.005%; Tazorac (tazarotene) gel/cream: These medications are indicated for topical treatment of mild to moderate plaque psoriasis. Per the American Academy of Dermatology, topical corticosteroids are the cornerstone of treatment for the majority of patients with psoriasis, particularly those with limited disease. The guidelines from the American Academy of Dermatology recommend that calcitriol and calcipotriene used in combination with topical corticosteroids gives added benefit, and that tazarotene is best used in combination with topical corticosteroids. The point of sale (POS) approval criteria are as follows: For Vectical (calcitriol) ointment; Dovonex (calcipotriene) cream, ointment, or scalp solution; Sorilux"! (calcipotriene) Foam 0.005%: New Starts: Each of these medications require diagnosis code of psoriasis in Medicaid history in previous 365 days; AND Require 2 claims of a steroid cream in previous 27-60 days, AND at least one claim must be from the very high potency category; Continuation of therapy: Each of these medications require diagnosis code of psoriasis in Medicaid history in previous 365 days; AND Incoming claim matches claim in history in previous 45 days for Vectical, Dovonex, or Sorilux"!; AND 2 claims of a topical corticosteroid in previous 60 days in drug claim history with at least one topical corticosteroid claim 14-60 days back in history. For Tazorac (tazarotene) gel or cream: New Starts: Each of these medications require diagnosis code of psoriasis in Medicaid history in previous 365 days; AND Require 2 claims of a steroid cream in previous 27-60 days, AND at least one claim must be from the very high potency category; Continuation of therapy: Each of these medications require diagnosis code of psoriasis in Medicaid history in previous 365 days; AND Incoming claim matches claim in history in previous 45 days of Tazorac; AND 2 claims of a topical corticosteroid in previous 60 days in drug claim history with at least one topical corticosteroid claim 14-60 days back in history; AND Point of Sale (POS) denial criteria will reject Tazorac claim if there is a diagnosis of acne vulgaris in Medicaid history in previous 60 days. For those patients whose psoriasis is in an area where a topical corticosteroid is not indicated for use, prescriber may call and request an exception to the established point of sale (POS) criteria by providing supporting documentation. Protopic (tacrolimus) and Elidel (pimecrolimus): are indicated as second-line therapy for short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis. The point of sale (POS) denial criteria will reject incoming claim if there is a psoriasis diagnosis in history in previous 2 yrs. Valcyte (valganciclovir) Oral Solution: valganciclovir is indicated for the prevention of cytomegalovirus (CMV) in whole organ transplant patients and for the treatment of CMV in patients with HIV/AIDS. According to the manufacturers package insert, adult patients should use Valcyte tablets, not Valcyte for Oral Solution. Regarding dosing for the oral solution, the manufacturers package insert states all calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose up to a maximum of 900 mg. Valcyte tablets may be used if the calculated doses are within 10% of the available tablet strength (450 mg). Point of Sale (POS) approval criteria will be applied to identify those who cannot swallow solid oral dosage forms (NPO) or for children less than 9 years of age. Testosterone replacement products (Androgel 1% gel, Androderm 2.5mg/24 hr & 5 mg/24 hr patches, Testim 1% gel, testosterone injections, Android (methyltestosterone) 10 mg capsules, Testred (methyltestosterone) 10 mg capsules, Androxy (fluoxymesterone) 10 mg tablet, Methitest (methyltestosterone) 10 mg tablets: Centers for Medicare & Medicaid Services (CMS) stated, With respect to drugs dispensed on or after January 1, 2006, the law eliminates Medicaid coverage of drugs used to treat sexual or erectile dysfunction, as set forth in section 1927(d)(2)(K) of the Act, unless such drugs are used to treat conditions other than sexual or erectile dysfunction and these uses have been approved by the Food and Drug Administration. Section 1903(i)(21) of the Act specifically precludes Medicaid Federal Financial Participation (FFP) with respect to amounts expended for covered outpatient drugs after January 1, 2006, when used for the treatment of sexual or erectile dysfunction. The following point of sale (POS) approval criteria for testosterone replacement products are as follows: Require gender to be male; AND Require diagnosis of hypospadias, Klinefelter syndrome, Kallmann syndrome, Panhypopituitarism, or Prader-Willi syndrome in Medicaid history in previous 2 years; Exceptions for women with breast cancer or hormone-responsive tumor will be handled through manual review process. Prescriber may call and request an exception to the established point of sale (POS) criteria by providing supporting documentation. The following point of sale (POS) denial criteria for testosterone replacement products are as follows: Diagnosis of decreased libido, impotence, or any other sexual dysfunction diagnoses in Medicaid history in previous 2 years. The physician may request a manual review as an exception to the point of sale (POS) approval criteria by providing lab results and chart notes documenting symptoms being treated. Humira (adalimumab) injection: Humira is indicated for Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Crohns Disease, and Plaque Psoriasis. The maintenance dose for Humira for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohns Disease, and Psoriasis is 40 mg every other week. The following criteria will be added to the point of sale (POS) approval criteria for Humira: For Crohns diagnosis in Medicaid history: The NDC for HUMIRA CROHN'S STARTER PACK of 6 pen injections will be allowed once in 2 yr look-back; For Psoriasis diagnosis in Medicaid history: The NDC for HUMIRA PSORIASIS STARTER PACK of 4 pen injections will be allowed once in 2 yr look-back; For diagnosis of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohns Disease, and Plaque Psoriasis: The quantity edit will allow a quantity of 5 injections or pens for a rolling 50 day look-back of the Humira 40 mg/0.8 ml pen OR the Humira 40 mg/0.8 mg syringe, which will allow for every other week dosing schedule. If RA diagnosis in Medicaid history: Humira can be used alone or in combination with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs). In Rheumatoid Arthritis, some patients not taking concomitant methotrexate may derive additional benefit from increasing the dosing frequency of Humira to 40 mg every week. For those patients who can tolerate and are receiving methotrexate, the Humira dose allowed at point of sale (POS) is the same as above, 40 mg every other week. If no claims of methotrexate (any form) are found in the Medicaid drug history in the previous 45 days, the allowed quantity limit will be up to 4-40 mg injections per 28 days. A Therapeutic Duplication (TD) edit will apply between the Humira Pen NDC and the Humira Syringe NDC, which will reject at point of sale (POS) an incoming claim if the incoming claim has overlapping days supply with the claim in history. The point of sale (POS) continuation approval criteria for Humira will look for a paid claim for Humira in previous 45 days. Xerese 5%-1% (acyclovir/hydrocortisone) cream, Zovirax (acyclovir) 5% cream 2 gm and 5 gm: Xerese 5%-1% and Zovirax 5% cream will require manual review for approval for all requests. Denavir (penciclovir) 1.5 gm tube cream will pay at point of sale (POS) without prior approval. Oravig (miconazole) 50 mg buccal tablet: Oravig is indicated for the local treatment of oropharyngeal candidiasis in adults. Oravig will require manual review Prior Authorization (PA) for all requests. Nystatin 100,000 units/ml oral suspension and clotrimazole 10 mg troches are also indicated for oropharyngeal candidiasis and are available without Prior Authorization (PA) required. Fortamet ER and Glumetza ER (metformin) 500 mg and 1000 mg: Fortamet ER and Glumetza ER will require Prior Authorization (PA) through manual review process for all requests. Generic metformin 500 mg, 850 mg, and 1000 mg, and generic metformin ER 500 mg, 750 mg, and 1000 mg products are available at point of sale (POS) without Prior Authorization (PA). Butalbital/acetaminophen combination products: The following butalbital products will require manual review process for all Prior Authorization (PA) approvals: Dolgic Plus (butalbital/acetaminophen/caffeine) 50-750-40 tablet, Orbivan (butalbital/acetaminophen/caffeine) 50-300-40 CAPSULE, butalbital/acetaminophen/caffeine 50-325-40 CAPSULES, butalbital/acetaminophen/caffeine 50-500-40 CAPSULES, Phrenilin Forte (butalbital/acetaminophen) 50-650 CAPSULE. Fioricet (butalbital/acetaminophen/caffeine) TABLET 50-325-40 and its generic equivalents, Esgic-Plus (butalbital/acetaminophen/caffeine) TABLET 50-500-40 and its generic equivalents, butalbital/acetaminophen 50-650 TABLET, and butalbital/acetaminophen 50-325 TABLET are available without Prior Authorization (PA). See additional information regarding age and quantity edits below. Alagesic Liquid Oral Solution 50-325-40/15 ml: Point of Sale (POS) approval criteria will be applied to butalbital liquid oral solution to identify those who cannot swallow solid oral dosage forms (e.g., NPO). Claims will reject if the recipient is not NPO based on diagnosis claims history. Age Edit: Safety and effectiveness of butalbital products in pediatric patients below the age of 12 have not been established. Therefore an age edit will reject butalbital claims for children less than 12 years of age. Qty edit: The maximum dose for butalbital should not exceed 300 mg/day. Therefore, solid dosage forms of butalbital products will be limited up to a maximum of 6 units per day and a cumulative quantity of 186 units per 31 days supply; those butalbital products that contain 750 mg acetaminophen per unit will be limited to a maximum of 5 units per day based on the maximum amount of acetaminophen allowed per day. Oral liquid forms of butalbital will be limited to 90 ml per day or up to 240 ml per prescription. All covered drugs with a daily dose limit previously approved by the DUR Board will have an additional cumulative quantity edit added in order to provide consistency. The complete list can be viewed on the Medicaid website: HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls"https://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls. FRIENDLY REMINDERS: The AR Medicaid Pharmacy Program reimburses for covered outpatient drugs for Medicaid beneficiaries with prescription drug benefits. Only medications prescribed to that beneficiary can be billed using the beneficiarys Medicaid ID. Sanctions may be imposed against a provider for engaging in conduct that defrauds or abuses the Medicaid program. This could include billing a childs medication to a parents Medicaid ID number and vice-versa. On Oct. 1, 2010, the U.S. Food and Drug Administration (FDA) ordered a halt to marketing of unapproved single-ingredient oral colchicine products. Therefore, all unapproved colchicine NDCs do not meet the definition of a covered outpatient drug as defined in the Social Security Act 1927(k) and are subsequently no longer eligible for inclusion in the AR Medicaid Pharmacy Program. The Centers for Medicare & Medicaid Services (CMS) mandated Medicaid agencies to discontinue coverage of all unapproved colchicines products as of Nov. 16, 2010. Hepatitis C Medication Therapy Information Sheet has been revised. A liver biopsy is now required for consideration of therapy for those with HCV genotype 1. The revised information sheet is located at: HYPERLINK "https://www.medicaid.state.ar.us/Download/provider/forms/pharm/HepCTreatmntForm.pdf"https://www.medicaid.state.ar.us/Download/provider/forms/pharm/HepCTreatmntForm.pdf. Pharmacists are required to enter the Prescribers NPI in the Prescriber ID field when submitting a pharmacy claim to Medicaid. If the prescribing provider does not have a Medicaid provider ID mapped to his/her NPI number, the two most common rejection code edits the pharmacist will see are pasted below. The pharmacist may advise the prescriber to update their provider information with Medicaid. The prescribing provider has the option of updating his/her temporary ID status or enrolling as a Medicaid provider. The claim will not process until the prescriber has completed the appropriate course of action. CodeExplanation 9071Prescribing Provider ID is invalid; OR the ID is an expired temporary ID or invalid format to a NPI number. (Check Non-participating ID#) Z740Verify prescriber segment; OR the NPI is not mapped to a Medicaid provider ID. FOR ALL PDL DRUGS OR FOR REQUESTS FOR ANTIPSYCHOTIC DRUGS: Providers requesting a Prior Authorization (PA) for a drug on the PDL or requesting a Prior Authorization (PA) for an antipsychotic medication should contact the Evidence-based Prescription Drug Program PA Call Center Toll Free 1-866-250-2518 or Local 501-526-4200 or Fax 501-526-4188. Please include any supporting documentation for the request with the fax, and include recipient ID number, recipient name, and Medicaid Provider ID with your request. FOR NON-PDL AND NON-ANTIPYSCHOTIC DRUG REQUESTS: Providers requesting a Prior Authorization (PA) should call the HP Prescription Drug Help Desk at 1-800-707-3854 or at 1-501-374-6609, extension 500. For Prior Authorization (PA) requests requiring manual review, you may fax your request to the HP help desk Fax at 501-372-2971 or to the state office Fax at 501-683-4124. Please include any supporting documentation for the request with the fax, and include recipient ID number, recipient name, and Medicaid provider ID with your request. An approval, denial or request for additional information will be returned by the close of business the following business day. This advance notice is to provide you the opportunity to contact, counsel and change patients prescriptions. If you need this material in an alternative format, such as large print, please contact our Americans with Disabilities Act Coordinator at 501-6828323  ./012KMowƻ؛؋{{k]؛L; hzEhZ3CJOJQJ^JaJ hzEhZ3CJOJQJ^JaJhzEh"%5OJQJ\hzEhKKCJOJQJ\aJhzEhn[CJOJQJ\aJhzEh"%CJOJQJ\aJ hzEh"%0jhLhLCJOJQJUaJmHnHuhzEh"%CJaJ"hzEh"%5CJOJQJ\^JhzEh"%CJOJQJaJ0jhLhLCJOJQJUaJmHnHu .0123kxkkd;$$IfTl4;F #*p M+    44 laf4ytB#T $$Ifa$gd"%$If $$Ifa$ # $ v`[E[ p@ PgdZ3gdZ3 p@ Pgd% x^x`gdZ3$x^x`a$gdZ3kkd"<$$IfTl4<F #* p  M+    44 laf4ytB#T+ 5 6 ; D O P p w y z ʹ暌~l^lO@Olha5CJOJQJ^JaJh5CJOJQJ^JaJhEVCJOJQJ^JaJ#hEVhEV5CJOJQJ^JaJhaCJOJQJ^JaJh uCJOJQJ^JaJh=bCJOJQJ^JaJ hzEhhCJOJQJ^JaJ h%hZ3CJOJQJ^JaJhQ9CJOJQJ^JaJh%CJOJQJ^JaJ hzEhZ3CJOJQJ^JaJjhwU$ < = ABth^hgdCh^hgdn] & Fgdgd#9 7$8$H$^gdww^gdqg `^``gds^gdz,^gd y `^``gd] `^``gdZ3gdZ3         . / G P Q   Q R Ķzħi[i[i[i[i[i[ih#CJOJQJ^JaJ h.h.CJOJQJ^JaJh,CJOJQJ^JaJ h]h]CJOJQJ^JaJh]CJOJQJ^JaJh#5CJOJQJ^JaJhsCJOJQJ^JaJh.CJOJQJ^JaJ#h]h.5CJOJQJ^JaJh yCJOJQJ^JaJh7 CJOJQJ^JaJ  Y Z [ i   2 3 S T t u >?Ͼtth,CJOJQJ^JaJh/CJOJQJ^JaJhsCJOJQJ^JaJ hsh#CJOJQJ^JaJh#5CJOJQJ^JaJ hshsCJOJQJ^JaJ#hshs5CJOJQJ^JaJhz,CJOJQJ^JaJ h.hsCJOJQJ^JaJ) YZstIJr`OAO0 h]h]CJOJQJ^JaJhO;CJOJQJ^JaJ h,h]CJOJQJ^JaJ#h]h]5CJOJQJ^JaJhz,5CJOJQJ^JaJ hz,h]CJOJQJ^JaJ hz,hz,CJOJQJ^JaJhQz5CJOJQJ^JaJ#hQzh/5CJOJQJ^JaJ#hQzhQz5CJOJQJ^JaJhz,CJOJQJ^JaJh]CJOJQJ^JaJhQzCJOJQJ^JaJt~,:CMӷ򩷘veTF8h ^JCJOJQJ^JaJhuoCJOJQJ^JaJ hzEhzECJOJQJ^JaJ hzEhZ3CJOJQJ^JaJ hshsCJOJQJ^JaJ hQzh/CJOJQJ^JaJ hO;hO;CJOJQJ^JaJh yCJOJQJ^JaJhO;CJOJQJ^JaJhz,CJOJQJ^JaJ h]h]CJOJQJ^JaJh,CJOJQJ^JaJh]CJOJQJ^JaJM^_01JKLMŷŷӡxgӡT$h4hZ30JCJOJQJ^JaJ hzEhB[CJOJQJ^JaJh!MCJOJQJ^JaJhJ0$hJ0hJ00JCJOJQJ^JaJh7Ijh7IUhCJOJQJ^JaJhuoCJOJQJ^JaJhcCJOJQJ^JaJ hzEhZ3CJOJQJ^JaJh ^JCJOJQJ^JaJh1bCJOJQJ^JaJ%>ABQIJn\J8&#hCZh5CJOJQJ^JaJ#hCZht5CJOJQJ^JaJ#hCZhC !5CJOJQJ^JaJ#hCZhww5CJOJQJ^JaJ hNlh#9CJOJQJ^JaJhww5CJOJQJ^JaJ#h|ahww5CJOJQJ^JaJ#h,h,5CJOJQJ^JaJ#h,h85CJOJQJ^JaJ#hHhww5CJOJQJ^JaJh)1ZCJOJQJ^JaJhZ3CJOJQJ^JaJh7 CJOJQJ^JaJ   %Mu4DɸxiZiZiiHɊ#hCZh~5CJOJQJ^JaJh=5CJOJQJ^JaJhuo5CJOJQJ^JaJ#hCZhh=]5CJOJQJ^JaJ#hCZhC5CJOJQJ^JaJhuoCJOJQJ^JaJh=CJOJQJ^JaJ hCZhCCJOJQJ^JaJ#hCZh J5CJOJQJ^JaJ#hCZhC !5CJOJQJ^JaJ#hCZht5CJOJQJ^JaJtutuz{'(5FL!M!""8^8gd s ^ gd s & Fgd s^gd s^gd s & Fgd s^gd J & Fgd sgd s^gdh^hgd s^gdC%8CFOtuvɸwiXXJ<hH1CJOJQJ^JaJh JCJOJQJ^JaJ hCZh#MjCJOJQJ^JaJh#MjCJOJQJ^JaJ hCZhCJOJQJ^JaJ hCZhD(CJOJQJ^JaJhjCJOJQJ^JaJ hCZhC !CJOJQJ^JaJ hCZhtCJOJQJ^JaJ#hCZht5CJOJQJ^JaJ#hCZh J5CJOJQJ^JaJ#hCZh5CJOJQJ^JaJvWX]^lnoz{  %&'򺬺zk\k\\K h shQ^dCJOJQJ^JaJhj5CJOJQJ^JaJh=5CJOJQJ^JaJ#h sh|j5CJOJQJ^JaJ#h shQ^d5CJOJQJ^JaJh sCJOJQJ^JaJhjCJOJQJ^JaJh=CJOJQJ^JaJhH1CJOJQJ^JaJh JCJOJQJ^JaJhCJOJQJ^JaJhQ^dCJOJQJ^JaJ'(HLVW^_lmt{κykZL>L>hjCJOJQJ^JaJh=CJOJQJ^JaJ h Jh JCJOJQJ^JaJhtCJOJQJ^JaJ h Jh3lsCJOJQJ^JaJhCJOJQJ^JaJ h JhQ^dCJOJQJ^JaJ h,5CJOJQJ\^JaJ&h,h,5CJOJQJ\^JaJh,5CJOJQJ^JaJ#h JhQ^d5CJOJQJ^JaJ h sh}CJOJQJ^JaJUbs{|#6DpbbTFhCJOJQJ^JaJh:>CJOJQJ^JaJh~CJOJQJ^JaJh,5CJOJQJ^JaJh:>5CJOJQJ^JaJ h JhYCJOJQJ^JaJ#h JhQ^d6CJOJQJ^JaJhtCJOJQJ^JaJ h Jh3lsCJOJQJ^JaJ h Jh:>CJOJQJ^JaJ h JhQ^dCJOJQJ^JaJhjCJOJQJ^JaJDS45OTVFQnw乪֎րl[J h,hZCJOJQJ^JaJ h,h3?CJOJQJ^JaJ&h/Jh5>*CJOJQJ^JaJh0CJOJQJ^JaJh~CJOJQJ^JaJhZCJOJQJ^JaJh,5CJOJQJ^JaJhAA5CJOJQJ^JaJhAACJOJQJ^JaJhtCJOJQJ^JaJh:>CJOJQJ^JaJhf/JCJOJQJ^JaJw  ( ) = Z [ c ! !*!CJOJQJ\^JaJ&hAEhse>5CJOJQJ\^JaJ hf/J5CJOJQJ\^JaJ&hAEh}5CJOJQJ\^JaJ#hAEhse>5CJOJQJ^JaJ#hAEhD(5CJOJQJ^JaJh#5CJOJQJ^JaJ hAEhD(CJOJQJ^JaJ hAEhAECJOJQJ^JaJ----------.. .).L.........*/,/-/x/y/z/{/////̜̽́ynyaVynyh#h#CJaJh}h yV0JCJaJh yVh yVCJaJh yVCJaJjh yVCJUaJhB 2CJOJQJ\^JaJ#hAEhse>CJOJQJ\^JaJhAECJOJQJ\^JaJh#CJOJQJ\^JaJ#hAEh}CJOJQJ\^JaJ hAEhse>CJOJQJ^JaJ hAEh}CJOJQJ^JaJ!/ 0!0"0&080?0^0b0f00001618191;1C1D1U1a1b1w11ʻʬʈveWvEEvE#hAEh$VCJOJQJ\^JaJhO;CJOJQJ^JaJ hAEhO;CJOJQJ^JaJ#hAEhO;CJOJQJ\^JaJ#hAEhse>CJOJQJ\^JaJ#hAEh+ICJOJQJ\^JaJhO;CJOJQJ\^JaJhAECJOJQJ\^JaJ#hAEh}CJOJQJ\^JaJh#h#CJaJjh yVCJUaJh}h yV0JCJaJ111111111111A2C2D2E2p2 3 3̽̚vdRD2#hK7hK75CJOJQJ^JaJhk)CJOJQJ^JaJ#h+N`h+N`5CJOJQJ^JaJ#h}h}CJOJQJ\^JaJ#hAEh,CJOJQJ\^JaJ#hAEh}CJOJQJ\^JaJ#hAEhse>CJOJQJ\^JaJ hAEh_I`CJOJQJ^JaJhO;CJOJQJ\^JaJ#hAEh$VCJOJQJ\^JaJhB 2CJOJQJ\^JaJ#hB 2hB 2CJOJQJ\^JaJ 3E3^3b3h3q3r3w3x333333333333334$4;4=4|k|]|O]O|A|hVCJOJQJ^JaJhzCJOJQJ^JaJhK7CJOJQJ^JaJ hk)hk)CJOJQJ^JaJ hk)h+N`CJOJQJ^JaJ#h+N`h+N`5CJOJQJ^JaJ#hhhk)5CJOJQJ^JaJh&r5CJOJQJ^JaJhV5CJOJQJ^JaJhf/J5CJOJQJ^JaJh)y5CJOJQJ^JaJ#hhh+N`5CJOJQJ^JaJE2:4I4J4557777777777 8/85878M8h8 $IfgdFfy>$Ifh^hgdFgdC ! & Fgdy:h^hgdhh^hgdV & Fgd=4?4H4I4J4S4T4u4z44445555O6P6R6ųuguXI:h M$5CJOJQJ^JaJh5CJOJQJ^JaJhC !5CJOJQJ^JaJh#CJOJQJ^JaJ hy:hy:CJOJQJ^JaJhh5CJOJQJ^JaJh?5CJOJQJ^JaJh#5CJOJQJ^JaJ#hhhh5CJOJQJ^JaJhhCJOJQJ^JaJhC !CJOJQJ^JaJ hk)h+N`CJOJQJ^JaJhVCJOJQJ^JaJR6V6666666666 777#707=7T7Z7e77777778ӷӷᩘᘩwgwcShB*CJOJQJaJphh&L8h&L8B*CJOJQJaJph%h&L85B*CJOJQJ\aJphhFCJOJQJ^JaJ hqh M$CJOJQJ^JaJh M$CJOJQJ^JaJhCJOJQJ^JaJhVCJOJQJ^JaJh&rCJOJQJ^JaJhCJOJQJ^JaJ hhhhCJOJQJ^JaJ88 8 85878h8y8z8888888888899,9-9/909L9Y9^9_9`9999999999999&:7:8:n:p:::ɹɦɏ|ɦɏ|ɦɏ|ɦɹɦ%hX!hB*CJOJQJaJph%hJPhB*CJOJQJaJphh%h5B*CJOJQJ\aJphhB*CJOJQJaJphhB*CJOJQJaJph"hB*CJH*OJQJaJph(h!hB*CJH*OJQJaJph0h8y8z88888889909Y9_9`9y99999999:&:7:8:FfNFfJFfyFFfmB $Ifgd8:Q:h:n:p::::::::: ;*;;;<;[;;;;;;;;;<FfZFfVFfR $Ifgd::::*;;;<;;;;;;<"<#<=<A<e<j<k<<<<<<<===J=O=P=========f>>>>?/?t#h!o&hCJH*OJQJ^JaJ#h {4h6CJOJQJ^JaJ h {4hCJOJQJ^JaJ#h {4hCJH*OJQJ^JaJhyCJOJQJ^JaJ%h5B*CJOJQJ\aJphhB*CJOJQJaJphhB*CJOJQJaJphh-<<< <!<"<#<B<_<e<g<h<i<j<k<~<<<<<<<<<<<<FfeFfaFfg^ $Ifgd<<<<<========9=D=J=L=M=N=O=P=o======FfapFflFf%i $Ifgd===========>>???@?A!A.A5A $Ifgd}T & Fgdh`hgdy^gdFfewFfs $Ifgd/?1?6?7?8?=?>???@?}?????@ @J@Z@\@b@@@@@̾qcUcUC#hQhQ>*CJOJQJ^JaJh CJOJQJ^JaJhQCJOJQJ^JaJhCJOJQJ^JaJh&rCJOJQJ^JaJ hQhQCJOJQJ^JaJ#hQhQ5CJOJQJ^JaJhCJOJQJ^JaJh&L8CJOJQJ^JaJ hJPhCJOJQJ^JaJ#h {4h6CJOJQJ^JaJ h {4hCJOJQJ^JaJ@@@@AA5A6AtAuAAA B BDBEBzB{BBBBBBBCC%C&C0C1CRCSC[C\CͿzzzzzzzzhzzhzUzzh%hh#B*CJOJQJaJph#hh#5CJOJQJ^JaJ%hh}TB*CJOJQJaJph hh}T1hh}T56B*CJOJQJ\]aJph#h}hQ5CJOJQJ^JaJh}TCJOJQJ^JaJ h hQCJOJQJ^JaJ h h CJOJQJ^JaJ hyh CJOJQJ^JaJ!5A6ANAnAtAyyy $Ifgd}T|kdPy$$IflF3G#G GG th6    44 lBaKpyttAuAAAAyyy $Ifgd}T|kd&z$$IflF3G#G Gg th6    44 lBaKpytAAAB Byyy $Ifgd}T|kd{$$IflF3G#G Gg th6    44 lBaKpyt B B%B>BDByyy $Ifgd}T|kd{$$IflF3G#G Gg th6    44 lBaKpytDBEBXBtBzByyy $Ifgd}T|kd|$$Ifl}F3G#G Gg th6    44 lBaKpytzB{BBBByyy $Ifgd}T|kd}$$IflF3G#G Gg th6    44 lBaKpytBBBBByyy $Ifgd}T|kd~$$IflF3G#G Gg th6    44 lBaKpytBBBCCyyy $Ifgd}T|kdx$$IflF3G#G Gg th6    44 lBaKpytCC2COCRCyyy $Ifgd}T|kdT$$IflF3G#G Gg th6    44 lBaKpytRCSCjCCCyyy $Ifgd}T|kd>$$IflF3G#G Gg th6    44 lBaKpyt\CCCCCCCCCCCCCDDDD@DADGDHDqDrDxDyDDDDDDDDDEEEEE%E2E>EGENEEEIJ~~ph[CJOJQJ^JaJ hbh CJOJQJ^JaJ hbhQCJOJQJ^JaJ#hbh 5CJOJQJ^JaJ#hbhQ5CJOJQJ^JaJh}T5CJOJQJ^JaJ#hh#5CJOJQJ^JaJ hh}T%hh}TB*CJOJQJaJph,CCCCCyyy $Ifgd}T|kd($$IflF3G#G Gg th6    44 lBaKpytCCCCCyyy $Ifgd}T|kd$$Ifl}F3G#G Gg th6    44 lBaKpytCCCDDyyy $Ifgd}T|kd$$IflF3G#G Gg th6    44 lBaKpytDD&D=D@Dyyy $Ifgd}T|kd$$IflF3G#G Gg th6    44 lBaKpyt@DADWDnDqDyyy $Ifgd}T|kdЅ$$IflF3G#G Gg th6    44 lBaKpytqDrDDDDyyy $Ifgd}T|kd$$IflF3G#G Gg th6    44 lBaKpytDDDDDyyy $Ifgd}T|kd$$IflF3G#G Gg th6    44 lBaKpytDDDEEyyy $Ifgd}T|kd$$IflkF3G#G Gg th6    44 lBaKpytEEEGGIIInJJyqhh__WW & Fgdh^hgdqh^hgdU & Fgdh^hgd}T|kdx$$IflF3G#G Gg th6    44 lBaKpyt EEEEEFF;FEFLFnFFFFFFFFFF8G9GGGGGGGGŸŽo]L hbhyCJOJQJ^JaJ#hbhU5CJOJQJ^JaJ$hbhB 20JCJOJQJ^JaJh7Ijh7IU hbhB 2CJOJQJ^JaJ#hbhQ>*CJOJQJ^JaJ hbh}TCJOJQJ^JaJ hbh CJOJQJ^JaJhCJOJQJ^JaJh[CJOJQJ^JaJ hbhQCJOJQJ^JaJGGHH/H5HRHSHTHnHrHsHuHvHzH~HHHHHHIIII*I,I-IBICIEIFIIIJIQIRIIII䜎rh#MjCJOJQJ^JaJhpFCJOJQJ^JaJh[CJOJQJ^JaJ hbh>eCJOJQJ^JaJ hbhB 2CJOJQJ^JaJ hbhqCJOJQJ^JaJ)hbhyB*CJOJQJ^JaJph hbhyCJOJQJ^JaJhCZhCZCJaJ&IIIIIIIIIIJJJ!J+JBJQJ`JlJJJJJJJJJJJʸʪʜʋʋzʪʜiV$hbh}T5B*CJPJaJph hbh>eCJOJQJ^JaJ hbhUCJOJQJ^JaJ hbhCJOJQJ^JaJhpFCJOJQJ^JaJh[CJOJQJ^JaJ#hbhC !5CJOJQJ^JaJ hbhqCJOJQJ^JaJ#hbh M$5CJOJQJ^JaJ#hbhq5CJOJQJ^JaJJJLKLLLMM-NsNtNOOQQ$$,&`#$/Ifa$gd & Fgdh^hgdXR & FgdXRh^hgd}T  & F/H$gd5+  & FH$gd?gd}T  & FH$gd  & FH$gdgd>e JJJJKKKKKKKKKKKJLLLPLQLrLsLtLxLyLLL[M\MMϾ}o^}RϾhbh}T5CJaJ!hh}TB*CJPJaJphh lB*CJPJaJph!hh lB*CJPJaJph!hhpFB*CJPJaJphhpFB*CJPJaJph!hbh#B*CJPJaJph!hbh}TB*CJPJaJphhbh}TCJaJ$hbh}T5B*CJPJaJph$hbh#5B*CJPJaJphMMMMMMMMN NNNsNtN{NNNNNNN@OBOOOOϾݟݎ|k]k]k]k|k|L hXRhXRCJOJQJ^JaJhpFCJOJQJ^JaJ hbhXRCJOJQJ^JaJ#hbhXR5CJOJQJ^JaJ hbh}TCJOJQJ^JaJ!hh}TB*CJPJaJphh lB*CJPJaJph!hh lB*CJPJaJphhpFB*CJPJaJph!hbh}TB*CJPJaJph!hbhO;]B*CJPJaJphOOOOPPOPQPZP[P]P^PbPhPPPPP Q QQQ"Q'Q5QDQfQ}Q~QQQQQQQQRR(R)RhRiRR{{l{l{l{l{lhhCJOJQJaJ hh"hh5CJOJQJ\aJhZCJOJQJ^JaJh>eCJOJQJ^JaJh hCJOJQJ^JaJ h>eh>eCJOJQJ^JaJh>e5CJOJQJ^JaJh#5CJOJQJ^JaJ#h>eh>e5CJOJQJ^JaJ*QQQQQ)nkd$$IflF0tG4G t 6`,644 lBapytQ7$,&`#$/IfgdVkdb$$IfltG t 6`,644 lBap ytQ7QQQQRRjnkd$$Ifl0tG4G t 6`,644 lBapyt$$,&`#$/Ifa$gd$,&`#$/IfgdRR!R(Rj$$,&`#$/Ifa$gd$,&`#$/Ifgdnkd$$Ifl0tG4G t 6`,644 lBapyt(R)RaRhRj$$,&`#$/Ifa$gd$,&`#$/Ifgdnkd`$$Ifl0tG4G t 6`,644 lBapythRiRRRj$$,&`#$/Ifa$gd$,&`#$/Ifgdnkd2$$Iflz0tG4G t 6`,644 lBapytRRRRRTTUU W W{vme\^gdYk & FgdO;]8^8gd^hgd sh^hgd{ & Fgd^hgdZnkd$$Ifl_0tG4G t 6`,644 lBapyt RRRRRRRRRRRRRR@SjSSSSSSqTTTTTȹtettSȹSDSDSh25CJOJQJ^JaJ#hy:hy:5CJOJQJ^JaJhQ75CJOJQJ^JaJ#h*Nhw5CJOJQJ^JaJ#h*Nhbr5CJOJQJ^JaJhy:5CJOJQJ^JaJ#h*Nh{5CJOJQJ^JaJh l5CJOJQJ^JaJ#hh l5CJOJQJ^JaJ hZhZCJOJQJ^JaJhZCJOJQJ^JaJ hhTTTTTUUUUUUUVVVV W W WŷssbQb@ hYkh^hCJOJQJ^JaJ hO;]hjACJOJQJ^JaJ hO;]hqz[CJOJQJ^JaJ#hYkhqz[5CJOJQJ^JaJ#hYkh^h5CJOJQJ^JaJhqz[CJOJQJ^JaJ#h shbr5CJOJQJ^JaJhbrCJOJQJ^JaJhwCJOJQJ^JaJhg/CJOJQJ^JaJ hg/hg/CJOJQJ^JaJh^hCJOJQJ^JaJ W>W@WZW_WWWWWWWWWWWWWWWᆲ|kZH6#hYkhqz[5CJOJQJ^JaJ#hjAhjA5CJOJQJ^JaJ hYkh3CJOJQJ^JaJ hYkhVrCJOJQJ^JaJ#hYkhYk5CJOJQJ^JaJhb5CJOJQJ^JaJhjA5CJOJQJ^JaJ#hYkhVr5CJOJQJ^JaJhCJOJQJ^JaJ haIhCJOJQJ^JaJ#hh5CJOJQJ^JaJ haIhCJOJQJ^JaJ WWWXXjYkYYYZZ\[\\l]^ & F ^ gdYf^gd)  & F.^gd)  & F0 2 gd)   p^pgd)  & F ^ gd) ^ gdO;] & F&gdaIT^TgdYk & FgdO;]^gdYk & F%gdaIWWXXXXXXX"Y5YjYkYoYYYYYYμudVE44E4 hYkhVrCJOJQJ^JaJ hYkh?CJOJQJ^JaJhO;]CJOJQJ^JaJ haIhbrCJOJQJ^JaJ haIh3CJOJQJ^JaJ#haIh35CJOJQJ^JaJ#haIhbr5CJOJQJ^JaJ#haIhjA5CJOJQJ^JaJ#haIhYk5CJOJQJ^JaJhqz[5CJOJQJ^JaJ#hYkhqz[5CJOJQJ^JaJ hYkhqz[CJOJQJ^JaJYYYYYYYYYYYZZZ%ZgZhZmZnZ|Z~ZZZZZZZZZZпᣒseseeeeeT h5+h5+CJOJQJ^JaJh hCJOJQJ^JaJhkCJOJQJ^JaJ hYkh?CJOJQJ^JaJ hYkh)CJOJQJ^JaJhVrCJOJQJ^JaJhYkCJOJQJ^JaJ hh lCJOJQJ^JaJ hhYkCJOJQJ^JaJ hYkhVrCJOJQJ^JaJh'hDCJOJQJ^JaJZZZZZZZZZZZZ[[[*[+[1[2[C[P[Z[u[x[[[[ɷɷɨɷɨɖufuUGhCJOJQJ^JaJ h)hjACJOJQJ^JaJhQ75CJOJQJ^JaJh5CJOJQJ^JaJ#h)h?5CJOJQJ^JaJ#h)hJb5CJOJQJ^JaJhb5CJOJQJ^JaJ#h)h#5CJOJQJ^JaJ#h)hH'5CJOJQJ^JaJ#h)hjA5CJOJQJ^JaJ#h)hYk5CJOJQJ^JaJ[[[[[[[\\I\J\Y\Z\[\+],]<]=]R]߽Ξ{iWF4F4F#h_:(hYf5CJOJQJ^JaJ h_:(hYfCJOJQJ^JaJ#h)h)5CJOJQJ^JaJ#h)hbr5CJOJQJ^JaJ#hh5CJOJQJ^JaJ hhCJOJQJ^JaJhCJOJQJ^JaJ h)h lCJOJQJ^JaJ hh lCJOJQJ^JaJ h)hH'CJOJQJ^JaJh hCJOJQJ^JaJ#h)hO;]5CJOJQJ^JaJR]b]e]f]l]{]~]]]]]]^^6^7^<^=^?^X^e^f^x^ឌ{iZiZiZI hLhSpCJOJQJ^JaJhSp5CJOJQJ^JaJ#hC hSp5CJOJQJ^JaJ hSphs CJOJQJ^JaJ#hs hs 5CJOJQJ^JaJ hs hs CJOJQJ^JaJ#h_:(hYfCJOJQJ\^JaJ#hhYf5CJOJQJ^JaJh hCJOJQJ^JaJ h_:(hYfCJOJQJ^JaJhg]CJOJQJ^JaJ^^7^___[c]ccDd^d6ef6ffDiFiigdA  & F ^ gdE  & F ^ gdw  & F ^ gdg]  & F^gdE & Fgdh^hgdx# & Fgd^gdSp & F#gdSp & F#gds gds x^^ ___#_$_7_e___________`p^O^O^@^@hGX5CJOJQJ^JaJh#5CJOJQJ^JaJ#hx#hHg5CJOJQJ^JaJ hs hSpCJOJQJ^JaJ#hz:hO;5CJOJQJ^JaJhCJOJQJ^JaJ hhCJOJQJ^JaJhO;CJOJQJ^JaJhO;5CJOJQJ^JaJ#hO;hSp5CJOJQJ^JaJ hO;]hSpCJOJQJ^JaJhSpCJOJQJ^JaJ` ```R`T`V`d`f```RaTaabb[c͸q`OA0A0 hx#hx#CJOJQJ^JaJhGXCJOJQJ^JaJ hx#h CJOJQJ^JaJ hx#hHgCJOJQJ^JaJ#hx#hHg5CJOJQJ^JaJ#hx#hb5CJOJQJ^JaJ#hbhb5CJOJQJ^JaJ hb5CJOJQJ\^JaJ)hKghKg5CJOJQJ\^JaJo(&hKghKg5CJOJQJ^JaJo(hKg5CJOJQJ^JaJhb5CJOJQJ^JaJ[c\cjcocucccccccccccdd>dDdXd\dųr]O=O#hx#hA>*CJOJQJ^JaJhACJOJQJ^JaJ)hKghb5CJOJQJ\^JaJo(&hKghb5CJOJQJ^JaJo(hGX5CJOJQJ^JaJhb5CJOJQJ^JaJh#5CJOJQJ^JaJ#hx#hA5CJOJQJ^JaJh>eCJOJQJ^JaJ hAh CJOJQJ^JaJhg]CJOJQJ^JaJhx#CJOJQJ^JaJ\dde4e6ef2f5fYffffffffffffffffffff°¢”¢xgXJghACJOJQJ^JaJh#5CJOJQJ^JaJ hAhACJOJQJ^JaJh#CJOJQJ^JaJhbCJOJQJ^JaJh?CJOJQJ^JaJhx#CJOJQJ^JaJ#hx#hA>*CJOJQJ^JaJhACJOJQJ^JaJ hg]hs CJOJQJ^JaJ hAhs CJOJQJ^JaJhs CJOJQJ^JaJfhhhhhhhhhh i*iBiFi\i^iziiiiiiϻ|m|[|J<h CJOJQJ^JaJ hAh CJOJQJ^JaJ#hx#hA5CJOJQJ^JaJh#5CJOJQJ^JaJ#hx#h 5CJOJQJ^JaJhx#CJOJQJ^JaJhACJOJQJ^JaJ hAhACJOJQJ^JaJ&hbhbCJOJQJ\^JaJo(hbCJOJQJ^JaJ#hbhbCJOJQJ^JaJo( hbhbCJOJQJ^JaJiiii*jDjEjjjjk1kKkLkMkkkkkkk l"l'l6l7lFlIlJlnloll߯߯߯ߓtftfWfh2[5CJOJQJ^JaJhmCJOJQJ^JaJh CJOJQJ^JaJ h hECJOJQJ^JaJhlTCJOJQJ^JaJh#CJOJQJ^JaJ hAhx#CJOJQJ^JaJ hAhs CJOJQJ^JaJhs CJOJQJ^JaJhx#CJOJQJ^JaJ#hx#hx#>*CJOJQJ^JaJiiEjjjLk7lllmmnn'r(rvvqvv & Fgdh^hgdC & Fgdh^hgdJb & Fgdwh^hgdGX & FgdGXgdA8^8gdm  & F ^ gdE  & F^gdEllllllm mYm|mmmmmmmmmmmmmmYn|nnνίweSeSeBB h=qhGXCJOJQJ^JaJ#h=qh2[5CJOJQJ^JaJ#h=qhGX5CJOJQJ^JaJhlTCJOJQJ^JaJhcCJOJQJ^JaJh CJOJQJ^JaJhs CJOJQJ^JaJh/CJOJQJ^JaJ hH'hmCJOJQJ^JaJhmCJOJQJ^JaJ hJbhmCJOJQJ^JaJ#hJbhmCJOJQJ\^JaJnnnnnnnnnoopp'p(p-p.p2p3pqqqqqqͻ᭞~papapppapO@OhM5CJOJQJ^JaJ#hJbhc5CJOJQJ^JaJh=q5CJOJQJ^JaJhcCJOJQJ^JaJ hchcCJOJQJ^JaJh2[5CJOJQJ^JaJhc5CJOJQJ^JaJhJCJOJQJ^JaJ#h=qhGX5CJOJQJ^JaJ&h=qhGX56CJOJQJ^JaJ h=qhGXCJOJQJ^JaJh CJOJQJ^JaJqqqqqqq%r&r'r(rSrTr[rfrgrrrrrrrrrrrrrrrrrss6sn\\\#hon$h 5CJOJQJ^JaJ#hon$hM~5CJOJQJ^JaJ#hon$h_y5CJOJQJ^JaJh2[5CJOJQJ^JaJ#hon$hJb5CJOJQJ^JaJhJbCJOJQJ^JaJhC !CJOJQJ^JaJhJb5CJOJQJ^JaJ#hJbhc5CJOJQJ^JaJhM5CJOJQJ^JaJ"6sAsBsesfshsssHtJukunuouvvvvv2vdvvvvvvw1w̽qqcUC#hChCCJH*OJQJ^JaJhM~CJOJQJ^JaJhCJOJQJ^JaJhMCJOJQJ^JaJh=qCJOJQJ^JaJ hChCCJOJQJ^JaJ hh lCJOJQJ^JaJhCCJOJQJ^JaJhC5CJOJQJ^JaJ#hon$hJb5CJOJQJ^JaJh2[5CJOJQJ^JaJ#hon$hT5CJOJQJ^JaJv1w2w*x+xxyyyy{{t{||}} & F( ^gdN ? & F gdO;]h^hgdq & Fgdh^hgdM~gdw8^8gdC & Fgdh^hgdC^gd+^gdP & Fgd1w2wwwwwww)x*x+x>x?xAxBxFxLxMxTx^xxxxxxxyy#yAyQyaydyeyfyŷӷӷӷuguYӷӷhCJOJQJ^JaJh"CJOJQJ^JaJh=qCJOJQJ^JaJ hChCCJOJQJ^JaJ hKhCCJOJQJ^JaJ#hB^hC5CJOJQJ^JaJhCCJOJQJ^JaJh~]CJOJQJ^JaJhMCJOJQJ^JaJ hPhs CJOJQJ^JaJhwCJOJQJ^JaJ"fyxyzyyyyyyyyyyyzzzQzRzozuzzzz´¦zkzZLZLZ>>hon$CJOJQJ^JaJh:CJOJQJ^JaJ hhCJOJQJ^JaJh2[5CJOJQJ^JaJh5CJOJQJ^JaJ *hCJOJQJ^JaJhCCJOJQJ^JaJhM~CJOJQJ^JaJh1TCJOJQJ^JaJhCJOJQJ^JaJh=qCJOJQJ^JaJ hKh=qCJOJQJ^JaJ hKhCCJOJQJ^JaJzzzzzzz{{ {{{{{#{,{A{F{G{I{J{N{T{f{q{r{t{{Ѵ򢓂tfffWF h:hqCJOJQJ^JaJh2[5CJOJQJ^JaJhMCJOJQJ^JaJh&7'CJOJQJ^JaJ hqhqCJOJQJ^JaJhq5CJOJQJ^JaJ#hqhJb5CJOJQJ^JaJhM~CJOJQJ^JaJhon$CJOJQJ\^JaJhqCJOJQJ\^JaJ#hqhqCJOJQJ\^JaJhqCJOJQJ^JaJ{{{{||(|1|8|9|=|C|D|a||||||}}B}U}Y}[}w}޼vhWFWFW haIhPCJOJQJ^JaJ haIhqCJOJQJ^JaJhPCJOJQJ^JaJh:CJOJQJ^JaJh#CJOJQJ^JaJhon$CJOJQJ^JaJhqCJOJQJ^JaJh&7'CJOJQJ^JaJ hqhqCJOJQJ^JaJ h:h#CJOJQJ^JaJ h:hqCJOJQJ^JaJ h:h&7'CJOJQJ^JaJw}{}}}}}}}}}~~r~~~~~%&`rпЮ򮟮rrrrddVh&7'CJOJQJ^JaJh&CJOJQJ^JaJh@CJOJQJ^JaJ h&7'h:CJOJQJ^JaJh:CJOJQJ^JaJh2[5CJOJQJ^JaJ h&7'h&7'CJOJQJ^JaJ haIhPCJOJQJ^JaJ haIhqCJOJQJ^JaJ haIhN ?CJOJQJ^JaJhN ?CJOJQJ^JaJ!.5=ERbjqrwx̀ҀӀԀ  !JYgʼʮʮʮʮʠʒʁpʮaʮapppph:5CJOJQJ^JaJ h&7'hqCJOJQJ^JaJ hqhqCJOJQJ^JaJh@CJOJQJ^JaJh&CJOJQJ^JaJh&7'CJOJQJ^JaJh:CJOJQJ^JaJ h&7'h&7'CJOJQJ^JaJ#h&7'h&7'5CJOJQJ^JaJ#h&7'h&7'>*CJOJQJ^JaJ&$%DEefl & F$gds 8^8gd71 & F$gd71h^hgdAh^hgdh^hgdz: & Fgd & F gdO;] & F gd&h^hgdqāŁԁ 45<=R`bhim{|ᷦᦆwweweeweTTŗ hh*CJOJQJ^JaJ#h*h*5CJOJQJ^JaJh*5CJOJQJ^JaJ hqhqCJOJQJ^JaJh2[5CJOJQJ^JaJ h&7'h&7'CJOJQJ^JaJh#CJOJQJ^JaJh*CJOJQJ^JaJh&CJOJQJ^JaJh&7'CJOJQJ^JaJ h&h&7'CJOJQJ^JaJȂɂ !"#$%+,OUVȃɃ̓σ/5=r򹫙Պ|||n|n|__hTI5CJOJQJ^JaJhTICJOJQJ^JaJhz:CJOJQJ^JaJhz:5CJOJQJ^JaJ#hz:hz:5CJOJQJ^JaJhJbCJOJQJ^JaJh:CJOJQJ^JaJh&CJOJQJ^JaJh2[5CJOJQJ^JaJh*CJOJQJ^JaJhCJOJQJ^JaJ"ńƄ-DL]^_qwvevSDh]eN5CJOJQJ^JaJ#h]eNh]eN5CJOJQJ^JaJ h]eNhCJOJQJ^JaJh]eNCJOJQJ^JaJh&CJOJQJ^JaJhTICJOJQJ^JaJ h]eNh]eNCJOJQJ^JaJh2[5CJOJQJ^JaJh5CJOJQJ^JaJhz:5CJOJQJ^JaJ#hz:hz:5CJOJQJ^JaJh&5CJOJQJ^JaJwxÅ-CDEϱϱϐr`QhA5CJOJQJ^JaJ#hz:hz:5CJOJQJ^JaJhay5CJOJQJ^JaJhz:5CJOJQJ^JaJ#h]eNh5CJOJQJ^JaJh5CJOJQJ^JaJhTI5CJOJQJ^JaJh&5CJOJQJ^JaJ#h]eNh]eN5CJOJQJ^JaJh]eN5CJOJQJ^JaJh:5CJOJQJ^JaJE†ÆĆ%&18ч҇Ӈ𱟐pbph0CJOJQJ^JaJ hayh0CJOJQJ^JaJh05CJOJQJ^JaJh2[5CJOJQJ^JaJ#h$h$5CJOJQJ^JaJ h71h71CJOJQJ^JaJh71CJOJQJ^JaJ hayh71CJOJQJ^JaJh5CJOJQJ^JaJh715CJOJQJ^JaJ%"#>?JKLMnpvĈ۾ۯ۠o```RC`Chy:5CJOJQJ^JaJh0CJOJQJ^JaJh05CJOJQJ^JaJ#h$h05CJOJQJ^JaJh0CJOJQJ^JaJ hayh0CJOJQJ^JaJh05CJOJQJ^JaJh2[5CJOJQJ^JaJh$5CJOJQJ^JaJh$CJOJQJ^JaJ#h$h$5CJOJQJ^JaJ#h$hay5CJOJQJ^JaJ !defnoЉ-34Maiqr|򺨙ֈֈȈzlzzl]h715CJOJQJ^JaJh:CJOJQJ^JaJhB^CJOJQJ^JaJ h6[)h71CJOJQJ^JaJh:5CJOJQJ^JaJ#h8h715CJOJQJ^JaJh$CJOJQJ^JaJh71CJOJQJ^JaJhCJOJQJ^JaJhTICJOJQJ^JaJh!rCJOJQJ^JaJˊlmv?DXY`tΌ qrS௡vdSB h]hE CJOJQJ^JaJ h]h]CJOJQJ^JaJ#h]h]5CJOJQJ^JaJh!r5CJOJQJ^JaJh:CJOJQJ^JaJht?CJOJQJ^JaJh!rCJOJQJ^JaJ#h!rh!r5CJOJQJ^JaJh0CJOJQJ^JaJ h%bh0CJOJQJ^JaJh05CJOJQJ^JaJ h71h71CJOJQJ^JaJlmqr ɐʐuv$v&`#$/IfgdaI & F gdzh^hgdz & F gd`Wh^hgds & F gdHgdBh^hgd[h^hgd=\  & Fgd=\  & F$gd71h^hgdAST ,ϏԏՏϽ|jXjIjIjIjIh5 B5CJOJQJ^JaJ#h:hSp5CJOJQJ^JaJ#h:hH5CJOJQJ^JaJhB5CJOJQJ^JaJ *h[5CJOJQJ^JaJh=\ 5CJOJQJ^JaJ#h]h=\ 5CJOJQJ^JaJ#h]hE 5CJOJQJ^JaJ h]hE CJOJQJ^JaJ$h]hE 0JCJOJQJ^JaJh7Ijh7IUȐɐʐ͐Ӑ^O~’ޒs̺raPaPHjh7IU hzhDCJOJQJ^JaJ hzhCJOJQJ^JaJ#hzhz,5CJOJQJ^JaJ#hzhm;5CJOJQJ^JaJ#hzhz5CJOJQJ^JaJ#hzh`W5CJOJQJ^JaJ#hshs5CJOJQJ^JaJ#h:hH5CJOJQJ^JaJh5 B5CJOJQJ^JaJ#h:hs5CJOJQJ^JaJpqsuvLWпq`N<*#haIh/MCJOJQJ\^JaJ#haIhBCJOJQJ\^JaJ#haIhzCJOJQJ\^JaJ haI6CJOJQJ\^JaJ&hO;]h[C6CJOJQJ\^JaJ&h>H56>*CJOJQJ\^JaJ,hO;]h[C56>*CJOJQJ\^JaJh`W5CJOJQJ^JaJ hzhCJOJQJ^JaJ hzhDCJOJQJ^JaJ$hzhD0JCJOJQJ^JaJjh7IUh7IWXkŕ>Eȶn\F? hhaI+hhaI5B*CJOJQJ\aJph#hO;]hCJOJQJ\^JaJ#hO;]h`*CJOJQJ\^JaJ#hO;]hlD*CJOJQJ\^JaJ#hO;]h1CJOJQJ\^JaJ#hO;]hZyCJOJQJ\^JaJ#hO;]hBCJOJQJ\^JaJ#haIhBCJOJQJ\^JaJ#haIh/MCJOJQJ\^JaJ&hO;]h/M5CJOJQJ\^JaJ$v&`#$/IfgdaIjkd֏$$Ifl0?0*gg' t 6`v*44 lBapytaIٗڗۗ -.34@E_lmrszll^MlMlM^M h2[h@\CJOJQJ^JaJhlJCJOJQJ^JaJh2SCJOJQJ^JaJ h2[h$-CJOJQJ^JaJ hh$-CJOJQJ^JaJ h2[h^%XCJOJQJ^JaJ&h2[hgs5>*CJOJQJ^JaJ&h2[h^%X5>*CJOJQJ^JaJhCJOJQJ^JaJ hhaI)hhaIB*CJOJQJ^JaJphٗ$v&`#$/IfgdaIjkd$$Iflp0?0*FF' t 6`v*44 lBapytaIٗڗۗߙ}~zzuuupnngdJ0gdevD^gd^%X & F gd`W`gdjkd^$$Ifl}0?0*FF' t 6`v*44 lBapytaI 3p()./;@QT۸qccUA&h2[hy 5CJOJQJ\^JaJhlJCJOJQJ^JaJh2SCJOJQJ^JaJ h2[h$-CJOJQJ^JaJ hh$-CJOJQJ^JaJ&h2[h^%X5>*CJOJQJ^JaJ h2[hCJOJQJ^JaJ h2[h^%XCJOJQJ^JaJ#h2[h5CJOJQJ^JaJ#h2[h^%X5CJOJQJ^JaJ#h2[h@\5CJOJQJ^JaJTgklƚ TUݛޛ|۸weTTC h2[h(CJOJQJ^JaJ h2[hCJOJQJ^JaJ#h2[h$=5CJOJQJ^JaJ&h2[hy 5CJOJQJ\^JaJ h2[h$=CJOJQJ^JaJhlJCJOJQJ^JaJh2SCJOJQJ^JaJ h2[h^%XCJOJQJ^JaJ#h2[hK Y5CJOJQJ^JaJ#h2[h^%X5CJOJQJ^JaJ#h2[h5CJOJQJ^JaJ|}~{|~ݘ =>ij͹~meaeKe*hhevD0J6CJOJQJ]^JaJh7Ijh7IU h/M6CJOJQJ]^JaJ hy 6CJOJQJ]^JaJ&hhs6CJOJQJ]^JaJU&hh"6CJOJQJ]^JaJ&hhevD6CJOJQJ]^JaJ hhevDCJOJQJ^JaJ h2[h^%XCJOJQJ^JaJ h2[h:hphSMhCJaJ&hSMhSM5CJOJQJ\^JaJhzEhSMCJaJhSMhSMCJaJ,hSMhSMB*CJOJQJ\^JaJph hSM5CJOJQJ\^JaJh DA-hR h@<B*CJOJQJ^JaJph'h@<B*CJOJQJ^JaJph6jhR h7I@<B*CJOJQJU^JaJph2hd2@<B*CJOJQJ^JaJmHnHphugdJ0 h;hR CJOJQJ^JaJ? 0 00&P1h:pR / =!"#$% F4 Ld41cJFIFC     C   D^" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?S(aq{{qm4HA,TI'-cWvqIQU^ zN!61Y"6|œ Cv<;_=~_]i?ٷ%VzlZyTB4wv<^/xGX5ohLK|++O~z'㾻ߵ72`еӴ+Ib.i1ʂ{(>BZ!  QzfKi~3"n]r 9<'t_2-E̷V-q)BP7l |]DmxU孷=Yd\JV%F?w/ WFD >KI!v 1ڠ)88O+|o&֬^91[y'#8N >x^GƟDEj7sy[Y%hff;H ~d ?P{>t[ǿtIR-i!BRLa2(bĩvl_Wߍ{| ""$P6cIcwUqNKŦA`1[C-0# nޘ^#!1iHK2ٸ5[d+eZ|!cY̚e$ҟY138; STᗈ5Cn447bتB!Kvc%}º m7N$B"iQ@EPEPEPEPIGYSN8c=nRzЀ(((((Dd ~  ZA?dhsPicture 1dhsR4.}8YZ&9D?F.}8YZ&9,Photoshop 3.08BIM,,Phttp://ns.adobe.com/xap/1.0/ image/jpeg Illustrator 2007-05-21T13:27:53-05:00 2007-05-21T18:27:55Z 2007-05-21T13:27:53-05:00 256 120 JPEG /9j/4AAQSkZJRgABAgEBLAEsAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABABLAAAAAEA AQEsAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAeAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8AX/5y38yzal5g0LyVZMHa Kl1cRg9bi4PpQKfAqlT/ALLFV3/OI/maXT9b13yVfH03kreW0Tdp4D6VwvzK8T/scVfUGKuxV8t/ 85mf8dXyv/xgu/8AicWKvEIpb3y/d6Td+XNaeTUriKK5dbL1Ekt7guwWBqbSMBQ7eNKYq/QyxkuZ LK3kukEVy8SNPGNwshUFl+g4qr4q8f8A+cq//JSz/wDMba/8SOKvlCDznfweQZvJ9tVLe91D69fO P92BI0SGP5B1LH344q+vvyC/KdPInlYXF/GP8R6qqy6g1KmFOqW4P+RX46dW9gMVeo4q7FXyF/zk 3rl55r/NGz8qaYDcfomMW8cSmoN1cASynw2QID8jirOf+cQPN31vy9qvlaeSsumzC7s1PX0LjaRR 7JKtf9nir6ExV2KvkD/nMH/yZemf9sWD/qKusVYZ5q/MV/M35YeX9D1Bi+reXbp4Y5m3MlnJEBEa +KenwPsFxV9Yf84/f+Sd8tf8YJf+oiTFXoWKpJ531PU9K8na3qWlxetqNnY3E9pGByrLHGzL8NDy oRXj36Yq+BbW7i17Wbi98ya7cWt7KDLHqMkT3XKfkCBIVcSRruTyRWp044q+7PytVF/Lvy+F1P8A TFLKPnqIkaYSSU/eUd/iIR6qA24pQgYqynFXYq+FPzl12887/mX5h1CyrNZaUjRQU6C1s2ETOvs0 jM/+yxV9K/8AONHm7/EH5X2dtK/K80R206ep3KJRoD8vSZV/2JxV6tirsVfFn/OSvmjzHqH5m3+j anNPb6NpzRJZWa19P02RXM4jJVXdyxNfortir03/AJxUtdItbnXotN8znVrb04TbaYyzW7xDk3qS vbSFowSeA5Rsw8TirzjXfy4/N/zz+aV5q8ekXmkyX948tnqV4k1vFbxwD/Ry0oVnQrHEoBAry6Yq 35d/Lr83fIv5p2erSaPeaq1heK99qNmk1xFcRTj/AEgrKyhnLRyMCSteWKvszFXYq+df+crPJfm3 zHqXl2TQdIutTS2huVna2iaQIXaMqG49K0OKvKtK/K/82/J3mHQ/MGleXry8uIUhvkT6uzhHNVkg mWh4tUMPGhBGKvtLRNSfU9ItL+S0msZbmNXksrlCk0Tn7UbqQN1O1e/UbYqjcVeXf85IaBrWu/ln NYaNZTahetd27i3t0MjlVJ5Gg7DFXzYv5C+fZPJLasuh3qaxb6gYJdOaJxLJayRIUlRCNwkgYNT+ b2xV9NfkNq/nK48mx6T5u0u80/VNI428VxdxOn1i3pSJuTdXQDi30Hvir0rFVG+uWtbK4uVie4aC N5BBEOUjlFLcEA6s1KDFXxbo35SfnX5m87XOqCyufL+qXUs9+2rXf1i0jSSRizKksaO4Y86KAOmK p3+Tvkf8zvIn5r2k1zoN6+miaXTdRvIYZGt3gkbh6yuVFYhIqSA06DFX17irsVfL3/OUXkLzp5h8 /wCn3uh6LealaR6VDC89tE0iCRbm4YoSo6hXB+nFWK/mx+Qvmqz16DUPLGiXV3purW6XT2tvGZGt bgqPWhdVHwjkar93bFX0n+SWlalpP5W6Bp2p20lnfW8Miz20ylJEJnkYBlO42NcVZxiqT+cn11PK mrny/CbjWzaSrp0QZUJnZCEIZioHEmvUYq+IdY8nfmnrN9b6dd+UbldUiJV7iHTmgkmrT4p5I1SJ +lfUPXqWOKvsD8mfJmoeTfy70vQ9SZTqEQkmulQhlR55Gk4AjY8AwBPc4qzbFWPfmFqGs2HkrWLn RLSa91f6s8dhb26l5DNL+7Rgq70QtzPsMVfInk78g/zh1NNUe2gk0DhB6Vwt81xaG7imqWhT00f1 AfTHJW+HpXFWf/8AOMWgfmF5U83XtlrGgX9lpGrW9JLiaF0iSe3q8TMSKCqs6/MjFX07irsVfJ35 9WX5qXHnfV5JfLUmpeX7hVg0qT6p9eWKNUC+pFLEGkgd25MV5Dc7g7Yqnv8Azi5+VHm3RNcvPNWv WculwNaNaWdpcKY55DK6OztGfiVVEf7QFSfbFX0pirsVdirsVdirsVdirsVdirsVdirsVdirsVdi rsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVfFnnnzT+Z19+cOs+XNC8x6pC8+qy2mn2c eoXEMSkyFURQJFRF7eGKpt+U35yfmF5a/MODyt5uvrq/tLm8GnX0F/Ibia3uGf0ldJmLtRZCOQ5F SvTscVfTn5jXVzafl75nurWZ7e6t9JvpYJ4mKSRyJbOyujLQqykVBGKviTR/Pf5i6jO8Uvn6/wBN CLyEt5qV+qNvTivpeqa/Rir7S/K3T9TsfIGixapqMmrahJbie41CWaW4aUzkyqRJN8ZUK4C17Yq+ V/zS86fmCPze1rRdM8z6lYwPqItrWFL+4gt4vUKqNlcKiAtvQYqn35C/mr56g/M2DyrrOsTa5p9/ JPayPPcNdhJYUdllgmcsSpMdNjQg18MVfTnnDzFbeW/K2q69cU9PTraScKa0Z1X92m3870X6cVfE Olfm3+Z+n6rp/mC517VLmxW95tby3c7W0xgZJJoDGzlOPCVQRTYMMVfd9hfW1/Y219auJLW7iSeC QdGjkUMrfSDir5J/5yF86ed9P/Ny+0zSfMWo6baGO0Edvb3lxBCrSQpU8I3CipNTtiqH/Ljz7+ZO ifnFp/ly+8zT+YLaS/TT70fXJb61kRzxZ4mmO3CvKoodqe2Kvpj819M82ap5A1Sx8pTSW/mCb0Pq U0M/1aReNxG0nGYMnGsSsOu/TFXx3pev/nTqnmseVbPzPq76008tqITqlwq+rDy5jmZeO3A71xV9 ofl7pGtaP5K0jT9cupr3WIbcHULi4ma4kM8hMkimVy5YIzcRv0G22Kvj/wDMv82PPSfmXr76X5i1 K2sLXUZYrW0iu50twlvJ6YAiRwnFuFaU374qjfzi/O7zLrXm9bny1rt/p2kpZWqxw2V1NbxmSSIT SllidQXV5ShJ3+GnbFX1N+UmuXGu/lp5c1O5lae6mso0uJ3JZ5JYf3Tu7NUlmZCSfHFXzP8An554 876d+cWt6bpvmXUdNsEazWKCC9uYYIudnAzEJG1FHJixoMVelf8AONUHmu81HV9W1bzhJ5ksoIkt YYBe3lzGksjB2dkuVRQwVAAR4nFVb/nLDzH5h0Py/oMui6pd6XLNdyrNJZTy27OojBAYxMpIr44q 8k0T87vM8/5V+YtBvtdvU161a3vNH1X6xL9akja6ijntzPyEnwq/Nd/s8h0AxV7H/wA4p+Ydf1vy hrE+taldanPFqHpxy3k8lw6p6CHirSMxAqa0xVhf/OS0n5saD5km8xWGs6hp3lS5e3s7NbS/khX1 zAXcehFIpFTG/wARXFV3/ON9n+avmPzBa+ZtV1/UrzyraNcRyR3GozSJLcLGFVHhaQlgDKH3FNsV fUGKuxV8p/n5+cPnTUPPMvkjypdT2VtaypZuLNjHcXd3LQFOa0cKGfgFB3O5rtRVhl9qP54flFrV jNqd5dWxuwZo7aa5+t2lwsZAkR1DyISOVD0YVqD0OKvsbyZ5mtvNHlXS/MFuhjj1G3SYxE1KORR0 r34uCK4q+Q/zZ89+e7b82Nd0yy81alptit/6MSrfXUVvCjcRXjGx4otaniv0Yq9l/wCcZx5guodc 1DV/NkvmZQ0Fvbr9bu7mKE0Z3NLpUozVX7Pb54q8G8/XWvaL+dmt67ptq73NjrE1zas0TvGXSUla gUqPpxVOvyp/Lvzz57/Mu3806xZzwWCX66pqWozRmCOR1k9b04QQAxdqCi/ZH0Yq+qvzNR3/AC28 2IilnbRtQCqBUkm1koAMVfBmjwPZTu9/oDapGy8Uim+sxBWrXkDC0ZPhvir7r/KbUdT1H8u9CvNR s47CaS2URWcXqcY4EJSAEyFnJMSqTXxxV8k/md5eu9W/PTVbJoZktr7V44HuEjJCpKyIWBpTYHFX 0d+WX/OO/lLyLrX6bjurjU9URWS1luAiJCHHFmREH2ipIqT07Yqxz/nLXzFdw+U9P8s2McksurT+ vdiNWalvbUZQ1P5pSpH+rirwC/8AIv5lw/lvp+pXNlTyo11JcWaAQ+sJ7gCF3ZVHr0YW6j4tthir 6e/5xl8y3Oq/lpBp16rpe6HK1mVkVlYwfbgbfsFbgP8AVxV4T/zkhpV7e/nRfJHBK0UqWSGVEZgK woCagU2xVD/lbdXn5X/m48Ov6YZreCWTTru79EuYAzcRdQsASBTc06oTir7WVlZQykMrCqsNwQe4 xV8Zfl1YXyf85JRTNbyrD+mdQPqFGC0Pr0NaUxV9k3lzHa2k91JUxwRtK4HWiKWP6sVfA3lrydq3 mqfzTczWsou7XTLnV0JVlrJFPEzgAj4iyO4AxVS0ryPqM3kTXfMMlrIGtLmzs7dGRuTesXeUqKfs 8E398VfUv/OLN3cy/lTFaXCPG2nXtzbqkispCsVuNgwG1Zz0xV4F/wA5E2N4/wCdmvTrZyXEHKyJ AR+LgWUFV5L8qbHFXqP/ADixrN5NqGtabaeX4tG0hIkubmUNdO73BYJEoM7uAOAcmnhiqI/5zCtr mfy55eWCJ5WF5MSEUsQPSHhirxbzX+Vt5a/l15X856bbySQ6hE9tq0KqS0V1FNIiPxpUK6JQ/wCU P8rFXuX/ADiDbXEHkvWlnieJjqVQrqVJHoR+OKor/nLq3uJ/y201IInlcazASqKWNPqtzvQYqiv+ cUYJ4PyukSaNon/SVweLgqaenF2OKvZcVdir5D/P/wDLnzb5Z/MKXz1osEsunXNzHqEV5bp6htbu Mqx9UAHj+8XkrEUNadcVYlr3mT80Pzp1vTbU2IvJrNTDbxWULRwRmTj6ssrsXCcuC8izBdtgMVfZ nkTywnlbydpHl9ZBKdOtkillXYPJ9qRh7F2JGKvkTzx5bbWf+ciLnT7u2mbTdQ123trl0Vh+5mlj jkIcDb4WO+KvrXyJ5A8ueR9Ik0nQInjtZp2uZTK5kdpGVUJLH/JQYqyPFXYq7FXYq7FXYq7FXYq7 FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq+TPOH/OTf5o6J5s1r Ro49O9PTb65tYy1vISUhlZFNfUWtQvWmKpR/0Np+an++9N/6R3/6q4qy/wDKv88vzg8++cbXQoRp 0NtQz6hdLbOTFbRkB2FZaciWCr7kYq+m8VUrpLh7aVLaQQ3DIwhlZeYVyPhYrUcgD2rir5N8z/8A OSf5yeXPMF/oWoRaYLzT5mgl427lW4nZl/e/ZZaMPbFUs/6G0/NT/fem/wDSO/8A1VxV3/Q2n5qf 7703/pHf/qrirK/yv/5yS/MnzH540zRbzTLXULS9kEVwlpE8csUZPxT8i7LxiHxNUbjFX0/iryX/ AJyN/MHzR5I8s6Xf+XbhLa5ub30JmeJJQU9J3pRwwG6jFXz9/wBDQfnF/wBXSD/pEt/+aMVfXN5r F/F+Xc+tJIBqCaQ94svEU9YWxkDcacftdsVfI3/Q0H5xf9XSD/pEt/8AmjFXpWkfnT+YNz+Qet+c Jb2I67Zawllb3AgiCiFltiVMYXgf75t6Yq81/wChoPzi/wCrpB/0iW//ADRir6W0bzlr91+REnm6 adW1xdEu78T8EC+vDDI6N6YHGgKDamKvmn/oaD84v+rpB/0iW/8AzRir6H/JH8xdd8xfljfeZvMk 6XNzZT3XN1RIV9K3iSSlEAHc74q+eD/zlB+cX/V0g/6RLf8A5oxV69/zjj+dPmjzprmraN5muo7i 4jtkurBkijhosb8Jh8AXlX1EP0Yqs/5yM/OvzT5N8w6Zovli6jt5jbNdagXijmr6j8Yl+MNxp6bH bxxV5IP+coPzhBB/ScB9jaW//NGKvtPTr2O+0+1vYv7q6iSZP9WRQw/A4q8n/wCcjPzY1fyJo+lw aDNHDrOpTM3N1SXhbwr8fwOGHxO6gH2OKvBP+hoPzi/6ukH/AEiW/wDzRir6S/IP8xr7z15G+u6p Isms2VxJbX7IqoG/3ZE4RQAAY3C/MHFUu/5yN/MHzR5I8s6Xf+XbhLa5ub30JmeJJQU9J3pRwwG6 jFXz9/0NB+cX/V0g/wCkS3/5oxV9UflJ+Ydr588l2msKVS/T/R9UgX/ddygHOg7K9Q6+xpir5q80 /wDOSP5s6f5m1ewtdShW2tL24ggU2sBISKVkUVKVOwxV6n/zjb+avnTzzf67D5ju47mOxit3tgkM cVDIzhq8FWv2RirD/wA5P+cetd1fX9Y80+ULmPV/rFy76hpQIS4hnI5yKnI8X6huJIbcUBxV88Xl neWVzJa3kEltdQnjNBMjRyIw7MrAEH54q96/5w6vLKPzfrlpJQXlxYI9uSaEpHKPUUeP21P0Yq+s sVdir4a/5yRvbO7/ADi11rUhhF9XhmcClZYreNX+fEjj9GKvMsVZj5L/ACi/MHziUfRdJlNkxodQ n/c2w71Ej05fJKnFXonkn8xfJ35MX2o6RFp48za8zelqWt2swigUqd7a3LxszIjD4m25N2oq4q9l /K7/AJyD0nz/AK+dEttFvLOdYGnadmSWFQlKh2XiVqTRTTc4qxr/AJzF/wCUJ0T/ALaX/MiTFXyV ir6Ruv8AnKnQJvJc3l4aFdiWTTW08TmWPiGaD0edOtK74q+bsVe0eX//AFlLzN/4EMf/ABCzxV4v ir7S8uf+ssy/+Azf/wDUPNir4txV9Kfltqp0v/nFXzZdK3BmlvLdWrShukhtxQ+P73bFXzXirOPy T8y/4d/NDQL9n4W8lyLS6Pb0rr9yxb2XmG+jFVn5z+Zf8R/mdr+oq3KBblrW2Pb0rUeihHs3Dl9O KsKxV9/fkxqp1T8qvLF2W5sLCK3Zq1Ja2rAanxrFvir5Q/5yN83/AOI/zR1FYn52WjgabbUNRWEk zHw/vmcfIDFWBzeX7+Ly3aa+y/6Dd3dxZRt/xZbxxSH6CJ9vkcVeuf8AOJ3m/wDRPn2fQpn42uvQ FEBNB9Ztg0kfXxQyL8yMVejf85i/8oTon/bS/wCZEmKvkrFXp35AfmafJHnSNbyUroOrlbbUwSeM Zr+6np/xWzb/AOSTirFfzLSNPzH81pGAI11jUAgHQAXUlKYq9q/5wz/46vmj/jBaf8TlxVPNW/Mt vIH/ADkZq9pqEvDy15hWya8B+zBN9WjiS5WnT4kpJ4jfsMVes+e/ys8keerThrdir3PGlvqUFI7m Oo2KyAfEP8lwV9sVfOXmH8jfzM/LDXYfNXk6U6va2DmWOaBCbhEoQyT24+2jKSG4E7VrxxV6j5U/ 5yt/LzULJB5h9fQdRQUuI2ikuIS46+m8Ku9P9ZBiqA85/wDOUWlTQtpX5d2Vzrmu3IKW1x9Xk9JC duaQketKw6hSgHj4Yq828qf84vfmN5luW1LzNcJosV05mne4Pr3kjOeTMYlNAWJ35uD7Yq948lf8 48/ln5WEcw08atqKb/XdRpNRvFIqCJadvhr74qxH/nI/86V8t2L+T/L03HXLuMC/uYmobSBxsi06 SyKdv5V37jFXybp9he6jfQWFjC9zeXUiw28EY5O8jmiqo8ScVfdP5FeQZvJv5f2NjqNlFaa9MZZd UaPg7szSuYleRK8uMXEdSBirBP8AnMX/AJQnRP8Atpf8yJMVfJWKspf8rPzHSwbUH8t6gtisRuGu TA/ARBeZflT7PHeuKsWxV7R5eBP/ADil5nIFQPMEZPt8NmMVeL4q+xNA1zR4/wDnFSeRryIIuhXl kxLja5kjliWIj+cuwAGKvjvFXsg1JrL/AJxYNrUqdU8wmEL/ADJHGsxPyDQjFXkulWgvNUs7Q9Li eOI70+24XqPniq/VLC70fWbvT5SUu9OuZLeQ04kSQSFDt2IZcVb0bTbrWdcstNi5SXWo3MVuh6sz zyBBufdsVUtUtha6nd2oXiIJpIuNa04OVpX6MVfUf5I+fodB/wCcdtX1SRx6nl6a7igRiN5ZgskC 0PZ5rgD78VfKs00s0rzSsXlkYvI53JZjUk/M4q9P1nzd5DuPyK0jynbSTHzLYXhv5S0JEZeVpBIo k9o3X/gcVee6BrN3omt2GsWZpdafcRXMO9KtE4cA+xpQ4q+mf+cq9WtNY/LLyvqtm3O0v7uO5gbr 8Etq7j9eKvl2zWFryBZzSFpEEpJoOJYct/liqa+dfKeo+U/NGoeX79SJ7GUorkUEkZ+KORfZ0IbF Upurma6uHuJ25zSnlI56sx6sfEnqT3OKvon/AJwz/wCOr5o/4wWn/E5cVYp/zldIjfmw6qvEpYWy uf5j8bV+4gYq9X/5xg/Nn9PaN/g/V5a6vpMVbCZ23ntF2C79Xh2H+rTwOKveMVYF5z/I38tvN18m oappnpXytymuLNjbtMO4m4bPX+anL3xVknlnyZ5V8r2v1XQNLt9OiIo5hQB3/wCMkhq7n3Zjiqc4 q83/ADt/Nyz/AC+8uk27JN5iv1ZNMtW349jPIv8AIn/DHbxoq+HNQv73Ub6e/vpnuby6kaa4nkPJ 3kc1ZmPiTirJvyl0vWdS/Mjy7DpEbvdxX9vcM6VpHFDIryyOeyqgNfuxV+guKvAv+cxf+UJ0T/tp f8yJMVfJWKv0D1H/AMlDdf8AgPv/ANQRxV+fmKvqD/nH3ynD5t/ILzR5dlYR/pDU7hIpGFQkq21p JC5HgsiKcVfOXmXy1rflrWbjR9atXtL+2ajxuDRh2dD+0jdQw64qlmKo7Q9C1fXdUg0vSLWS8v7l gkMEQqST3PYKO7HYd8Vew/n15fj8leRPIvklXElzAl3falIOjXEpSpU9aBmdR7AYq80/LS0N5+Yn li2FaS6rZBiKVC/WELHfwWpxVmX/ADk35b/Q35r386Jxt9Yiiv4vDk49OXfx9SNm+nFVT/nGDyz+ mfzUtLp05W2iwy38lenMD0ohXx5yhh/q4qwb8xLP6l5/8y2lKCDVL1F+Hj8K3DhSF7AjcYqp23m2 /t/JV75VjqtpfX0F9KwPX0Y3TgR7llb/AGOKpLBBLPPHBCpeWVgkaDqWY0A+/FXqt9/zjF+a1lZX F5NbWhhtonmkC3Ks3GNSxoKbmgxV5Pir0rV/N36X/IfSNFmfld6BrRiC7V+rTwSyRE9/teovyGKv NcVfYX/OUH5XHzF5cHmnTIeWsaJGTcogq01lXk4+cO7j25e2Kvj3FX0d/wA4Z/8AHV80f8YLT/ic uKsD/wCcm5xL+cutIAR6EdnGa962kT7f8Hirz3y9r+qeX9bsta0uX0b+wlWaCTqKjqrDurCqsO4x V9+/l3560rzv5VtNe088fVHC7t61aC4UD1Im+R6HuKHFWS4q7FWOfmB570TyR5audd1V6pH8FtbK aSTzsDwiT3NNz2FT2xV8F+c/OGs+b/MV3r2ryc7u6b4UWvCKMfYijBrRVHT7zviqSYq+2vyK/JrR fJWmQa6J5LrW9WsYfrLvx9OJZAsrRxAAGnKlSTvTFXrGKpP5l8oeWvM9rFaa/p8Wo20D+rFFMCQr 0K8hQjscVY7/AMqM/KT/AKlez+5/+asVZi+m2L6a2mPCpsGhNs1vvxMJTgU+XHbFWHf8qM/KT/qV 7P7n/wCasVZL5b8qeXfLNjJYaBYRadZyymeSGEEKZWVULbk78UUfRiq3zH5Q8r+ZbZbbXtLttSiT eP14wzIT1KP9pD/qnFWDt/zjT+TLXPr/AKCYL3hF3diMnxp6tfuNMVZp5a8k+UvLELRaBpNtpwcU keGMCRx/lyGrt07nFVDzL+XnknzPdRXev6RBqNxAnpQyTBiVSpbiKEdziqA038nvyy0zULfUbDy9 a297aSLLbzoG5I6mqsPi7YqmPmbyB5M80TQTeYNJg1GW2UpA8wJKqxqQKEdxirfljyD5N8rSzy+X 9Jg06S6VVuHhBBdUJKgkk+OKpbqX5PfllqeoXGo3/l61uL27kaW4ncNyd2NWY/F3xVCD8iPyiEhk /wAMWnIilP3nH/gedMVV7T8l/wArLS6hu7by3Zx3Fu6ywyBWqroQysKt2IxVmjKrKVYBlYUZTuCD 2OKsG/5UZ+Un/Ur2f3P/AM1YqvH5JflQImhHlq0ETsrslHoWQEKSOXUBj9+KrP8AlRn5Sf8AUr2f 3P8A81YqzllVlKsAysKMp3BB7HFWDt+R35SMxY+V7KpNTRWA+4NiqdeWPIXk7ytJcSeX9Kg017oK tw0II5hCSoNSenI4q+K/z8uPX/N/zM++1ysfxbn93Cifd8O2KsAxV9X/APOJXkrzHpej3/mK+neD StYVVsdNI2k9Nv8Aeo1+z3VafaG5/ZxV9B4q7FXx/wD85cXGvf8AKwrW1vJ2bSVso5tLgGyJzZkm O3Vy6bk70pirw3FWc/lL+VWtfmB5hjtYEeHRoHDapqXE8I4xQlFalDK4+yv0nYYq+9LS1gtLWG1g XjBbxrFEtSaIgCqKnfoMVVcVQWta1pWiaXcarq1ylnp9ohkuLiQ0VVHy3JJ2AG5OwxV4Jrf/ADmP oNvdtHo3l241C2U0FxcXC2hancIsdwafOmKp15L/AOcrfJmu6hb6dqmn3WjXd06RQvUXUHqOeIUu gSQVYgA+nTxpiqM/M/8A5yNsfIfmuTy/Noct+8cMU31hLhYwRKK04mNunzxViX/Q5ml/9StP/wBJ af8AVLFU98k/85P2/mzzJbaHaeWpoZJ1lkedrpWVEgiaV2IEQ7JQe+KpF/0OZpf/AFK0/wD0lp/1 SxVfH/zmXoxcCTyxcKncrdIx+4xr+vFWd+W/+cgfK3mfy/q9/oVrPNq+j2j3s2h3HGGaSKIVdonX 1UantvWmwrirAf8AoczS/wDqVp/+ktP+qWKve9E8xafq3lmy8wxsI7G8tEveTH7EbxiQhj/k9Dir wZ/+cy9IDsE8sTsoJ4sbpASOxp6RxVFah/zlxa2CWhuPKs6m8t1uo1N2lRG7MEJ/dftBeQ9jirM/ yi/PO0/MfUr+xg0iTTTYQrO0jzLLy5PxoAESmKpp+ZP50eS/IKCLU5mutVkXnDpdrRpiD0Z6kLGp 8WO/YHFXjk3/ADmbd/WCYPKsf1cH4Ve9PMr8xDQE/L78VZ1ov/OTnlbV/Kusavb6bcpqWiW63V1p chAV42mSEtHcKGTZpR9pQfbvirFf+hzNL/6laf8A6S0/6pYq7/oczS/+pWn/AOktP+qWKvWtC/NP Rrr8uYPPeuR/oLTJleQRzP6rcVkaNOPFQWaTjVVAriryjVv+cytHhu2TSfLM97agkLPcXS2zEDoe CxXHX/WxVk3kP/nKLyZ5n1S10i9srrSNRvZEgtQ3+kwvLIeKIHjAcFmIG6U98VfMP5vXAn/NLzW4 YtTVLqOp6/u5WSn0cdsVZP8AkH+T0vnvX/r2pIV8saY6tetuPrEnVbdCPHq5HRfcjFX23DDFDEkM KLHDGoSONAFVVUUCqBsABiq7FXYq+d/+cxfLhn0DQvMMafFZXElnOw68LheaE+ytCR/ssVfKuKvv L8i/I/8Ag/8ALuwsnnknuL8LqNyJBxEUtzFGWiRTuFTjTfvU7dMVegYq7FXzd/zmTrGpRWPlzSI+ SadcvcXNwRXjJLCI1jU/6gkY/T7Yq+bvL8OhzazaRa9cTWukO9Ly4tkEkqJQ7op2O9MVe5/lZ+U/ ki6/MjRNV8tebbTXdJsZDeTWE6m21BJIULxUgkA9RRKAWYAU8O+Ksb/5yp/8m3c/8wdr/wAQOKsB 8m6J5R1W6uI/MvmT/DcEaBref6lNf+q5NCnGEqVoN6nFX0F+Qv5e+RLG517zF5d81f4me1sZLNl/ R89gIGnHPlWZ25lliI2GKvlzFXofmP8AK2z0r8p/L/nqPU+Vxq8phl02RQCPikHKJgatx9L4gR36 4qr/APOOcl0v5w6CkALLN9ZjuEpVWha2k58h4bVxVj/5peUG8o+ftY0IKVt7ecvZ1720w9SHfetE YA+4xV7F5V/Mr6t/zi1rNq0pGoWMkmiwD9ox3x5qQfaKWQD/AFcVeD+VfL935i8yaboVp/f6jcR2 6t/KHajOfZVqxxV6F/zktp1ppn5lDTrNPTtLPTbK3t4/5Y4ouCj7hiqc/wDOMnmCHy6PO2uzDkmm 6R9Z9P8AnaNyVT/ZNRcVeO63rWpa3q93q+pzG4v72RpriVu7N4eAHQDsNsVeoeVv+cYfzE8weXIt cWSzsEuohNZWd08izSIwqrEKjKnMU48j86YqyvSfyv1fyZ+Qvn26160NprV80UHpMVbjb208fEqy llId3Y7dQBir53xV6dYfl3+T95JbQJ+Z1Lu5KIsH6CvdpHIATkXC/aNK4qzP/nKWO40HTvJnk20Z hounWNUoOKyywhYQ7Cp+JVWv+zOKvE/K9v5buNctofMl1cWWjOWFzdWqCWVPhPGiHqOVAfbFXvP5 M/lV5P8A+Vl6drnl7zVZ+YdH09JbkWrBre+Sbhwi9S3f4iqs/LkKbruMVZZ5r/5xP0TXvMOra0mv 3FpLql1LeGEwJKqPO5kcV5IWHJjTptirLT59/J38rdAt/L8eqwRpYJwWytj9ZuXfq7SrFyo7tUkv xxV5b5u/5zDnYvB5S0UIu4W91JuTfMQRGgp7yH5Yq8c8yfnD+ZfmK4E2o6/dBUcSRwWz/VoUZTVS I4eC1XsTU4q+nPyE/PO186WEeha5MsXmu1Q/EaKt5Gv+7Ix09QD7a/7IbVCqss/O3y5/iD8rfMNi q8p47Y3duO/qWpE4A924FfpxV8M+VL62sPM+kX10sb21reW8s6zLzjMaSqz817jiOmKv0exV2Kux V5T/AM5Gv5CHku0i83xzejc3qQ2VzaBTc28jIxaZFb7aKq/Gvcf5VMVfMXnD8qLfRdBbzFo/mjSt f0UMqKbeUx3Y5sFHO2apU77jlUYqwnTNTv8AS9RttR0+dra9tJFmt54zRkdDUEYq9L/5ySu5bz8x Y7uZeEtxpdhLIngzw8iN/AnFWGeTfJV75qubi3tdQ0/T2tkEjPqVytqjBjSiMwPI+2KvpH8hfLcP krRfMlhqeu6Pc3eqhDZw2N9FOzenFKCOPwmvxClBih8m4pXPJKyojsxVBRFJJCg77A9MVfUf/OI/ lzyXJp155gglefzVATbXUMtALeGQ1RogOolC7ufAr81UN/zmF5O5RaP5vt03QnTb9gOx5SwMfkfU FfcYq+bo9Tuo9JuNLDH6rc3EN1Ilfh9S3SVENPGlw2Kvc/8AnETyf9e81ah5onjrBpEPoWrHp9Zu QQSP9SIMD/rDFUg/5yp/8m3c/wDMHa/8QOKqP5H6Rdax5c/MXT7Red1NoZMMY6u0cnqBB7txoMVe TYq+x/J3/OTv5aP5Ts31m7k07VbWCOK5sBBLJydF4kxNGrJxalRUinfFVPzx+ZOh+f8A8g/NuraQ kkMNuwtXhn4iUcJ4WVmVSwHNWBG+KvjzFXq2gfkpq9vqenahL5j8uCGKaGd1/ScfMKrq5HEr1p2x V7l/zkNqP5W6r5W0Ya/dmWC7vHi07V9NZLhrYiM+tLxUkSxghFkQGu4I3AxV84+dvytXy7o0Wu6f 5j0rX9HnkWKGSzmpccmBPx27br9nf4jTvirFfL+u6poOtWesaXM0F/ZSrLA6k9VP2TTqrDZh3G2K v0a1KJ5dOuooxykkhkVF8SVIAxV+fr/lZ+ZiOUPlLWCVNCVsLlh9BCEHFVv/ACq/8y/+pS1r/uH3 X/VPFXf8qv8AzL/6lLWv+4fdf9U8VR+kflp+b1neQalpvlvWLW8tZBJbzi1nhkSRKEMvJVOKvsX8 rfNHmfzH5bMPnDQ7nSdat19K8FxA0UNypFPVjqOPxftJ2PscVfJuo/kb+Zlr5tudP0zQbyS2hvnh sb8xN6DRrKVimMhHHgVo1T2xV90QrIsSLK3OQKA7gUBYDc07VxVdirsVeE/85Nflp5+84jSrry/E l9YaXHL6mnq4ScyysOUiq3FHARAPtcutBvir5fu/Ivnazufqt1oGow3FeIie0mDE+w47/Rir1L8o f+cb/NOt6xa6l5qsZNK8v27rLJb3K8Li54EERei3xojftMwG3T2VTL/nI38u/POufmZPf6NoN7f2 JtLdFuLeFnj5IpBAIFNsVeX/APKnfzU/6lXU/wDpGk/pir0v8gvyi832fnO41bXtFurCDT9PuWtD cxMnqXMyeiqrXqeEjnFXmn/KnfzU/wCpV1P/AKRpP6Yqz/zn+Rvmqb8vPKGr6boty+uRwSWWtaak TeuOM0jwSsnX7Pwk+HHFUs/LHy9+cvkTzda65aeVdVktwfS1C0EDgT2zEc06dduSnswGKvq38wPL MXnX8vtT0f02STUbTnaLMpR0nUCWDmrUKkSKvIH5Yq+Jv+VO/mp/1Kup/wDSNJ/TFX2H+RfkiTyf +W+m6fdQmHU7oG91JGFGWaeh4N/lJGEQ+4xV4Z/zkd+XnnnXfzNuL/RtCvb+ya1t0Fxbwu6FlU8h yA7YqyH/AJxX8keb/LvmHXJtd0e702Ge0jSGS5iaNWYS1IBYdaYql/5y/wDOMWqtqd1r/keJbi2u Waa50WqxyRO27G3LEKyE78NiOgr0Crw6f8vPP0E7W83lvVEmU0KGzuK19vg3rir1jyN+WX5q6d+W Pna0utGmitNZtbf6nYPvdyXMNyhBW3ALqvps/LlQ7DY9lXm//KnfzU/6lXU/+kaT+mKu/wCVO/mp /wBSrqf/AEjSf0xV6r+ZX5EfmHL5Q8ow6Lape2ei6YI7rTomC3KXlw5nu5OD8Q4Z3C/CeXw9MVeK z+R/OkF19Um0DUY7mtBC1pOHJHgvCpxV6/8Akr/zjl5nvdfs9c822T6Zo1jIs62NwONxcyIeSKYz ukfL7fOhPQDeoVf/2Q== uuid:082FE9AF093111DC89058E734AFD0A4D uuid:082FE9B0093111DC89058E734AFD0A4D uuid:082FE9AE093111DC89058E734AFD0A4D uuid:082FE9AD093111DC89058E734AFD0A4D AdobedC-    u!"1A2# QBa$3Rqb%C&4r 5'S6DTsEF7Gc(UVWdte)8fu*9:HIJXYZghijvwxyz?ǿ{{ȿw߅=#bX켟vN[[_]uZ}omm vK%h%q ƚ=K/lSKؿ{?cSwM)i;Ge ۖ3RXwSd"vzL!h[_PŌ~U~~~~~~~~~~~~~-V}w^76st?HUǁ6:.MSQPEK(28MNG${jٲOy/G/bG͗9{?~~i?C?fl_Ȯ!ԙJEpF[]+i]6ܝaxpd=E-d-=<~~#zO;uu[@_G|j)c-08瘈-k)cCr5~~.0{+~onܟ%n-&ό_lv;3[3[ʌv>axaOLQG߽߽1>ZX3*L*%N'zj*%/43Ĭ)RG ~~^,09~dczWR˹h*a;6hzA3<l0ͫ/s{{gP>7f6t>^:6gTN;)UO>͗9{?~~qtrvf_iuJ3:SV?3}S:ڗJoZ~DP.xxc4_w{5YC5y6{ULtmJ(V,nP߽ȧ/ ?r/d~Eoiwg~v}Lw ..*Ϳ/Y:LG 1=Dkwn諪zvܛzyYY1g25تX"sPR0C4T}߽_O{--9?]XRJTL 2 =߽Kſ?17~vGNؽ[UJ tfq{7O{~TLbeu.{{#߽߽߽߽߽߽߽߽߽߽߽߽߽߽̿\̏Gwޑl{okjN8M6GR_l{U?ٲOy/G/bGg0T+~/bnM5oOۗ-7NȦ#{kS=WY^}ڵT+Fe$?߽a?#6[wv|>Un:UN*p~hSqnǑnb-DP[W ,߽ǾHgt"{ssUS7m1m=F&*,]HQ¾N-쎣PM4[w;)hi3rII+ĕ> :f{[w]|\vtvnېE4Av֫1t{oͶ6zY uZ8 _{{#߽߽s.]e+Zz,n/K-nBw!!ɲ~Ⱦ\evA)QY-pvlztuڽORF%j6Z`qTRX(i fҷ=2ѿ'̽c4EXeߙQM,?mOlXg q~jρ*s~g|j_Mt![Wxf*gQJ숋vK'rH:{{ 6ڙZ\FYg`3|+FKU4dJ8߽߽߽߽߽߽߽߽߽߽߽߽^_-?{{`}߽]O>u{u=]{zsڝ7.=úkmwDdDf b8J߽ޗ L%oKZ=SYVd=&hĠ7ؾjV#ie}6~wQ2?}߽߽߽?[ؿ&v7fRo>f:n?{#{_sf9 Q6fzgk=Ԙ\=&rm+><rt_pvOPg*lN9Y_ >ISψ3Ggu1!X{{+~h&?>]_=қ:@jj:]0\;KY9eSl ~{{{{{{{{{{{{{~߽߽a}߽߽߽S b;r-o}|H]/ZVT{B}[霭u>#UUae>~?{{?U1/H~~{{{{{{{{{{{{67C`ۓMrn UIi^}Fzڇnl% /~d:λpt&5=뼎3mzMY,RU^Z qTɭn~{O/{E.-.l}VSw׹/]f#6wx#/~{#/{<ٻ}dwwavb}d;kc[0zHvfK-=߽߽߽߽߽߽߽߽߽߽߽e}:{WzvQndwFvZxY7'=@&~~{OȞ¨zho܁ꥬ%C?..iqxeqph=U~1oO>Z-=޽CA[ssy Ϩ9֪[*ƒ}%W2 ' CםS31b.NUtSc T{{o{{{{{{{{{{{{{{‹~_Ώ^򮮬nha"I!LvڽwpNOCBI3O3;{߽2`$E˹Un<:MGUbj)(S  eX㔫20O߽]?E~t#eO{]7O4v_Еխ|^JTOA{>n'guoynnmu~&qYI`@԰ml i%~w9_Wy1}~{`ѥ`z\WgY:~gLCS"_Br<,>)Q}EnߧXH0v}7vgVQ{=dp*4߽_)Yܔ݋+9ѻ>]U3ͫOELNzqc0#%Ui {߽> oOWS߽߽-7Tn_]ݝ.ɉwjΓjb.3mfi" /6%Ǥ[?&%oϚc;eDcgwܸΏmn u^DAMSWfhM~޳/֝gڽwջ/lXe-mM> M[ Ű5>}5I(]#߽?339bng۲< ljmG0'goOq~e~~~~~~~~~~~~P?_{/{{1=Cq۴]=4SIҟve^|ULm"U52$T4+aC~aXv|6~$#{Gcgv>f %hj>[[K,i"߽oOK;߽߽yDy-QOsuIv>B|3o={waVCfc;is* A nVY଒yiB?'>.g?#>'Fzd.{)+]>ksغ* gY27e {{/xGW,Gȭ;uoKvݽ| z6*EiK4v+ښ)zhz&{{{{{{{{{{{{{5<-gmj=Ov A:lNI#q,U]OZ&dž<;,~)ߔ=f= r!r~5oݵ|̟Ũ('Q~zl{g>t*˶cvNя;~yL?MM2vr[mSh)З==߽߽߽߽߽߽߽߽߽߽߽ޘ/!C׹0#>o.xlom<ɮh6=%ҭ& _%t`m@UPӨ߽χ?ŸL|hZHk{NI!imkw- RWSO!#C߽a~{yGOqt}pn{ǂJ܎'{jli^IE)cHk*mBA~P_~~|nvRIn/ૐSI]Gݙc OS&6J#ɑDz~zu{{{{{{?3F1gpdf|Zf* Nz|vN9f8E5NCP${߽߽߽߽߽߽߽߽߽߽;_eoeၼ{7{{O~|Rjhn|jbk~A3,m-E54ht,߽WȞ쯋}6Κ[`n\2O]- c&(ZXj* gR}%qgߔtU럑c:=[J*}O>ؙ!a\/%MR4MYR;|m[Gqwg^_ܻWsc)8 "bUO ?~~~~~~~~~~~d5~EMgM.m 1u?߃w;}]{Gp@L Tܫn5\PPi)rت#G [E߽l/;4<=$Ԙm+Ur;/6mTW-)Q ѧ߽~~<:̫b_>89{~~~~~~~~~~~~ u̳7swpozS|lmYJR4,uO{|YQR&He>~6Mԭ%GhwcgmM&][=n)3"߽߽߽߽߽߽߽߽߽߽߽߽߽W3/VޝarÝuq9eݽŕР\v#,lv|+j߽3T|_ɟ+$x~? m4Po_qt߱r$Z]`~_~~~~~~~~~~~(?S7t;-ݗ4qkz|]ŷ{k~L3b7?w^GQ<#OM[߽߽6?+7pti!3{W'۱krn .LEWmm=:y´OoLz*s{{߽߽ 6{umy;g=&6sl"bzXͻRD8E{4#߽d߽W%|+&7{[{~Z6ʸ0wgr[ryzy\v:}DtѠ(~5=ۓ:Kn'Y~ovgcxl`U}Wf2bhfd<{)D]9x, ?G{|~?f,3ywhn>;w;ͽ39͝aq}_x)$H'xIHE{Cc?^χo~ ڛcWu)src&: rbjdY#ueb4=D+OP  Ϣ?2}+ }=߽o~~~~~~~~~~G|e?#q|C^-Mc.[e6*]{_ /u_~~KoM߽߽) B:];wg@azr7o+v3VfX22d65Xh^(7gućk6rojNjڃ>c}V3Q樰xL_! MFB$QGKVH~g{{{{{{{{{{Ko5^;oc+_ۃ Dӊ&"$"iSb]oM߽߽|Z#n]ݛS\v.ܻ~6b{)eo3-eo~~9ˆ?9=Iu9]_خܙGٿeM֛][Q6"*8k"b~O|~{ k+NcwYOpoljn)+gX*lڍIvyW!9*W)WJzZ8߽{{{{{{{{{}D~q2asG~#^vVx6EeqǸ&V;AQ$p=LoKG&?",;K;g05j>6~ٛJ6f7Uc{sgZ a vhOb_6]6S}~Rgr8@m6~߽?/JEJ~Aߒ|u`C;=v˛56cdNŊvNgHG5{߽ڻW_͋fGj|t;KQU&vatV#WsN';YG{xY~T [qz06rolMgYGM#Թ ]EǪ~kvG23Rfvj)mMX`@o{{߽߽߽߽߽߽߽߽߽߽uIGh]ǂ =߽ނ{Sܛ?Ln61][MgjS=]LTS'prTGKV4)N߽Ѿ0c_U(E[Jti*#(RgTARX)#ϟÏGWۇq_gtmrTR\Y^U]*8Z 3E/~~N-S4|d2m*lR2~tw)93+G o zjX Jx {{{{{{{{{{NIEVsқn6#=xq2`1--uV7]XgTr{{H;'{﯈;qݜmYϻ3VP|9$}߽٧\𒿞!t||[?Q۝[9Ē]ѷ팿YYJN퍹Wr9޶&B59J|#ΥPA{7{{{{{{{{{{{{<]ȸ&ѹ7n-ʹrvf+s+<,9d%|O;10#~a^_妠[OI:+7h|d; @*ո[ j~l(?WtlXV>42s;|m~߃is7Pn ˃eo8 (x߽~=tgs{v/l PSt4hҍGy{~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~e~i|9џO,4|988=ݽսS` mV4g18m9hgcx|кjԌ߽_YK#lo~~+ʈ))?/jzb!ZIF 1 {w]}yx؝ѳsϷrqˎ*뱵Tr{{T{{{{{{?t.uyU>Ht]o|U.b &%7iڨ)ZuYdB{{ ؿG__YK#lo~~/:k/%t[c:Jc+sy(;Kjl/&? i1R+Y{߽~~~dcp4壴sͩvc'.?-z -l9v6Gi96GUe {߽?;|߽߽m}7vbomOks Od* cwMm\O 3=E=]<tUKU U4" M4r,lYIVR6~y߽߽߽߽߽b_ ~5n|v@<tvuUu^mKK 9Z NW YKdQ5;RMr8_{{ؿG_hutl|fbl^m ]Fݸ %=F]>vm|W-$X 6!є{߽߽߽߽߽ج+'\&Yf2ՔV'!+$AI 4ҺGhYPO{{"_YK#lo~~v/e{,7{{Sm?[Zyj$?]ӼGO ÎZjV5 Q߽߽:zzx*')iI)E6hX2m{{{{qS}oq]*)7G_GΓmU))Ss|^{QU4 @ :~hv/e{,7{{;|߽߽aOyV_w?Px<7˯Lg1ch{z܎K#[:C4Xo{{{{,WƝŋ#Z|f ٜ¦~Ř۲V#bu`rY ,,mE:Eg0р{gY>d|u[C6߽?y3sm=׶tppm,-Un;#ii!uxݕ>~_/; ŮuXZ=KSu~۹,~~ v16S 5K YiEbѸ~ñ+/g,߽{n-C=[Ouaq{kmɷs0do=V71cjH* d~o^ñ+/g,߽߿ؿG__YK#lo~~`:/ŏޟZ>K| A}]zpwGWM>~?{/v_`l=;{o\'jY,ܙں 6hñ+/g,߽?3>|fv>@-9p#ޝ_٬Z"q{t竱x+HVx#+@~c-7p7ioֽ{q{l.ٻc=ùn; ,5LF&{{ae?>:~fXXAe_ܝu7߯xxd~c{{CGfMfval~덩OOW;7fclKW]K_rUS2F wP}ñ+/g,߽߿ؿG__YK#lo~~`3wſS~Cl2o7Meom6t`MG?WM>~>{{{{{{{{{{{.*")ww!UA,Ā\{)ڟ=>>- țhnS-®:jpPxȕFV=klg[OtRi -OCYl ;BWJԒ6.0YbbwPdF/k"Y2>j T.9bu #߽߽{{{{{{A?[r]lgi>W6[Oum̍Np˷/,ԵUPSKS*+({;|߽߽Y>d|uΑk37qm\yÀ`A_3{=]]2BƑ]P6{{2~ hO}߽ޘ^1~ukPչk)g`1 voV6 k͵hPKLMM$ ~[?z|V/wC>D-\4?xVY{i'S{z<$Ե/$4~p^ |~z{{{?_Ϯ=8,%F5fwV}YZ7C띡`tRiVW{߿{{{{c0/_%o_~~O߽߽߽?ݟWXsvN{v-Պgn줹\oDnzl^+!UO U+>{F鎯=LlL~~~~~~O8h*l^?JGXtq9L+`_zuO~u%?}|>#>{IjXdIVݥwm~m}u~~~~|Y+?n?~~~~~~~{fV?u|wտ7an-gvO`a6.Ud}Y۵}6&BiWo64ch)kZ:=Y2𠼭~c0JqQwTrxMfL&* GcQF,߽8{{{{V%2&w4K<8Δpxj'FlʭiU7eu\ N.k8HգY7v{J.oȣ6GimΩRc6>-єc^!Tnm&,~t`. ]ϸ= ef|0Ѳb"߽߽߽߽߽߽߽߽߽N_M+|yqO~YwvUGJ!O]٨\v7읕F!wI5F/H&p}1Q?ɿ=߽O g.SAQ%,QvǼ,71{Ͽ{{{{{{A*]ve>u٢y!^Zꍋ +ѾGjfA߽Ծ=z{wk~잹}wj>󹬌]֗F ʬ~&Y %η>ܛã VTbvO3ri̹Q<[sf#F9k=]~~~~l|U=tng(O^UO{fUTׯ_)]. Td >bϏU3e:+"~⡚Lv{ "#Zy^!=4{߽٩~~~ooMe2?"߽߽~~~~Od|UY/6QJʅlޖۭG̨i'Bѡ>~g{{?쾾(S~~{{g/{2|{J}׿.>t}շ2{vuwnlDmlad6VfWS)tQ5~7{{Koqtu=MB=3wf5la]'Igdv J,=H}Gl~~{{S <׾x?g۟1?(>|9ڿ 6}-޻vkQ]ոz)?aZ|@O'+7c~wo+.߽߽_uk2]iW6a n涖_u3XԦzPڪ)%>D~wg >*϶~adoL^ߐk{ m8;[[cunjTj<}AL{߽ު~q ݾoV[s}%G7['t$Ī&w5k~~e}߽L*t|x>e|U y]YɡDܓ;Z)(}t>f͗Vu'RMz 6ج$H"֥۹z%WHI߽}߽߽߽g u߽߽߽  ]ht>z_*p?#p}zL.#*_fRVgSNi̎O~~>j3/ ] GZwRQVu&ؠIqFL${f: |c2MU'(__ۻ.Lc;&thSy1vnJŴBA G߽}߽߽߽ް+'Cڝw]忳Cz2jbTY;5GB$55Ej+UkznC%D;tgrռrUKKUSR/P DR@߽߽ؿgU՟K|puye˝ܮoнXoY=ٵwߦi!]V9%D,~~VG폎{ÿ=̮K7WZoZ=Ok(v zj/l}rk'SXʱ{{o~~~~4r{0.JSۻ[^3]tӭ*LmI"#*ՂZ߽zqYtyZW4sRd>At$9nRAQ*GM&ĪhZQ{bjkj+kj&Jj枢yĒI>?{{6;tQ:殭^Tv֢3O5ۗuTF'U3{߽߽߽߽߽Qun[KmUni>8Gը{߽k~M]=YUc`6C:m]'&'Zi%k<9,ğ{{߽`:t?Q.?7DU[mMk8-}ܴ~:$ MyU{T߽?'Y7=ǿ{{߽߽_ōwWgl|n,Qg6e&=%5~;hfcQ" r} !@.=czz9Aݻǫw'_o=k14#`dv$x|.Ũ߽mEO_Q}h[+eT|f+fcEo' ߽ЛDl ӟ;voVѕ5SX*, K?[CC,Q}B)UK./a~c/{{{{{{{{{{SK?ӿ˃:jf|,f w&XgTߛ]*Ujmf Y}k/J?-{ ~lU[9bua[綫vccwF;ga<؅QSV>=ibt?= .^9۴_7\n,>3lP<4,kughVBjӹ)w&Ylj!~B/~~~~l_Y#+߽n׿Ϫ'zc݇չ!콥Wٵ9SK\1hh_ I{{??=`{K]]~>vǿ=5>{a.;5=*7xWgCk"h߽w{{?쾾(S~~{{ۧ?}vh|WdI>5b:j7b>lg1櫩V%3-TG߽=߽cVwz;iZ} *ʻS0X-MKFѭfJ#k G߽߽߽߽o ~v ^_߽ңǼ~()΋?}k:scnix=ۛ9%x/cǿ{{~~~~a__8p>K޾{{{}MS-vc~9ͅ|f[;bQQf'OxWb*zlmy-۶q#fz Q-SN#J~zTQAWI<ԵTEQMSO+QOQ2 ȡV~~R1):׾:Bev;Lij(mhj]]YŽ߽g u߽߽߽߽߽߽߽?,Jy؟̃dv?$۽6 (w ~oa>9y&Z>|ݞ-srcs9کbzQqS%߽3S o/^.??s? ߽߽߽߽߽+}awfnX]lվ<pU&1I*X%͏߽߽7> ˸wn૒=smǛIkrJW䩬wbKrI߽߽._~QEUQC$l}p?A{kIԳ:q[00&gҠmG!9տgS57ct W(4.|aw Rɯ{vfV<|yQ&S&dmm+r,0&{wh12uXÀW[oTZ\n9 ijd߽߽{? TOo{~~{{{{d G|i{{{{Cͻ+{}~~~~~~~~~~~zCݺ=)#Mvm"Ô.`%q(0F`z6WwPYN{{{$}=sG/--8e1lhߛ0bcK.eMm䫫T{<{_{ ;zmyzp1u{n=G}˹QbpU:ǒ=߽ݣ /WD Oi"gp}N쨣@~_o= ݿ%=F':_z&<=uYWU3u*wI%{߽߽?m__P){{ ߽߽߽߽߽߽)?$>/>Hm͟}vO@}B)w,v/r70Nb 51ahfMU=uO~~~~E`~F?Cd{{p}߽ݟ7cKUwo]ӽڻeoN(hb6(`hw5O # T{{{{{c0/_%o_~~&)^ݵ;f<vٛMۛnv:)J\6FXR-0%%Lˏ<2$&荅Qh:`$H## ߽߽F뮾ꍧ][voZl-O{la6vӻ'nmv H )bM^C!cj{/`ݙxONYGvQW?A$dFa~c=Sc޿~Qm yǺwG@vۘ =M=vW7m*Lf+Gy({{++՘_6RI&TcQ5M\`E%MvdPDld~{{>X,ܟ{{C{{?S>Av\i9ݾzvΚ>f'tl|vJgi&V*ȴԙ'U~ZY6[n2=gpY*6k%c*rU Eu dHȅX~{3ek.g;t5ߔY6t*aox0Cb|R't:斺g+H"+tt!Հ*{{{{#Nā{{ |~_~~~~T?CЇa;OVkgIR*~Z|w%'J㧦uWm9(RC{{{׿?? OOg:ʟ&OpvCobz55@.{ e9*7S r߽Cn|T^dg;s/Jr*>띥 H^$Z],d:J&Br~m'^fJBX祪M; SUB"vOIbOGo\75JmCNOnua`VԕBHy:{߽s߽߽߽߽߽ء=۟+mD>^?݃ovm)³Xa+3uSa䦩3ub=߽n<7]=߽_3~D|?{Ⱦh{ 1uT{=m}{U2.2vnVQ.Mh8k~~X?γ!ƿOx|{{{??kvm|`1{eo g 6| bp٩"pVHe<~~XۣW|j?dnyu]M*쫠wutra2Y߽?'Y7=ǿ{{߽߽߽߽ gM_߽߽߽^!ݕ{~{>{{{{{{{{{{{> l_I>#oYgz7_oJOSCtF'JLTHǽ߽_>S|YO>8yNn6?7(QnM;i*X+==];+^{߽iix% &h]c`U7PUqdy,uFO1^!t"FYeAf$(=߽ۖ{~n}Fn3Wg7eᰘll9 S#Y2E#PI{{{Eg7A;"\?j 6}YAQM[C;yjdLC%$J}=߽߽߽g/̏~bR._[>\1 ٿz'=U]cԱTw xOMṷwr5kIG1r4 G߽.q߽۟jCR-D W{zU&٥:^׬i#Y)UQ}`̈́캭Pߚ ~F69wOju~ TPNKQ(fdO߽OPi_=~f,]-8mCM6՝lXq;)AHPQ{:%N;s{{.q߽۟%{֟ɯ߱nwܖ| j0{)w:66rn﬩*џ {{~~~~~2Ͻۺu]]ڵ;v'O=a`rd!ɘ0, M*{߽$ > |{oڴ{:0X=Qs4و9;C)6.M;F 7߽߽M˗ދ6ftO:uudG _6onyzYl IQ2T)f#{߽ޚUĻIn~vS0}U^>]S|]6Okm\Sb6%/1`kw@o5DԻf|}̃ǥcMܽjw_TRnwHEC썣٦XHVv\nfR<\^IӪb]?o{,'>`u]q6S Fifood򴝥1]k)i5ԐK~hNvwX7Zϑal=߱CLݛ!##NRQ&@ʱ9]%~.q߽۟ݕ)LV/0,/7gr1{e9)ޔTr[9E[xNJmK%Y}߽=#}ks|ڟ)wWDZۊ==烤Y U޻f[{U![PU2{߽5:%N;s{{g>6G~>Ld6n˳ٛ+r4[;(i6)8O2,9j`3 '{wa_qY?V}Þg>;mْ Y#2HbX }=߽Y}~n'>Im2+Tԛ&NcS吝]4^Dt.~o{{{{ /o}|<H rlMI*q v7& Ln{nA%=nw G1Aԅo~~.q߽۟ɷPm_>=ݑۓ3[*bd jl[:=1]IVwH5{{KoyO}ۙ VJ?x~9pX ߽{̮~uo-ɗE3w>?pm-ò*?f'[i:X<{=߽߽߽ވUĻIn~~:%N;s{{.q߽۟^^ ?nMs T8<}՞޻sViqnMU2*gFvT{#!>.d]VƠ޽UYh1g6>aSaÔj|Tb~zlW{'߽߽/UD{c5nݱ[sww5[o?\o::؛7PM\7[{ً߽pA~]ջ7>mn;8֤Xcj\$hTk]JB1 ~.q߽۟$u'3ݟ;?ِC?{w1C[~)55!~w('Crw~kz˶X7cPʌD{;s>֎iiT!tY{{tؗ`8i/=0fˏ{f6&˭]]M[.9tYq>I*ʽ߽߽߽߽߽߽߽߽߽߽߽߽߽m1o7lj 򣬚smY6'rjM{ K4Իcz67)NYy_da3Ѵʒ/߽޿^ӥUfɰ3b ޽o{J|ai>޸P3#[߽߽z #N9zkgSueb7zzuUqե=Ğ)b>~C\MMwb;'>DUJJ|O4txf}\"#SG)>~t^Kn;soJg|ͥIx.ת;neGxvlUApnJn&jVI {{LkLkLk~>f~~Fޯܽ_6P(*fgje2l6;-KQ%3ȳ$519P!>~${{Ӥ3woqu_Nc.-BSQCݹ|E>B sxguOQs?p??c_~~p??c_~~p??c_~~fp`v\ݛC9ܻg;wxһ UVtn`Е"{{ t|YkgOY*6o,^Vee&O KG,ne߽߽Ä-{Ä-{VN#cu]wSv~^{7QMIQ_Q#oM~[%44 .nRG߽_~~vztFcYn.^vlv%}SB*j(qU/VAN|, }߽'LkLkLk[CvzlնTkhg1lqWaj^N6Q,_~~QQOIO=]\-EMMD ==<(M~8{{{0~$6l^IӬ&:);;6fE%!cDHV߽/'/)n߽߽'/)n߽߽b~yq,k!Ea?"z#er51}𚮿!_W2E 1#,Ab{{5oߘ:vevh|?6^ SGۛs8|=\hSM-bk)8+#Mf?'Q5%~>dwX2~~.>?p_mO2!g;K~^b-ٕV$x#v*H{7'/)n߽߽'/)n߽߽'/)n߽߽6wb>ٶwT}vb> daJVNO ]5>Ms9FewpX 63kq6#K-nK+V;y"$gv ~eK'/)n߽߽'/)n߽߽'/)n߽߽Yޝ%x[ugam.0zfӏ"E3#z#~~){+#bM "hӴzvj'ӻST- KВB~{{{{{{{{{{C;_puCܪݽۻnԄ#dwSSRWW1Jz:XgHv~FPo\OS v=߽߽߽߽߽߽߽G{y~,O[opc_S߽߽{{{{MG;}߽߽߽ yX?_~8?~~~~~~zA{߽߽_Gւ{Kw{M*{+Y֯,#)FCjIPe>~~~~~~w L>,8y,cWf/o}M?蜇H?&tBH߽/߽߽wX՝QK ff$U~i0'`'N5f=_jf=Z|UJL6ژz+T䀔U9'C?5>L_->D|Tᠬh\D0iv~ӊς.n{{{{{{\gks,ŻznKk<&4u^skRU#{߽߽߽ޘ O?K߽߽߽߽߽߽߽/6+܍yUn>ToIfҒuCQ0*A!O{߽߽߽xLTu|PSya+A)(TI <>juH{߽߽-߽߽߽߽߽ dO|~1Z f\u :Fs}ŏWd6[l9<;)~~~~~~~~~~~~w|蝱׿'uu$c3om24 `Y~S ѽlk}QCQQ޻z  ikZiv-M}b;VTA~bOz;'gR쾮L,8M%.ݻrҶyn'\QS+#_{{1\/U+w~~D~~~~~OEO˿?O⯿{{߽߽ yX?_~8?~~~~~~zA{߽߽?oO~~X7_~c~~-c,aﺃ߽߽߽߽߽߽߽ۛ+w~~O?WݷX%Q>Ld!fGm) =Ot6;j0ۣg 6yzFUm6[q*(rʇ=߽Wg`U|`Sm<8~龺Jz*iHSo]0lQQKG2%߽߽OoS?kuy^[^\jmzs 1c1~e~~~~~~~j/q_'{Wg=mjj41iƥ3>ս߽߽߽޳ϙcc.- KA_OeWݝœuR|-v6ܬ[%K{W{{{{{{{{5z?=ɗe9`STP7sY}KQ"COO`7U.ںǣj*~L?[?'\ oh~e]zlmɒ;Fʰ6J\5A$,BTV̬~iƶ_D;՟&'ߍNv'|ldafס|pӽEUM.2٬0GtF{og u߽߽߽߽߽߽߽?K8?`:}w~~+a|?N;}{klH"vU?Y[.[*lURa*eI^ktTU45UURVQ%5U%U4 E5M<ʓAQQe`A~~߽߽߽߽߽߽߽߽3?˷vHN|b3,P az7+6ܒΰLˑDh2##U,r~~~~~~~~~~~~tͣcbgYk z{!ZCLisWxby1fx|kɤH"{}@lYZI:t=,Fg#;a`%uzt7&`uk ~{M{{{?+keώ TOsSAA;>]d .nagO*5BO{{߽߽߽߽7~[-I1*754n6v8碫A 0>/ύ>/|_w?{whlJ2[/pPgcד&/0MIW$rM"::S~tߝ?՝]w;?d޷jサh*G%լAK~za>(S/~~C~~~~~~~{k[8;c+|e܏[Tb6Zʚ~)R^Z,ĦH<Nii)~V8Uݝu+7/OvN2 Ze ,hR*u p-^o%{~~{{ wtu^{{|ʋ19E1y}ۓKEQR͑JP|UH߽߽W2Bw/iuW|鸱g((vgbĭf)%GO37{{3NgZ͸wNOsX>@t%[Dg#]vw?WGOQY+02#~tEQgk:e9l?`|Di%_]vD9k3[GHF=/<_#f{le;32gլiEAP=?Vm<_2-}m~tI/ßr1%Knט͵qHwaWMKzɧpF#g~z¯_#c{'{{{{{{6OwOZ0]sݡ0y rXm^Tg'Qe)&MIAO3!5'J(~f?{{Cͥ¡IWs\uTee+ᤨ06~a{{{{{{= so=Xηƿo{l{{~~~~w}? |wh{Ͽ{{dAp~?Ϳ{{ۧs0/]3KV8IjG:)"V%PtU&a~zj{{{{{{{{*Q1~ϗ-&oҹ-;2=o^ᝩ!kƒ`~D?O_)[OAlWdJjš V&]ǹTr@7{߽޾-y>` [\CvƵBh{fzNUwoG$2e~{{{coylߌ"{ :}=_GrkJf۹ )WVfRRFMU4q;{wv*{#{vTnm2[4!F#@~~M{_Vu}HJüsw NC0YYcBZ4[='ZbXD.۲|rLt$}UX޾ E%J(R}߽ް ~D,[1&G|.JUM%My.Ǘ):ydw3tqX,8Q} ~{Z{0l@p){{{{{{{{{{{&Kp_~re>K6ꌎѯԴَɶ[[Y 6W1!榼)hk*i|߽߽߽߽߽߽߽?K8?`:}w~~+3:O3~>|}峷^J]'Wy,-%7^~6;k^{W-mLDF'?OJ3ľC~uuoI|ٮQ綻59i[ae&TG.y Xhf45m \hf{{Q|OO5~>uɟwjml'dq6sijfv>?)D^D߽ى~~~~~~~to?~U&go5?+_v;OGSR{{t`[/sdF SPqY]YQ#(}߽?,X߇KjzwdodK& rI$ʭ9tt]H~{,kŶs5S੨wtu\$c*=@Rg*7YFrD O{{_nX8]p40c0{wnp,.6tN#.?CM PƑ{{(#G-ϋ]2liR~E?pT;F)ìULehh(M=<=Q/z1_vLޕoj6ZmESmN4svoY++&2UTM'߽~~~~?&ѿ̷wۓuVUl^ؙrm&;=7e r16uSQRQbUդ=U<ĵ~nؽ=׻#:kvO\l0Tk[Sli,.:KRGfvvfbI{{{ nJ;߽߽=߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽ۛ+w~~u5e=߽`{{{{~_G߽߽}߽ސ%~~~~~~~gnm^g߽ͯ?Ϋ]e%_a1AAQ-Bѷ\uNnE21;2ƨC>g߽߽߽߽]썏jڶzqoKqX`Fbb׼nZAJ7{{ }߽UM<]psa|:vs{{&fziNdT$0 ٔ\{{(ٝ;IvKQRk*$oCqd䞰r.ZM m"~h_~~*b3Ȳ&]]WP̪Uf{?iw&XYIAC3B\D*co$z+~~~{h5tl?歼z殭~*n֢ GQvv֝kjsQ#ف ߽ԣ߽߽+ :7xϊw,OeQtT<5}7U[ʢ6\kP:Xꨪ*::{{x{{{{f+4VcouN|S|Оo}5.t{ܵ6{m_sPjdݝG0'Mݻ0nH'YL49͐!4_߽}߽߽߽͟ϙTW2C_1[sTT8; $M"b-Qp0 zM_{{{{0l@p){{{{{[؛ ge2_zmmYrW~ƞ=$~or'Ow3442h`7.O(4{)!^dľ;zW Y}zs,Sw>SnNeP$2NCsύ?H{߽߽߽߽?K8?`:}w~~+ f.I"35?O8m]{35xݧº ZJ߽w]_ʋ\C1]d@*+VbZ8l⪉뱨.BIƻOuٙ^o^:r8]Ŷ:/ؼ.*yb"~j~~[Okommw&>cbU`՘̦>!)#q߽߽.]sڧ'Q[L[ui)UoL=olqݙjMeMQnJ}ّb,440qVG :~L_? :=O۵ӦC{#^ȃ)(_u21ej}=߽.ܛwh`{vg_mi^37R F@'OMAAKaIdD{_*|؟_#a9VvX2[׶Lv쥠1ykqB{߽/ߑ=;t=ؙNm#S {g++1[bmvt[\M+KS4I~o>|ݺ_hJٝ[KYc5pmMLЦl中|аhd<߽߽C_ Ț]u5>gs2G2Pn^ݸiv AE"`!{ɾ+KIO?]⊍:. OO+ڻ|j7nKYc9񋪪;o_Td&͊u3K7%4P?ev1Fnj Hu>~J#jʈ݈UUU16rO{{R:og&onmъ66ڻ_l2BO%DgWO:)X{{/߽߽߽߽ %|H?Ϳ{{b:{ſ=߽߽߽p)ijg6]NO*BQYݙIIf"S {{{{4KwXwc%K$PuM*FN3e.E_#_{{?o_3~YjwvMƘ;? +ck↜(XQU@{{{{_Z*z;Jr8M2#">2{߽{{{{{{{{}trVRIc魢hZ(GYo# lS-L;ˠ=߽߽߽~;yO/ڵMK^ƟEBw=',T5VHE+D Ge흩Ǔ량x|_})fG}˴j+3=Y$P,+\S,O{r}߽߽߽-[7̟=qו7'IelmiRޛƳ&ߦ<\52E&YR;~{Hs_U(O}o磷۽sGܛ*ڝ}M ̈́*>5lzҽL߽߽߽߽߽ڻ{3b*ݶVVn uXܾ>`A~~5mSk&Hi]Ի+ ij7&ӨdO5v܂RXR='X|Q/^90/?onzsu1c*hqiۙpNKxVLQ4=\o~~~~[1Foyn*[LŪs;Vlzͼ,Q`j܀{{L{{{"c,^ﺟ߽߽M?Gޚb62꣖#ckjtI"{{{$O>fOrdԹuTdqzt$USkl"7EQkH~~~~~`}|w返}k=Q{/SgA`'5q5V=@RdhA4rUh?=7HJ(2h+G.4eV\#b~{->Gw~ޥ옟gt?!smjW5O#;nlᣑt0W{{c-;S fm>j1wf}{Sn(Ud1A h/~j~~~~~~cVweDE.*%T x߽߽M_]zvvCoŽo{]#P=W,OQM=_\zltm4_ ?߽KS?.kb^=[ܵ=}s]yE_MQO٪=^+ V AZUX"~~~~~z¯_#c{'{{{{{{ݷi>3]*6g h=C]ٸٸ珂GGQ<4mZ/~{!ɷxg{{g+~˿(`{#{O7vݒo~oJY}j(iki)֊kI,{{:߽߽߽߽߽ۛ+w~~~{ +CmUd~Aw)Sq]vUMo|x+j{~~~c_;^)2ǿz;fmc+;O3K'Yx5ei)gA{߽\'w'`vĠG6-}uM6'תڹ7ѿᒒ:^kpvtI0 eGcI/~X1*8匰e,`E{Vi1ڽG./ _&ZvڝGis؜s=T{UIH= J ~n|^_^7[|ݣژhg]ꠛ {k^MZo8Y%h4ꡞѷ߽MCa)|OY;m/{喠UfOR')֕꼏P߽ϟ^4x2|i CG-Gsnfiڞ#mpŻW߽߽߽߽߽߽߽߽߽߽߽߽ {)8M>#_kb>]v~ȉ$['NMOB`+ ۦd;x7!Ɛ5ubv>E,g2UTb6FQRÊE ΰǓj2Zu%p~{{{{{{ nJ;߽߽=߽߽߽߽߽Sn_u~zA>v=߽߽߽߽߽߽߽G{y~zw~ fvɾpUetie)ܝcOS.ѪVSToά*\t*Iu5lmƯ{{[߽߽߽߽߽߽߽߽߽߽߽߽߽߽_?>&Zld;x [O6Y[7XivN2oX?ڄ ~RRlE)vЊ=G9b)( #`\:~ޗh`*HNdO{{{{{{{{]oS5-nޟ>xmh n?s X|J09$45_ >6n\DbuMulе?aVSog`B?ECm3-}oȣ;٤30K-{{߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽'&qa~ښl8-:߽ O?K߽߽߽߽߽߽߽ ]U5տ>7VU%MU]UONl٪*jj&gzrK3I${#`]WT4w^1TAܡhX\ĮRhE6IxJ12*I=}\0~~~~~~~GD7Xu?{{߽߽vc~1f*z>%7"%q%ƫ{{{{{I3x*?K<ٌC߱ϒ?kجd)wZW_׊YTjX߽?coٻ+h?_աCOSGMougs[se[rnB̅Tj\)*~9~~~~~wDBd~魢iޡ*m-Udh"{{½>-?E5֛j|QSS|zoGw.0b|RV^ɛ}߽ެ~yDņ]Vg|Xu-WQ F=Umͽy3߽?ϻhG? ʔ-}ǻUMr8 `MԲIm9~~~~~~~!o]Uf;׫՝yI7H4Rź-Rj}=~~~bQn0Fn}m)#3ϸw|,+ 4.K)&u@C|X{{ c޺Sp/\tm]}ٽ#,lN&[inm%&Y)$l*m d^YZ~HU un2%qT5VJuTTƯ ~~(_UGWGUۿ:=5m.XzFtrBX t)Տ߽}38o/3QEG8 S- ieHĭX*"O~~dS/Hv>]ػldR⠛_{y)+"o-5LEgD&I{߽Ň/~X4c bzoqUMwO 0R>A - S+c~uo%{~~{{Sf~uczH`&g#irQAiX a~~~~~~~?$7 uYU_ JBlw3'+UC}C)MN{nLcy*( ~~~~~~~~~~~~~~~~~~~~u?L*?&J]ÿs-UaHsٳѴXEuvL+P=rGJlfVj|&x!PChh蠎$[{{߽߽߽߽߽߽߽/x̨`,s:Tb*jRsltYL<5mώI۰ʨG5+ Z m/ݛka$ٽ7Vms5P @7G~o/lZ߽߿%<_?{?6˓5ڽ =WKqOsA[35FN(2 x X7[~z˜џv Fݻd{zQXpٝj)V@*{:%<_?{!Kx=k~~C{`ʗeE]~5w.wCzRY4lRTe(Uii@&߽߽_!7t?.=#Goru^X_flTy,yYcP 9,ŴY: RpM߽ޕ9sd{n5mWWA"2۟gTJP`ko<.Y<epVCLŗ&C0TsO:?ucQd֘hn kUyoh2_{{#1?[眓b-D7f>>\RίB;iv:ycn۸ΐU F*+;1))$[J{ؕ?Mj׫[ݨ Tcϵ: %H>( D-ښ@{߽ˏ-W>9u2;^1'hR^C$/lJ Vb}58CQ ߽߽{{G~5^l\z6wkI{/e qCUQ_ X>&B)b\/߽@9/?߽߽ r__{{8Y0dAVSE__u+塢dJȨE 1α #өoq~VzzzJx)) 驩HiE 5X(*-/(jO8ݗMRiv~2jީrK/m<p$~7ֿ~~7G~|^;[znwM=qtclQAOVN1#h [NuP~v#s"V7y|dwU 0՛fz꘧(|uOL*yuPldHgXgU 4`8~~k߽޽Qؾ3zޜ8ϗ9.n*}ݴ7-n6:unGY%&6<.Y֛+@ 5r{{'?%<_?{!Kx=k~~C{`+_ۣ>Ml=Gw8>ta>L-kUQS-B0 Yy~{2{h[okގ |f_hLM{aqawn8ɱٽF-b+'btO C${{/jk*}|}u{fG c*0ظʵ.Lm#WKVy[$~w='cBvW_;eOU-"}u[#mWI[r!F|Ua~ܽٳVm]AFJRUFZ,U:vg? Ң::z:j{{~~~~~~~~/%z`xno;cVvWJ臦nwwbun:n=b)T:CO߽<|hgύ}Ez[OWI A6FF+3iVgITVh_$[~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~',8?T LӝwqʲoO? )u(edT(kl}o63~hl&Sp>=J&ꜽm< Ydɬ<gh4*RVU{Wvv؝ջ:|l}مTbܸ|+G%ut5H,]H~~~~~~~~~~~~lpv9Ng69l^Os:abxi'gHق}߽ɇG+GTtg1A#Ox%N={z/#ޛO/Ii6bؼDLR%[{߽޷ 6Og{{߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽[ m)M"^kVGpG&=qQ'w/!PJ..{߽g߽߽߽߽߽߽߽߽߽߽*?=x|ONmY՛>=v^nH+(7㒫3]OhCk)srN byYղP߽AXLaNaGYۻO97#kuגc=?_Md\ZLt"}a׽;_~lΰ덷={NA9}ɺ6Nc`ԋ%fK%YQ*@~N+K|WnNwkχXvo3jLmKUOF*3{>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~lÀڸa3aT1tяN=߽vo S86 PRlj1'v OD`sw|kl5kaVu-]*)ω%{{{{{{{{{AQ?ˍ`:Ţ8ΫJdSϦ!$c62dV߽;Ǯ=mߢvꎨ4[WgOࢥ-M~FKsټVk/Q]]Q,I#~cO{{{{{{{{{{{{Ч_Q[nIPf]7Ta}iM_߽}߽߽߽߽߽߽߽ۖ yVجw?Px<5 VS1e*X50A H%}mO~~~~~~~~~~~~~~EQR:]ijŒ\=A*-;Z'\ʚv%vW J`x2Jͯ&S-|o:.&C(hee}25]j#Ty)(h߽+o^Nɞ{/7U]DuuU;yn==MT(SQ6w%_$FK*~b7Z[98=AoVedh]uܽ딠EQ;sqe*5[APǿ{{!gbm?wIপڽhFJ:IU&#D;g{rhuYwd|__|l] '͟~Swyͫ02P`1{nwn/ݝ6]=dRSO CF{{4|пϣ>k鎸~uS>NZ6~hj2****ui瑤rğ{{v/{,+7{{;M|߽߽>d|0`V|uHf>V c'i.b.#߽߽ޒ6:.>]vvv]HAƕ[mPv23TK务_{{.£zo{oO[nekkzC emd5[D6J+Db&G'߽_>iD|u+/ۛ3{dcEluPofbZl>{o0 K&kN @{?ؿoGȯ_7YK#Wlo~~%K|̪ϕ!;j|=Ozwoc6~jt穰d:onJzH櫑D/.}7ᾪVetZM")9=לHq,ly{{v۟qf `6.mfU9#ۘ,aCA OHi#@@~iv/{,+7{{v4OϺs] n-ǖ`p8\g,k/Y?C؏5UvB8gse>hSQ2?O4#iwjf:'dzs) *ҴQ6{{/v/{,+7{{;M|߽߽%?(_">A?lw?lmwrv.rols2z D 1<2.߽̾|~g>Uvv6CEP%$Z6͙ݛ"-=4e)I*jdyS+yCmQAO߹B|o*ʼ6c`uX.%_E)>,̖ =U ",ǿuTLɸ;W7VʫƘ+7>W'-,(JGHK*P{{}߽&~Db0o_alVͲ*kM,,te*3X aeI駎$nT߽˧;j l*_]rKG'nu?n>hY $X^łH^=]$ϑV_9{f|^X X]ػ1k;lfv~-2 ^tY߽ފ__7YK#Wlo~~v/{,+7{{;M|߽߽>d|e?>E~w +~m6dtU^{/|nݥ30;so~Wa2z +!x12`{{{{o©zS?~W֨o}ߛ= ;_ f̓vȍ~/[7$k)߽ވ(T{N`sLSnޖzJ, s73KEx\ SO,[|2/7fW=A$P[1]gif%UY-e<噑f$}߽ٜo!uwG1BA"bt۪ +=.љ\xKي{ǾyOel}han|v+AIh)Egg`L7zٍ%:߽6?E?p/7ds"fا3CKߋө@gM6\'(5n%1Tle>~.'qWn/-+j$|\|ma/ҮUJIQ^vsG.M4z{{+߽߽߽߽߽߽~?vʞ돏]r[;[sP]q < Jb08ZԼt y't'a~dzPI] ?r^{oۊCfUA^׊F(HC,Օ5M~vuCE[6}ݧ %ܥ6oOFC)57߽s}߽߽߽߽߽߽߽Nɼޝ_O~OVQ~/6| EQnoT0ϔJqs5<5jV{߽ѯ߽߽߽߽߽߽߽߽߽߽߽߽߽߽ha{OaYlnkvi6gLl >}*hNޙa|N?s9uXZП*>~yúwkS6Kwo*FK7KRQPD8(i"88~~~~~~~~WLMw<9blXڙ 0뎒%vC5 .7F`"-S߽߽o?K`; }_ϋh|1=?$CVώeu4Jt#߽٬1K'GO݁iVLn*'{yi.z|=MK~sfO\'-CIdg!:*:Ydԕt`A~z­~Q@dawۢr ؒ}w\]o^l .F HͮX6|$funX]_WWyISMϺve/0¢Zj57gqh*ɩ}G+k7#߽߽t~ſ_z߽߽5CL*{5&#oRb=sō#jM,1*(w,EO߽n1ҾH;mOj/RuN&~2U6٣V/Ef^|h:zz{{~~~~~~~~گo۽ژy;ZNT٬;}d}w2KJŔ5cDu~{h qtv?  (O_)'! Ŀ=:O_J{߽ޘ^5==EeDMUUU4T< CM4UAfb~TL>w*FG.ڴ0Z_ߏMJ>)Vz+*FA ~~~~~~~~~~~~~~~i㴰;hn#m}Krc&5EǝflFd&Vi]g^ ԖBÐ8kLV|2M~O?V_aL\V4$4]My(">Ԩ%L[]߽ yX?_~8?~~~~nSc࿛/:~\Mamm˱ez6f(hنt9ZZL|u4HZ~{{{{=F[p'2uB䅳oD0ZMFE_Z"Ȯ'߽[Xu{{{{{uJ~a>.nt?wj{Z٘h ]v) ja#j%}lӪb]?o{W{'߽߽oX_ :݉Oq੶[}n]/Qxc+14DxKH]߽?S˹{kf#:w5$Ϭv7v[7\Z¯U{w߽߽߽OGWviܶMUGohv\[v~-'b)wg+WGA-]..t3TN:o{{ϖ/]>%w7r|g"9ue/wuT*Pb'ov.?%#Z7`It?߽껄|o]'?NvwKe&Gv];[vn,F~Q S/{{_cG/ h~N j}њ|UGVC+ZUecf2eh~z{{{2gq|Ur67υ=F7m.-TQWTKP9A7 2kh{W{{{{{{{{{{{{{{{{tf6g,}Unn>ƪg<5FL>*ɣd|cd w"[C[6%e_/4t9j)iGzyr  {{{"°?#w!=߽޸>i .a~&.n럓_,zwkco\NۛC?9Ⴀtxܽm5LzۯuR5 ѭ~u] n?f|w迉[{;>7b tyvĦ gÙT/YajLFA{G=߽߽߽{ikq|PO6T`kWNT~j6Pu-]oc Icy> |~z{{{#oox~<>zvuj"?+P} wghlZeK2L;3AtoV=߽߽߽~73͋~nZkˡrG]{KeZ[k l^"dw6~aju7W}Yܽ{{O} cw>wrȱdpZdY"rDeuV~ 7cOG;|cٲl^h09\zDRbWIL y7.K8آFcs!#Pl_ #>ܻo?S~=n,u"TOy :˿no~رw4^`KGMCR_Hwܿ?ǿޟ[CiO߽߽Z'd|9~Nֻ?;7Xo6^y\ܻ7u^/ OEg3Q5g߽_Y?̓ Mϗ_81[jJx*9/CzZE5Je T OQ֎$$s#e,i{fN1|fYQ$X^ _KG_ݍHN^hra0YHGS~[ͣڻkcl'jlݛ}040c0{n`h pu*GMCcPƁ@~j/~~~~wɯ6xOFY|Y{odWMTx)Y'icYeA{e>a?Ff=#yQ4,:nMVKYcj|~RMLfO{{_+7|9LUn͋aVEݺ|si-ڻ&$6;u쪺@ׯޛ;OtsXɋ[?ٸ.[ ylfbr*)K Z0n}߽# ڟ̋>M|/jofV٩ȷ.1\WT p>dm~8~~~~DvmԔ|/|zE<]YIYSͫxբ#Q=d_~~~~~~~~~~~~~~~~|1z3؏vGomzZ W<5·FQdUyHfPJ}Wi&B}Gd`+84.Wr(#7e<-K%Q8jX}d{{~~~~~~~~%;h|[ܻO?5sT}kەuwmuRȡՋ E$WU{,|ŀ/P{{{{{{{{{{:fZ@ٿ}߽߽߽X_;\~~~~~~~~e( IDaFYGQgIUM{{ fel?>rt흔nREF?md5Ghe5:n7B›*{߽Ӫ((((a85 QF$qƀPX{{mu~쮘lZMb2G|XoẂױ{{c|>%O݇.}iyikfBaEE>~w3Of>'=Mi|Zf㓯${M]8զg1RH{f~~~{3Ϛ]Stv=߽߽߽߽߽߽߽߽߽M3S? lq*NmzG~WG;gVV*|zWz~C_L U}⊓;Y#c6JJIb{_mvuwZ )dVPlQf:iW'݃ ,x\PƵ2cj|r*Ixǽ߽~~~~~~~~s8&}}Ȟ #%=]/kTųpˊي tr WaF}_?toHlM.*ZXYh;#\HGKM婕O߽;z0?]/zQ4SlTQԯU ;uDmlfMO{{[+sLNĮY)魽{gǻ3+24$b;v@_^yN~ݷ B#[!լo+1 {߽߽߽߽߽߽۲7Ooڝ[ qbf{c!>+?:^[_L-=U%LAX]X${{ 翱R=ɒ;+GWaUͤ1b1ǵS[UYU3V+O:eO{{߽߽߽߽?,?ίZ˄ٱ,fJ~+J;.KqRH8섪#/DN^OlCÖfi#IwOX͑銉5{Xکsy2>~{{{{{{{{{{{{{{{{&_G.;?))hkwڟ{s-V=]_AE]5"~~qkڭ~06Ij&:86{E9~P+f襪 J>2+Qcu~{v5GwiQw>ҵK&[ow^ssh3t2^u3O_9{@7&_:_FmDZ0kl6^]_6?[,v"T¤͍YXGo{{ӳ߽߽߽߽O/zt|m>9vK])~ze{{&ݙmk6uMR~ *5m:R@<{߿{{{{qbW}CQoǻz8Kv YI1+f}=߽o ~~~SF?q/=C,|VXp)l\;K&r&ĭh<s \k}rPj2QMQ}}߽߽߽yη{[!ݿpGVRcn݉d[=I?xsZtkDtYEE j}߽g.=ӕYǣn;rzE=F.:J훶o]#˞jsx哛{߽9|mH0ݗ;gYZ}y|J N PӮ_ltw,nf1ƤS"}6x}1?7Ž?#@+нџo6; n-oU:qUv3 TMtԔCݎrO{{[Xu{{{{{Ag?l_{6và}k;l{{l^<ۢP,YPW{? e??ʾo1?||o18C̔b`!N@tbف߽߽42[6kc|;[Ԕ܅v ol=YiYLeڢۙi9!KO{{'_G''ƯI{9Kg~'wƩU2dk#&t2#KE(=&m˶[r|y$bVm\=\YEN/dnznlv=H @~K[9K|7ssG1?klIz%jG.]7]+0S㖺zzsG~tJV'a?u|c迈}ɒ*vu#3r`p{nn'/ LR&}[-Fh}?}]]]͓ޝUyS+:ef 69~~~~~~~~~~~~~bJwGhtힾ>yn㱷 T!f!x/OYEUurMSK$m~\WF;qC럘QNZJ裡GEnmedj޽WJeI߽߽crج%=~7'GSPēBt0H9idt`C+x~ $|=jζeݙJ ){b:JU*X~V߽6Ǫ9#jc6+ 7jj^)gK4)Sf ߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽G M(|xY2Ȏȭ>ì:^*ebjA;'sR;pMW@SS#[;(Ų藳å͓Cl?neڬq\S(QH{5>j';qVj߻%%SJ5YL6ԉ7-UF)jJcO{{(^aL<_|+Wu>MVhd>l1WQ$MirS ]$ʕ4uQȒ~'{9|$gR8k-vzw-킚X%eT(T'߽mX$wg_s=g;6m,eGy|I-By`7O߽{_n 5_|*<->jf;o-x7ɪffz|u"k߽߽`_c{lޏʪ*)7ņM QV& c`L` %}U_~~#˥`6\ }3&>7]m=R:%fO))RFL=Q~To~~~~~~~~~~~~~~~~w|b>Woޝx.^ځVXIR7nOE̕T߯#GCZL4g+cqnБE7QG/PvLQoU!]&":YJ~Y^IO/j`tVQb &N4y(flEdaT~{{{{"°?#w!=߽޸>wG?['}߽׾D_ vߟ6ۥ}jߊQifrng|tQi7^YsʑWT]&e|;i3[;|mw~Tbwxlܘ #걙^'S?C2{cDj9aڽO;xV΄Ysv%,B~zo7<:G{ޙ]q㷻 C#gx߸;CֽhTSGΞ{~~~~~~~vޔ; 1 g)F#1e"*}$)Wde؝O:T;:} u/m+N7?//~Ͽ{{~~~~+kW`rd;~n-mxz"Cظ.Ç9%T}yϿ{{ҷf%+*_;P455o¯ )U5|CU2/ "¬yO~~%/O{{+/K3!_~~W^gC>ܯy-)}߽߿_{[|R{j#*tY٣4o$+mnsTJ*Є5~A?W~~ X{{w?_O߽߽ٿ}۟?m^r?g~?mXBôK߽ ߽߽ \Uk|ݟ'69mՕzwA#}Cczʋ'zZ̫߽ޛXW':*tgYX?Le*{-=,d[3~~%*qG=#|^O'8;:ى'S(?|}߿{{ٯ߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽3޿o?'쿀)%㿃}~χVM߽c'$MǞS]ZjVf'm?~(_3#1fe>bD.:Їu !Pŗ2,3Pb]n3I.cOUS7zFX߽ݟT۟[1#(%:[ONAPfvgZBƮ,n٧Wɷc %_}}a?O߱_߽߽{{mO-׹7>m]vLC&gO\] E$'>G_߽߿mw-~~~ _߽߽w&{om~~_߽#TOjVt"vUwt۷0o]2N8sOZZY~z‰W?;NQ)>2쯊9Lhꍨ6`2;ZnkE2FAh±{? _߽߽w&{om~~'%/Oy?^?1%G˼R`;%;$DZ G[ryv:qjig+ڽ, ~C?Wt|C>r-1=޻Oϓ~=e꣘}ͶqMwwޝԲK9.~~wM?Eÿ6;k{L;k?OSZ5k;_ᅧ}?ӣo~~曞>tޕ=Y8]C16Wev/d?zļ~c?{{KMM>[x?9_7? %a:pV{rsfun--t{nBf/~M?Eÿ6;k{:O+ U|r]h&ڠY7i{&gd.~*j㠨N>3߽߽߽߽Dno|ܟߧfvWO4uFa-s5⢙#Z aX߽cZ ;o=k7{{ bm'ɬK+US ՘.^;=Pg;Uq;T $@2}b?~~~~}é?o:-7]zߩׯ#l%|S'_cFӜn?;/Jw<1Bj}CA{>#(aқ Q'M4EKPpU D,V(e[{߽mr3$}= eN/ʚ kP߽ч qv05P{mw-~~~ _߽߽w&{om~~_߽߿mw-~~JTSOfV|}XDahc{mJb2jr_n3A-{{Qʯ?]2_OK~G~y7|zgYOUXk3v>~2&F <-s*iU>/+?ߴ288<-M6~/^$a$㏕aS9Eu?G20LR'ޘ A>|iV>mc:mo=qaO hdc(fZx{;w`9ꯎ8gd3H24ߕ[v5&)6~ٞ6`{h*19*y㝣I;kY-._t [)<a;xaYOH(䩈eo#Kf;& `xEZ#fXt s @}}kOJu6K[1|">.{k6PZm |HYIETp%ٿo7_ש ~ۖ~_| ٛIm>M[PaVd[k3&eW#~8~?v|/{&Uȉ6;nU&ٽ)#jXo#>":'<[: IV y,w "bX|xOG<im~0c<׃"Vd\ bu d(9#]rTV{,o?`o'NY=aN𿔑D^i ȸ&w!|>v 5K_.Oχb&MNKV6Uw9?oω_=?MtBK{=J$̀p0P2Έ:?b%?g߉)hVm⟇_Z7Vwڼii&m B n5^=)CZjPiUΫrknJdU,qJjcA&՟$|9_]x4{ēZG 9! @ݸc?~~*5bIR%UȻHi\(#,>":cB_\+O{(.|ˆ/,2[]>q dUnk"큫Muk^Zx;Neӧ\݋i$ m#i'X1M80t x'GbxMi^xPRa׬opͱDkΪ[f ~_|#%t!R?.icI1kҊֿgaV,g4 id6nAݒr?GC_췤 YA`Kw&kH\]OȬK+d rqZkBz?<~~в^Q/&=voEў$D[(]VKr3\ऺohB-_]EoM|\JHL}8~Kς;F/)X\ 1PĹopXq7o+|? z|=|otnU5 b&&- 捇Rbti xFu(ݴ>gC.!)Y̿.F+%7eַq~ٳ15_6u[.HF1$-):+'y.I$X fP"I^Nc)G~ߟloG MApP9pS^`1i(4φ_|e[zl4,5莡6 A*||Pcu$/M=hx[sdJgtx+~/G*Wk|$h,խvg7AW+mCpIN?RF&ޡ5줷L@z#9+A𿏵5̿I?[$j Ad}F F:~ei,?xP,@=o#=QMjRqOf&'[߰SQ@>Ꮙs_/%<;Ys#߲_9/v^:?S[6wn|I{86ˀ9,rk⯊è|@ࣟ IB<'2őDu)D۩ R$~bVRv韴OY|j.?!EխdKM>Rȱr|;?3>?d|/s&kGY ""]K>V9Wx k xkW&>ZﭢKUgU+XJ߽)},|USڞ,{M!Ͽ}Ex7ˑz!{3}2oH2Д\@ Sg>">׵_tlOi nX 2`8+JAįkSӍ泯jwP1Vk<&1̏E_ ~=~$ş Ðxbu{x-|>Upіy'\lnHE%W23gߴn3h6>&ݪ|%cm6^ '9awH$` 7G~ -V?h+8,ސ Mˌ$"sSٮm#Jk&x^Ӣ}m!q򧘫Ý쑷~7Co;?fMfe&_LMse Vt&*,]]mb_94"HJ09Tis"O4?|o}M}v -E/ۥUo$>edc2>J@ѵ+:EjW=$S$GRC+)08 )FWvfqź)-YAEPEPEPA8/sை?d ~"Wr9gu_Ro(g'X7<[܍/߁i/|EɅ$@\@A?0eٯ{#~_Bѯ'4߇PP n]f+s+- f8?~2~^yƉ'|[Yb<8(?6A__[eey}ܤe4H6G),3jC|n?d"WO w?}}3F5j c'q1)')߲¯)ShuikWWL~ܹ10VRk{dp= mHxY~1SL>[o+\-Ae`齣0iE?۟H?no _?d/K.Z̊!K2- 3HF$.9Ne/%ԤU(HS$f/ 'x~?|eʶ:NuyuKkXYDY[8"8a|% 6TL~ܒǭ4~͞zO7Kn ݔu{ Xp V؇եS?i/߆rVG^/!^dXԓY>ZD!?t_&QO? f|G_ bzuR RwMɋg*Li+F[jKnW11"hs-4 q_]~̿G?kK8>>|a2x M"em4,e #r$zg LA ze6_w{$nXK yd$F^ 5ߋzό_Q?ȭίYgq۠&EiX+U`DU@0c 1k')NOmq#)GnJS!lE90 ^Vz')ӭ-bKKvH|M{ȣX$f/u07Rf7H"|![ uZ,2[\Xax:0F΍K~Ԗq  6Ꟶ/ 5}KD.3NԣOFP!,DpI߱_ "Z:RǛI =YĤg-_|k}]OAS~͗/k~!nuH>m>@qѩ \pNOa<=|977{}70_vZ3nrG]_jO8sW |%ԭ#j[Cwnj+"I^ܐa?ox> hI#fxn8Q0?GLA?Mk<|^rx:j^i:njhѐ_yjc3)AVŬa?w(yZ&7Ὦgaʂ5IGƖ+`vnL+_?~ OxXtl_kXiu0x_?a~/mOx ^c ;H,Bf1Se|Z~П| &xKZGO -<)-]/v%Kƃ66Uٯ⿍_<=)|l%$OTbx54ʚePNx&he2H``0z?fO_ 5ğtl7ؼ1K9]MbCֲA!a #I7$fԹdg( ?-~0iƽG d[xRů>-؈[4l$O4ӹqwCeQ@R7Jller@kGடv:1_NP,VIJd)>7|Eo׿^;>Hz>KxVA\ym %MCf5 4]Nfq`j4=+úE666V PD@@kۧ |K:|5| {_5O4qQ>K}摉vbYMy/EGk:i':1Hy .%żvove^F -#ᇄs(̒IZ6HEC!DIGrgv1}["u{MC\N4Wh`DV#'Ezl-_@Y=>&kQmwiݵb".w`HZ|D7{ my@%MᐳBI+Ak[4'MvGoecA]ZL26dP79Ol[ڮ\Gwӵx&Mkݖ"eHLLR<*]OFzo$» Q8#Yevu Ǽ/*j01I,Rt?4zmG^yb$)92eٷgگw}?>"=It]O%w\[>2(KTG;h INi /=3]xLg|EaБ+"Ns#@Sp#ɯu_h_*A{}:Ya`Y^9b!HKtxʰY6V暷+;|M|mX;0G st!  %x?kw]B0ki:֝4Z 3 y[wo_F~\c/ٟm<~v.&:[]\ia*:ZvJy͕40kioDp2ƙ#tQW3_7cGA׌?i .oGgb-/D4W]*.ьĆ6 WU/xC $?Q@C]Ŏt`U?RH~k?>&i705~'~ ?M3Wm7%x0pblkiOُ3Ӽ97#KlV HA zsҼ<1ݍFxHke'sZSFaXq ,tG~/%#Ͽ]F_E;t5x\òQà=@e'oD|>I #ޯcFwмd.Ao͹Tw0Uj(m{`_6O'KQuKNvw*q "#^<+}5o$=x69tŘs\Co,"3`zלKHw|okjMmg*dcPz[N{:5|P x_Cy⹵hL#G5ԆV<-DK) |Fmx ⏇46KG] hdy"Wh3#:e;coj?^^ ŵ (hP8-ݗ%w ʖ/Ye& FX|O5/C')nD[ DV*wB|.m9mW;:g0Cs\98\XmMf 'Yp$~2>?hx' t;+; ƱæXVpvOknsv!9|Y#b;m.2sٻ7_ZEƋx.#-i) Q><떎j#a}OWr8{pYWl/-.8m쎣Sڠt/241Ma@h!uH ImYWBN<0zzI^[Gxj+eg Bh@8rMzĐ/=FedyWOٞo:!~))W~-Ωo 3Hī|/''Ƌ>,  $R`5 ˝BI@")H=^O|i>=rǂZx6:)u82$I& 2Qk SxA拆caV$)瑊 'Ǎ~#~/ūItגS Om| &85"lUS^KXK3N.nm7cׇi?R_TL{{C4܌D=5%ͺޯ {[=aa\&I,Pcߞ(_Mo0~H57Y!k/xRm]'&H#UFc +a#5UUG 8b@oǾ8uDo .|S$cȒn蟲c_[@Nᨴ[KVu+8=jMhys2u [eEΟja߇~އyf,t,ܫ #xk3 L|mxP rKKʎfg@?D $wP#D")-+Kk:>9~ןt G}u?w6{|A}oGHHnbt}h8} ruІ59%?)ڋXq<'C^葬Z65h./^?{_WP 3Ux@ ^Iky!.F7߳g?c?iO:/GǦǥ[C1F3Hb#2(@~۟qϺ?-`S=iqsmǨZ>Uݔ׶[8[y++jo^G?k/~߱>/>/>!\+,mP3^[$ɯ+6^o%~۞K-JD¾(\.aNv=#81WsE)b8ͯVShq~-υ|PL}@+LF*pYeQ2硈3ibz Z~.|@go)È> _zeX}5ߕ\\ de ڱgX|J5).oβ<=;i~xKr~R.Aڳ u~vƯ'^45{N ˩=" q+,#^D~Կ4u}w𶟦xWMҚ۬XDe_~7Ǿ_G?o^' 0.>iU4C,O9 )j4 4~㯅x>uym*V14M,kffP |[=o~ ]||ѮáKq(KIéhl ǐvc?aO+$!3xPx/LvkO &q-x.VXzjXs]_ߋ`w-\(]> |>W >d10;O{Z1@ݽPk$t Q牤7:`qyxsqs^|$bY_K9Z_62Yc_?~ٳ}?i}c#uμh&BK.}phqXƗ]WEp s dOc!k$c_O~ޫ.m9:QWZs!n{[ojQ|GrXdAxi-$^a>.!e9W!]w63xk#y,Vю ~]&xv=_:lOjFҭ,ObX#dsX_u=kMMKVџ˟ZjrC>$3n)!xO>.{Khmoo4뛈µ3=Wxo &y!2jY.nFLN Kj Sl#Nu__<&{+ĺKـ%F3bB[,Z> ^@Ҽo<=}7NA=1q$ r!.5|Fڗ~xo%<}ʑ[$,z~\>XU!z#}qo)-[4"=K:Gl ˸vMlz-Lj%|(^ }i{]F\Ӆ[cmm[7Fkxdg,g6"6j~9|?h5]PJXXI1ڂJ$}9bxbaO~6og ~k;{VKi-y ;,z͵!;3|FV |=R:ψ+Gs]@lh&Ub0!/cD@1խ> YM"x_inc<LGh>6֎y}Ptt=7V5ƍ^\x[QYcY)>f\q~zUMW]4Mmд#4ڪ~`$l7?/Og֟|@k>+at]IGq4Z̐+t3f~.x~|?|wdυ`1~K{cgmz6QG;ܝf?Շ/O5pڟgѭ"G#걕n#{T 9_<3/m=kƾ Γ ˕Ēi sRy-ϖ5r A (AEܝ)_)PCjXX\leG7Ip:q^^~)c=|(X-%]>ֺyw 1$ p?+Euڋ\'|kB1sxƿK`EgZ.,VUHPm7Vi6xOߎ>'Y5 Oq\/eUG1;Dk rY] #ڼ# a?]oK7B7N-MgqJBpD~̿/Xg8=.HNˍSPⳑq'&4v<}~)ko]jwQ%Z;m `X_Nֹw?>?^OkD%o%mcm4I0|soka0uȟ'> G Կ rAq4kDoFFF ~?_oeovnC&,c^b+%fI-kN HIDB1,ȥ^7PU TS(%'ïK0m(]u| ?ח31;-pi__<3,Og Zjh rȍ,J]=v׈|aѴ_F4x/Gh_xCG&H'Vyl/O<ׂ/7:&xC%ǃ|-_Z('hp9ϥJK袊?ix3%ܒYaC̯%{O <a^`8s1E'լ*ILgrFk8ƺ_/ZK; OH XCH֡ g mा'[?ol00n쬄ώ7nx3/xwEm$4b;[x@"2 ȯk>Óx Ό!Q'4 mVPۗ$h>#HѩvV"~߷\d~Ҿ_<|(k/]K=3c6C쟔='7!%_%7s[8-&fFx/ZFcFue_5u@Ȗ4e^wËYxBh \hrha.T:<3_>GQ=J5/}L.[;X;?h}M3v _cß~xM&1Yx[+F(XGkClVzϦ^[?./Z4Cس#yFõ19v>8~#j~̞mw^I.XK(gPk{hn̂د|2?~?O}>TSm.lep6=Dms>GHޙ:箹}-CqZ<6fXM$bbdrx>Ҿ٣2&o+-NV{]fu Z~cpVɟtHһG~'px;5g6nt.̉"By#$Jz~Ŭ_RhpjvlTf/*JQx^Nq_ODwjo*:BG8_S :쵩x^2> r x]54ГG֗ ̲:#n an[w&U~ TX˰IcO*gåX">=x{rx;FE(I m,6yQSFk/'ď6^$Р bd[|fMAܳFA5ak G><>'tM#E(mkOq; ݵ: l18¯ 4g)_x'ow/!E[㸐ބ+Ux'0*nR_i7-3YK]C\\-{KEFi U2QN7rK]s'_5g-ꩪxXڔ[gI(lGH+d8"~~;5j^4a`6i(ȔG>m*GO|]A!Д@5eAs)_*{rHo<+ ?S?~?4_*h#>xz3w]G-#4%{2ܞj%4VTщ2-8dEՎn m!s8`2fH~]w_&x.C>m o-Vމy/ڙb9K$(Ut_|? Y_>΅E܇y?yވc,&ug7I6{n{ğ[us:nuxr^L$m<62$P\yw90E!5&,i~$-㋟A-z˫Hi8Xf9T2HX4jϸsex~|_oxN#^-l2P`.7١$Ƃ2a^[|%_"'ҢK+\[.aSyqqrwY@lԮQbt}QFզ񵼪.t[in~#|AzaVR&Mٖ8¤2 k?m8#zZ\imu<%KH ݖL(۟ 5H.i})C%Ƶ.mR{誮 ' 7,;A>~i$Ś͍̋#edKO3L(޽ai@oum^ռs}d19{leI#ȔBf,!i~Ͽޓ~4ϊUŎ[=_ [^;4w<0L8Rیo7m?|:/smeqe4z|M0XfasQg.'cxSú`ӦXn#ծ凟-"::1Beq&??i?t|-`|YuIχ6Ơ !EĘr>dF aXV;oY4(E;7X=F)0 L_?gg_7OxFmsqMH㷹n$m ݣxG⮙_hk55mW^My:YKmg "m7{S|`i٦~|PР5kHnƑﲓ`q4gV X߲yZ»n͡Ҩϖ|Rv$8œ|E߳In8~Əyv#Iue 6` 秵0W?OhdG(Ik^*k D/3c@{q4ҡ+hzt ENM]2ضBK݇ʏʼ&tf,nXG5GLd,}LʽeE~;I¾8u=*CWcwu7E]hFy'5tVڭm3R'7 Bƭj?5[(KXAdGXT Gx?u!7~ͮ@gW o\0,H4j&fm,E|wiஞ,@֟ 3:]Qi>_t3@)dm !o3ػJ׺4{? &Nč[A}k|i-x\/k|YX{+ Wo:Y-Ua1*? O<Ӽ+/wn,|;H'x[W,IjhK;%BurLe# j/ GOj:_Ӯu?z8J|T/Р˩ E- 0L4M'͏/>;GN?cxg/[ɡ|Dva?<colMiiZ9ݥct{;m~+u^MoxO"JcmaC͛({Wfy W}OګF_Ӵ M[%iVԥi˧%p<ڜb/W|m~?O}>-n8}[I.cV'm1'u27Ƞ%߳u/_g&· 9!>IgDI$n f[T|QjjQZ 9g{c:* gM-54'2N&7M-unKoe-DmKh2cxf; /iڟ=k]ҼK_3ƺfK?43JH.&yʯ''?U3|ǃ+hzhȚb&I ^XTjIe`9RzťC4ym\N{}DUA%!Е+z_ |"'ȹY}8MOQц:Ȭ-C!۝,cG~ڴ%O,|)7<7Ieqڞ*%im[wAxg>~0/\F *G S o2)'g.Y1fY>S~ ?ÿ>tmRFۼWό5Zn k}M:YMI#y%f oG=gڗſgB~;\J=uhwoZ,p+aV><e)FG&Oc< 3$ךRg"mEtcZMkz/ψtżK}Fզ'&{-ݨBȶ% <6wV>+xMu Cbռ1Ec55a=p${9,PH<UUV[޷G\|c5!f-?Aj6-u/Ǐ'sk:TAAݛRn~}9vp|>/.'Ÿa🊵m[%{="(t Lpy"wepz*G O ]V /uiSn5}:Y)|¬brϕ|mfx|o Zx&~թ$0YEY|qY=HW/;{'Ž[ַ4#D5]~Smjmm4sujKwy#K#p4aoxi[mV&Q @ ($pA~S+~%BI3~' o_x3Qs7R\ pg+ \ kfaYexoE4]?NbPh*"  n ᗈFIw ʾ\`_I߉:ΕkݍrZo/0W`$ӱ'~xcmozci~8#AMQ~(?,gEװ3?OFCk>.eimige,\)q+j \+|ۯS^al#č- O+[7>4[Pwh~ 9{s;=v缎i =ڔl[@T) ĎWJ7gڿ^ Oi.Oi7 y=Af[]EBu-߻!~?h?zw`sk7m7VoCPH120|^KVm-3QR"쬚3 09'3()i_=cw9+ SnB]>gx 2|_?f?,-g4fy"w.cCcǒ6X߱¿c~G/㯍%dt #/'2ɍQiXoֿ%y;d6I$[>,^ⶅ+ia&pFnE8bzVw}#ßRۧf)▇G E.o*dֽ __L_kX>4ֳvޚQ)kX$;_<0๞0񟇤f~<~>_mo2Uso@?Ef,&@ z___l.>%iռOڵ%\Zjw;m"lʨ,Web~bf|mU$|m\j_]G[X3x"};ML]yk~\nlL>v)~$A"o.ofkf_)4@7Pca3.7?dž?c&Wzޥ{wiv3NZ\Ks^[L@4jG ᧁ-kjikvAwk P#?0XhxWK+_h~u$58YѾ_ٽ5lՙ 24G–_+g/:ׇu_>3 4.vծB-v vwk? G>%xrcψy.1=^`XJv 7-~L.ySYm//JW!gV~$\j>=7][i,7 K=t5OΗ:׏o$IXCYh#.GKU?+*n4hk!O3PV[$$ޡ{~)|{{A@߆ۡX%$R\ZIܭo椽}iztt]!oj;%X\[F 0E$\&f`l< G~o;é}]2Zbs~la0Am?].jZuVEU[]7OZyȺLP5^7mmxgPm*LA+RԖ'{B߀|k$֎t?[Myk#L˶T +c/k:dͣ[T{ i!,0sOnx<9Z6Zmiv͑ =eV"Dg8O. RsIӵD[[O-KԶBʅ/ڻ7M6?q^O Ke࿋>1mWN,M{QGKmhn!2>u/|W4|iZh:ݯHwi}d(e8HطUo~Z ZeC,KpOD;+ +;^S-#>^ dL7ZΞI[&kd9 |sK ă%<W\h Bm"V}]j5pV5џQ1c^FB>I"(H!}8y4=7_ Isb=+GE1'%`zp+ o %ދUO3ݒ' as֛/Kwjn.LcinSL;>wzL 2g)z`?iۣg)[+?iE*F^ .nT6~?o|<៍muaؽqk!{YVKO-BesPs4 ?fxP;z߈5 >tvtվ?QR=E+D?`GA _~ZF_Ŗm/{泔g8_ >>:gxҖupI 5ˉB >H-07I._ޯ~0H=^%~׿d O,`鶷Qj*WIsBvv8Eɦ&{!x0ܬUGpA2׌%>x/n#;yc+Foh,:Fʧ%n[N~^!t !K\xWGH*~g3ǩ{=G~&xA޹d6zpJ2"e>E~<|06#j_59|Iųhy,$6Ry6853?n/)ǟ(k?—^m/`vL洏]8f,,X5 EYc ^E\C:ĺ^ 㕚7d7%:'FJCZ8#Y|1AqamcYA*DTҼ; GTXc đ[h8>xU<9xwZOh/V_ɚw pY23733w"k_>_5O Zk^Ymvip ! kC0 0iɦxE:T ެg'ʁKa**4Ǘ ψt~ bFa%vPSdo!ZA&ZHarÿ ./߅ kzx'Gڭcqo-I =F6]2? ,뿳+k$WI]Pix~MFTNAuj'gfr ס|@ R|>G"WserRQsiPL0$a;e;z?C7~ =iH8}6Q@w| J6=Eu=-uj:j6wo0jKxY1SŞ)񎹥鿲^+k[lox\--Xed4"P j|X!?iX~6?YQeo^MIn+K^ehF $f~ݟ߱x<1*-3噔KRVE$7]_|6Ѿ]|9sN7Ꮐt;W΂/hAK\9G ?.x #lu՗OH y1=wp\3_hk:7/ڦ喙1'{i֯dueʍ=w}5 ;n?p-S8Ե–+7\$uLG?׊ྟ1K"ǻ 2=V˱?мAf^\_{Hi/B^77ҿ5K?2D<huIcY..dT`v?]#?T/Ѯ5XxBH 3" g0$.鑺n"'|K|>x [ۍ/OytȞYͷqp~d^F!pXKaI|'K;o^3n,[׼%Ygs*j3۴pB"Ы"24Nݛ'ֽ_<-}h:мx7z1GjI4{nѐ˾p?_ý[ڧtد[߷Vguoy$DvNCᑙOwW:7>w%]j+wNČԒV:ihi?r_jmEtt4w63-MR,_~WTLkFq+]y WkM;úMq(G*h 6At0k0d5}'XҢ\ޙyZ+Im邔ݚ|PwL\NS-uglci=K*Zҭƞ2)r)o<2kOx x7mXڄm(I$9{fuyHW&M?gjo\]m?:"Xm;<͹| ~|L%υV~>"Zi-#zun(g&Ydr2AifۚI<>•-SU?|,<#w>7x{9i!nQ9)B8T{PtM E@^ Фrt` 3E̷'־f?h?_V}֮^G{aa*M^QTVFNC-}~ϟ$WM(sv-#uy^^׋cu,%$R\%ۛS_Z(/Oڳ])_5R]k{EFB~ZNj>&iWOkV n8UH$`'R[ͶbY@o'5մ&ws74[;M>.x#iTz]XxHj>߇MW{]ON]\ {|JiO| OOu?>2vh^c}zpcY s6KqG5>| < ۍ}pIKbr8 MW?uK_7O2h | x[Hok1 m% )+7o¿?c_5cL6Magnr@܌Mu`GQH`FF+Wٓ IO؟֟ <1G-7Zƞ蒱&[f%~ɿ?t ^ F8_ ]'|Ac,JFmT?M<_߲_# ;S5?ό4a~j$y{6Y kZ!* % |j'xpj֮wvZ+-0yču7$dx:mtQrkP_V Z]WtPL Dƾu~(xNBm^1qjj:1^0L(v%c| >$4 ,M{-4ډn j7X`5yΏY]Ix~2-tY/s} NP׮Ќ$ckh6@?,K_KSx&Z|;iF"4X%%'ϷKK,emj_o/|5π{`K?|g˥xF׼5kpcsoq1T,aՠ{D'>TW鯋S jZrDc8i،7O}=c?{/ %wO>!]i7Z=Ĭ Ei[hi %Uz? XWΥw|C|7a#M1"WiDwq{W/!*&ҰGcOFǿ >$Qq}tjw=R(vFG @'*8KCď-Nk:Ei5=a1AwJ Q'>^c|TGĺLi6̌Fp)^6>#~~2,xm/ ~>l1"ŷO;A>  w`x*l zxlIf g8/kE5{GfװdO ̓[4p}=’@LI{O¹/1Wn<&/)l8e&>PAeb=cXmKVs67,eJ{IXr߳s e+qu<\z>w%Kp's~IB~>x_'iO eњfkFe gݼ_6O4_\h~U44PdH|m qJm"aYsj|Q|e^iw׿gmR ˅Z)m!7:S br)R<pw|<3o~Eg}jk0~Z)cE$V2X<{A+]٧g 7ğ<]sWmZ_6a,KDE %@дabZSh|0ee :Zm aZ5uL4WGV?R{m>kvzd@rHbWP  f _kq]x{Ꭵ=uÌẉrw3^ #+>Z\x>b˙`c#tp㝶{f+DZx爵-PYmKӼ?ygo,JIy}B^v&˺Z/t~UmKf]c'nrꖷ,(2?|#y主DE$lNq#(vN+|TU#JנA g,KE2D e.ʪd޼B( _4Gïixghm,qigHU>v`Q|d9.ki?{O߁'kOsNS[;B8.5)O&ԿM}/o?㏅.=xK7JZY3'<$~oZ5 w->\q/mM v: 919?x#744:?u:C-O,2/#} i>+??C>5xQ|LEsimo ei.tg'͝?c /> Ծx$|C ʭkaEo4qȑl*YmSq$YcǞKv}nOĚ~j [=j*u1qw~+?fxl3-Ɉw\[h4P/'F1MpЊ  .>`?go IP7%mf*Dž`5rdFC*z'ᗂ~2h>qKkٮxReFgLm(Yp1=7"jڒ>ӿeهA_G| ` RX޾XCuM}bCM5k{Ji"'XBB!O,_{ *xQckk!+h|Iaye6]GPࡾ,c~ǯ(GƟh-$ ~HPs̀" H݇>t/~! )wqCᾨ'SV>BV)?)Y*"o \R?^'mτ~|i/.-ts]hh]cWo2Av(h?㏇c i)EUeGFn@R1ckc7]ɺ;x޿)hʸ*|[|zz-o:RM%mJ:qRB~nnሼoC瀯" žܲ+;&#ֿ54?goxKH%/>,^jibݧnWl0.>ρ7м'&O=?Oo~5HM$5T0va;'Wok..ZXFuFٮL lgi u8fF7~?㯁m+F՛&wY|U.m/,o/-+#|6RFUͿş|MqE|UR;{OE6 E$q$MB 6Gg9_~[fSQM'G&X%6LI`H?R~?f & x7/>IaƷ }DY&qFi`O9mc< ]ҡ6wj&loa3g$rny.HI_R~Oh0G=Lxʞ']"e/$خX8ݥJcXagCAԞzwIiW$LN-Ws>?eO X]> |?xucwHKmUS|PXTtOسwwSRı-D0\di&pGmY1o_ um_ᇍ:<EL5a^;i%Y>r~KH ^%~e$^(čW[[mn۵ Ii"}܉WL>iݏ7)*3<㞘ѿ+_~)Z_ ̆MWSƟ:FY\(`~?x ]`w|aIo;p;1mCVnmV9#(z{^*4;E}7xCw#u&'ĺVCKV=͝ޫc l5o$Rg+؉  |J[_ If SPEܞ k8nh°2Gm}ͼKF q~|>Ⱥrxo~om"N"6&1xr2ʌOt~wPyy9ck cvb2z(I+W3ο߷ψ?co>|o|"|1AQ O V_=x>5jO'~~ɚD>2xK]~Co.z K&+t$` -|3`&υAO캆g{jD]s%[pd$ lI~_@:=(w-!4i<&բ`֭0G8h%%.ם~)٦R<|n-PLKѷ;$τdY- mW`s|G߱ul63Ur5; LY\ɵC-\h?xB?;MQ;O?,fufH/ +1Y19v0ebUQ>*j^&ox_KZ]Vqq"Ifm{kXBFSh,k@5ZiW|t{de_2iPJ-qrChPKvQПcy5?^|wPm6ӯ-'n\+n"?t=FhMu(~sܴ$֭^*E-6ኟe_ڏ-~͝ߑj |BU}QF?s"Td.pmهvf-X,]'xn890 'dI"8y}ngO?٣XOtojW\?mau$/n!<)!CnlN( h||AdV?^:xR|CLVm V,ѯ!fIt0n_ޭQ|DwaCM-OGW3?I9ggCF#GT~VG,><)cD}E ,qX;VI#ko+df{~Z^|-9(D7 Hpw M:0po3VMt_R+{n>ڷApA6c)"SY0dV3WSnvveƉ&c Hmc@1.~ſ.w4m/|C/g*9;P|T^>vͪkZ\ȱ j2]* $>;_ C1km㷼kڤVt1Y/,ŭV9-9@~|>,l//l-+;{OԠ`V)#F1àn &7㇊~ЇZIᏀ !>0R1'#8-_< ܟ,D1m8dOsmڴQE ( ( F]sKE+ >8.zs sD|2 qek[_K/ X1Pv2о~? .l|Je/`]}om!J䪛FI7')7ߏkOVa{MPCӐH'ڊC . |KI~/ZdEg.h-oe(LhoF>ؓ(.a6a\ѼMg|zAy@4}7M I[i(ң՘dWn\m?1_wÏk;=F8h?ُZ3rdV QPB;\$Wo|9W-t߈>.by cf÷ϴgeğR5KK~)~ #ϘG߅&4Rc>V4>.?fOeֵ{|Swڵ\QI$ i&׻nO ώg (I/*EYʍoۆ*\Xl:콧|8&(mmSp74ˢmri!d$seiylw,R)Y"C+B{S?1>L?'4~/otq ZbABbM Q)4+-lNxcœ'Rs'!0\-!blzƗ?gOyp KZO}: Hv=H|R4h/7PY~/ڇLB|[ed"Aq̘!!;QM$*Ь]H [{[k+hl`H0ET@0`ҿgn6i.%O *28|+|z?Qx3(X`jr8'(i@Q%wh}=<9\ mWI0VXX ,R/ i/;GJ%V'`i[%M`tNb!7 ϨXXb|iLpBzթ/ G*~tɶW>9 J#3BHg𿇼Zx[Z%X@X 6(¢"bhWJ0_$?wlc~KMS3j7@g+{C qy~*|kҤg;a{\cRHlXN]0jV+wu_u|Z?x 9o;6V'e3f?-d~?Ua _>}Wkd-"#܂%et!_%û/IMOƾ {L> k9av,Oݷ F+?_~6'YwZ*_ ۟~ekv:'+cmL\ 4i4|1=~$G)G$u/_c-ɖ(花P`*Zdh7?P8fY7=চ?_7|k mB!jv\HTyq, ox'=:Jl2;q#ww*7Hv%kԜt,|aß ο|/=rmGLѭ'Dh ti۽O2+Q#G&7~ο_ğYmA>!iKO'nմW͡un Q4i/^zD|/|8У~!j>& xFf9B:D*CeY7c7{_|I?o7ZDAhx >HE$WI3]2ÃMӖ~QR|t;?Z%uƏ&e,|3|O%1=?~ c{Rcj!/i}>Dkh`yAFƂ6&B Q_{w ߁ƺ!e@iPk|Q&}ƙ mYw=9Yu7;T- e !xV 9n^?oKG/?MN|a2YX]b|eW Ѩ^9s%ůvȚ f{;k'O9l[% G/'EGE^r]13I&ж< |=~?Vg1*FtV\~ekQ@Š(((=-' |Hn'7E51Mj W.PGV+'3Ox{tl5+ ZG'>\2Ωm#UR[`Ϯ+ -F~~?xJ=Rtm5}prA:P8Bܓmx/߀ĩd}JKx(Rdpv01/9c5jr s~B|fg> /.3 [vd4h[YuT$J:ʅw Yٗi>2~jςdڎxH[Et6"yi1O{ c("cqfoZ7|e&81{GӵU&òdq"nB!I$wB QA-1 rD5xw=WөR C벢< cѳɴ> Āp7T~[$2QԹ>{6J=`weF%= G&[Lд]#[Z!9)m?%Q@ .JZ(++1<7{/xE چ^%c#4-u?ٯ |W'|'VbXtn'JƖfV+^Bijd uW|SsXxrr& K U|gO38xuѼCkׁ 0r6`a1g@NI'}lߌu/߷G?gٞCiy"EhȚP53 uy#%?O e?~Ś,3|Kk 䉑5 22J/R>2^?-,J_ ;O~|Qu٫3x,Bեv<~k]AFk:6w/+OOy^>֗8m//c1DۖRNDbC-W?u{BJR_ >|U؏_Ao*-RY'8ɯ K{I,)TJھ9?MگS|E-/л$+&tRGh~?[tکZNRηMpdE8RN:WfgD\;SKh!t rcI<:__ß^? ᯎі?>eV'[H@IzF~5Yӵ)n3kRE`Eyo?i(ݏ+)?7 Y$1\Z-휯!jFj9q'֬:dy.mr <'*qذbl@zz綥Vh&/KK>KCKm?>)AdkO 韴3ęWM--'W 60Ov< '5=7OMWK 0qv (kO[?bWŸ&^|Km)4?48TР- k7Ÿ5=%?hwZY-npĶAHq>~>3qOi~ɞݒ;F45kP c8؀>WTI.}_PW Ky&[|l#d*k*Ĥ (#!Iox!)_I,/K,VzVJ#y+szӢ|n4?ਿTf<={Kc+)@ D)#8 ?gnnb|9Ei"5cO9ɠg 0; UJO;/OI=,ZAw\܇op[8bχp,~ ѢDin$=Ff>PEPEPEPEPEPEPEPEPEPEPEPM)?:_ iwAaJ8Hz ׄxϚ"{'>|Y \q=[9= "o6w7?0ә;^"d(uHP*$~y#0O_ o#4og@w<{mcg~¨aуKEQEQEQEQEQEQEQEٔ$$If!vh5p 55#vp #v#v:V l4;M+++,,5p 55af4ytB#T$$If!vh5p 55#vp #v#v:V l4<M+++5p 55af4ytB#T$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t(&,55 5555b599/ /  / / / /  / BapFyt!o&kd<$$Ifl֞ $(gg GgggbG ^ t(&44 lBapFyt!o&$$If!vh55 5555b5#v#v #v#v#v#vb#v:V lL ^ t<&55 5555b599/ /  / / / / /  / / /  BapFytkdd@$$IflL֞ $(ff FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t<&55 5555b599/ /  / / / / /  / / /  BapFytkdpD$$Ifl֞ $(ff FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l^ ^ t<&55 5555b599/ /  / / / / /  / / /  BapFytkd|H$$Ifl^֞ $(ff FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t<&55 5555b599/ /  / / / / /  / / /  BapFytkdL$$Ifl֞ $(ff FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l^ ^ t<&55 5555b59/ /  /  / / / / /  / / /  BapFytkdP$$Ifl^֞ $(FF FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t<&55 5555b59/ /  / / / / /  / / /  BapFytkdT$$Ifl֞ $(FF FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l^ ^ t<&55 5555b59/ /  / / / / /  / / /  BapFytkdX$$Ifl^֞ $(FF FfFFbF ^ t<&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t(&55 5555b59/ /  /  / / / BapFytkd\$$Ifl֞ $(FF FfFFbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V lL ^ t(&55 5555b59/ /  / / / BapFytkdR`$$IflL֞ $(FF FfFFbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l ^ t(&55 5555b59/ /  /  / / / BapFytkdc$$Ifl֞ $(FF FfFFbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V ly ^ t(&55 5555b59/ /  / / / BapFytkdg$$Ifly֞ $(FF FfFFbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V lL ^ t(&55 5555b59/ /  /  / / / BapFytkdk$$IflL֞ $(FF FfffbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l1 ^ t(&55 5555b59/ /  /  / / / BapFytkdn$$Ifl1֞ $(FF FfffbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l^ ^ t(&55 5555b59/ /  / / BapFytkdLr$$Ifl^֞ $(FF FfffbF ^ t(&44 lBapFyt$$If!vh55 5555b5#v#v #v#v#v#vb#v:V l1 ^ t(&55 5555b59/ /  / / BapFytkdu$$Ifl1֞ $(FF FfffbF ^ t(&44 lBapFyt$$IfK!vh5 55#v #v#v:V l th6,5 55/ /  / BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ /  / BaKpyt$$IfK!vh5 55#v #v#v:V l} th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ /  / BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ /  / BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ /  / BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l} th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V lk th6,5 559/ / / /  BaKpyt$$IfK!vh5 55#v #v#v:V l th6,5 559/ / / /  BaKpyt$$If!vh5#v:V l t 6`,6,5/ Bp ytQ7$$If!vh545#v4#v:V lF t 6`,6,545/ / / /  BpytQ7$$If!vh545#v4#v:V l t 6`,6,545/ / / /  Bpyt$$If!vh545#v4#v:V l t 6`,6,545/ / / /  Bpyt$$If!vh545#v4#v:V l t 6`,6,545/ / / /  Bpyt$$If!vh545#v4#v:V lz t 6`,6,545/ / / /  Bpyt$$If!vh545#v4#v:V l_ t 6`,6,545/ / / /  Bpyt$$If!vh55'#v#v':V l t 6`v*,55'9/ /  / BpytaI$$If!vh55'#v#v':V lp t 6`v*55'/ / / /  BpytaI$$If!vh55'#v#v':V l} t 6`v*55'/ / / /  BpytaI^& 02 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ KZNormalCJ_HaJmH sH tH DD KZ Heading 1 $@&a$ CJ0OJQJJ@J KZ Heading 2 $@&a$5CJ0OJQJ\DA`D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List 4@4 KZ0Header !4 @4 %KZFooter !HH  Balloon TextCJOJQJ^JaJ6U@!6 Z3 Hyperlink >*B*ph\1\\J EmailStyle19+567>*B*CJOJQJ\]aJph<B< evDctextx<7$8$OJ QJ >R> ^8 Footnote TextCJaJ@&a@ ^8Footnote ReferenceH*.)q. EV Page NumberBBB 7^ Body Texta$5OJ QJ aJ<@<  List Paragraph^DD Body Text Char5CJOJ QJ 66 V%P0 Header CharCJaJ>> ) listparagraph^PJ*/*`,Style1 FJOJ $5Default7$8$B*OJPJQJ^Jph<< qFootnote Text CharFVF E FollowedHyperlink >*B*phFPF "`W Body Text 2!5CJOJ QJ aJH!H !`WBody Text 2 Char5CJOJ QJ >>2> $j1BTitle#a$5CJOJ QJ aJ<A< #j1B Title Char5CJOJ QJ 6Q6 SM Footer CharCJaJPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]   uu  tMv'DwM!" %4&Z)+-/1 3=4R68:/?@\CEGIJMORT WWYZ[R]x^`[c\dfilnq6s1wfyz{w}wESWT|ORTUVWXYZ\]^_`abcdfghijklnopswx$ t"E2h88:<<=5AtAA BDBzBBBCRCCCCD@DqDDDEJQQR(RhRR W^ivlٗPQS[emqrtuvyz{|}~0 L &,'x'z'' (8???TqÓXXXXXXXXU\^coq ! X,R$Ld41c< A# AA@H T0(  T<(    c dA? "bridgesSIGPicture 2bridgesSIG"?B S  ?t@ _Hlk1724441211o50oT40o50o50o60oT6099PP]`<A[_jj=*urn:schemas-microsoft-com:office:smarttags PlaceType9*urn:schemas-microsoft-com:office:smarttagsState9*urn:schemas-microsoft-com:office:smarttagsplace>*urn:schemas-microsoft-com:office:smarttags PostalCode:*urn:schemas-microsoft-com:office:smarttagsStreet;*urn:schemas-microsoft-com:office:smarttagsaddress *!*-7"&(-.239:=AFIQ^ghkly|\cdh +25?LSVcltweo:FW\]a&y'z'!(E*P*U*_*|** ++<+G++++++++++,66666666 777 7+7/769@9N9X9Y9`9u9999999999 ::%:1:E:N:X:a:{:::::::::::;;%;2;=;S;[;j;u;;;;;;;;;;;;<<<&</<A<G<W<`<r<x<<<<<<<<<<<??@"@H@O@?AFABB!C(CGGGG HHIIIIIIIJJ JiJ}J~JJJJMM!N,NKNWNhNlNmNqN OOOOPPQQRRRRSSTTUU7V-y0_JMd4p+ 8y:Yo C (^~DV|^H 4Ir/OPT^N4>p>U s=cW`vloZlf*n]c~3^(uwj_vJ"%aZ_ kz(hl8 iqBr)q4_xq>NmG5tls"u ]uhezwt8Fy-TXzFnUi?{ @{`|\Rh@Ԝ^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.p^p`5OJQJo(@ ^@ `OJ QJ ^J o(o ^`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( P^P`OJQJo( ^ `OJ QJ ^J o(o ^`OJ QJ o(^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L. ^ `5.^`.L^`L.d^d`.4^4`.L^`L.^`.^`.t"L^t"`L.^`5. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.h^h`5.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L. ^ `5.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.^`5OJQJo( ^ `OJ QJ ^J o(o \ ^\ `OJ QJ o( ,^,`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( ^`OJQJo(l^l`OJ QJ ^J o(o <^<`OJ QJ o((^`(o(.^`o(.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.h^h`5.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L. p^p`OJQJo(@ ^@ `OJ QJ ^J o(o ^`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( P^P`OJQJo( ^ `OJ QJ ^J o(o ^`OJ QJ o(8^8`5o(.^`OJ QJ ^J o(o  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o(8^8`5o(.^`5o(.p^p`5o(. @ ^@ `OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o P^P`OJ QJ o(8^8`5.0^0`.L^`L5.^`.^`5.pL^p`L5.@ ^@ `.^`.L^`L.h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`5. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.h^h`5.8^8`.L^`L5. ^ `5. ^ `5.xL^x`L.H^H`.^`.L^`L.h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.h^h`)^`)8^8`)^`()^`()p^p`() ^ `.@ ^@ `. ^ `.^`5.p^p`.@ L^@ `L.^`.^`.L^`L.^`.P^P`. L^ `L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.8^8`5o(.^`5o(.  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( 8^8`OJQJo(^`OJ QJ ^J o(o  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o(h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`5o(.^`.L^`L.^`.p^p`5.@ L^@ `L.^`.^`.L^`L.8^8`5o(.|^|`.LL^L`L.^`.^`.L^`L. ^ `.\ ^\ `.,L^,`L.8^8`5o(.^`o(. ^ `o(.  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o(8^8`5o(.^`OJ QJ ^J o(o  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( ^ `5.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.^`5o(.L^L`.L^`L.^`.^`. L^ `L.\ ^\ `.,^,`.L^`L.p^p`.@ ^@ `.L^`L.^`.^`.L^`L.P^P`. ^ `.L^`L.h^h`5.8^8`5o(.L^`L5o(. ^ `5. ^ `5)xL^x`L.H^H`.^`.L^`L.8^8`5o(.^`OJ QJ ^J o(o  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o(p^p`5o(. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.^`. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.@ ^@ `)^`.L^`L.^`.^`.PL^P`L. ^ `.^`.!L^!`L.^`5o(.^`.L^`L.^`.p^p`)@ L^@ `L.^`.^`.L^`L.h^h`.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`5. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L.8^8`5o(.^`OJ QJ ^J o(o  ^ `OJ QJ o(  ^ `OJQJo(x^x`OJ QJ ^J o(o H^H`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o(^`.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.0|^H3^G5t(hl ,PE)s"u k\:PTF\d4-k 8q=cWloZB>-'y: iqxp,iXzj_ezw_xqXV)q C^~DJ"%a`|Zs0>p>U4Ii?{*n]hw/Ou @{8Fy00                           `        d(,        X        `                          xp       b                 -4        8)`-p       U (X f´6            P        X "f:H(@K`                                        (^B                                    ʓл                                  [   `    $L]        b|~        R        `        ,T                 XRXmB2r     Z        L                                           B        ܊                 d@S6=[$V$N$lJRAbK P'~ i *  >89I/ pwT Y,y\^lE )h C"!q+"; "Y?# QKo$$1%E0+(-t(v)*y+R=,k00j34!d4]5qA7f7 #:pU@s9AAKCdLD|DsE4Fv`$H=H:H/I>/ 9IqaKy1MFvN Qq3vR0SVVc\XUbX#X[(a\C^1_VaX\-d{lfztDhnzkrl'ljo)p KqVretztY?#K(u uMovH8xuK^zc{1}[l~o~@'yY+Ikyt>#( *7A YZ&ALgS=_k7@}T3= Nv*$XhzxB6<vT~ 9_xxN{ 5 > B k m @w jy : =\ .h u ~w y 0 L * J + O t v  2 3 C L YY b{ jFOhhqp i1no %$419 DlT[^ >MU[_UXR7^kM s"{#jp+K67Rc1> Yu-}9Ua3ry/Ao%>eyg0ppZyz{5PXq &Hn} J0J:R;{jRy k1L2%EDJD7/?[CWn]fUI.0_gz .P~~ \ z C !'!7!H"d"s}"q)#=#B#bK#g#$$-$ M$ i$y-K.r.//3/4/J/g/Xl0s0x11M 1,"1(171H1jS1B 2J24+292Z3 3w3N3i3o3E%4&4&0434<45$5,5A5B5Q5W5d5!6#676@6F6I69Q)9J9^9.m9zp97:F:[:y:z:;6; ;8;m;)y;N,<S-<7<M<Iz<$=QC=]=C>BD>P>se>f>Hg>v?N ??3?^?i?t?Bu?0{?@@@%O@z@o(AAA DADAYAk[A~A5 BBpBj1B{XBeBiB;BC C$C3CEC>LCjDD+D'hDevD? EAEFE-E#E$Ey.E3EYGEPEWQEnEzE'F+F/FOF|UFpFuFGGG HTHHD H'HsgHzH[IV"ITIaI JG'Jz,Jf/J/J3J=9J ^JfJjJKK5 KKKRKmKOL LZL%LELJLM4M!M/MAPMSMLGN]eNrNOMO5O":ONOnOzO PV%P+P,P1P5P:PnEPYP]P$QY$RLRQRS2SHS[T1T1Tf2TET=7UV6V$V2V6VEVEV;NVB_VjV yVxWWs1W(VWI\W(X X^%X<@XGXK Y YWYZ)1ZP8ZCZ[Z [[![I2[x5[=[B[U[qz[|[@\(\]] ]:];]O;]h=]?]AK]N]P]g]~]E ^5^@^ho^E_O__I`+N`Sa?ab=bfb#b%b1b=bmXc?dd2dX3dAdQ^dad4*e>eQeTeUe1 fEf&)f+fWfG{fg tgh hAhMhQhIThuh{hZ iix3i_BiBi vij6j<j+j9,j3j#MjQj8Sjkk[kJ.kIkllr l l)lg1lNl9\lkcl"ll mam m%m#'m1mjm?rmm nm+ntnoo/oW3o>cmopq >KKfqM~08;qDu / |ACXk}tRIl~00w;Ojy59L8,=K2 $1HUhU*y7 gm*3Vi> uE0Ij_boD}B#8<=^?7S[fDUVV|t}$)8NL%J_cpv><Smhk.CCN8RC|Vl =nJKxele03IJNg y[y%] 101NiI_y8 GIQ6Uq&r v 4=AUg !Q:tgk O;A.uQQna!1Hw22sJ-MaMSUGXARhVh']1CbGv|}M=JT |^D(sKlU.'57I 0FiKy'H:wO^ m *c+:>YW`?uyBJg BMQYf"%/;bvee?t D,07J c-'/CJLHgt  $(rs7P+<2O^ y)Zaxb$ G9.TI\bc-rU w%?LQdqgy"&,/VY ]j|W(.L|jx~7-QVo}Q6zpe2_}R 0[3hww0(86zCoB"Lv}2JZ}+[}Yk7p_p/@Taf(zUbdt >HMw V  !J*Y16f]dUvyQ9jAa 1<>~W,^ru (.V2[`,F0Y7I"MOqc^hkk{k[J^ii<I vd2f[k"layl{ x# PeuXz~BY ^%z+`44@\-qv!n',Pl}OD:!&0#9KZ#  (5+/A_o[48hnt.?E?SyX#k)9@a,q"Be!;lJK`*-6PXlw<_Qms,!x$Ma[AttZ ,?RKL'1lm\\=8N]W`q| !0+Y"Zi&$-F*N\.;`d<n[Vb@IXhw.`5>\f_caN4EhlNPdu8?DFPFZZhzo8:S-@q 0[CgL MB^bjV e/kBH"#BanbbQry7@De!*Vf.hq$!i%"PJGdFz?@iB9j (3`vzzH !d,5Jg[ATYyA k-.0 ?X.ZJbZkz&CT7e't|}E zKS|a 2vpvw 3^^#03j{&HKg1s ;'!F @dXY[\]^H@H`H@HdH@HhH@H0@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial;AGaramondEAGaramond BoldO.  k9Lucida Sans Unicode7.@Calibri5. .[`)Tahoma7Georgiaa LLBKHM+ArialTimes New RomanCNComic Sans MSK,Bookman Old Style?= *Cx Courier New;WingdingsA$BCambria Math"1hP)P)}K }K !x20d >qX  ?"%6 xx0                          ! " # $ % & ' ( ) * + , - . / Oh+'0 px    Normal.dotm1Microsoft Office Word@@犭@犭}՜.+,D՜.+, `hpx   K  TitleH 8@ _PID_HLINKSA0!http://www.medicaid.state.ar.us/?;Thttps://www.medicaid.state.ar.us/Download/provider/forms/pharm/HepCTreatmntForm.pdf?jhHhttps://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls?li Hhttps://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf?% Lhttps://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.pdf?1tLhttps://www.medicaid.state.ar.us/Download/provider/forms/pharm/Suboxone.doc?jhHhttps://www.medicaid.state.ar.us/Download/provider/pharm/ClaimEdits.xls?liHhttps://www.medicaid.state.ar.us/Download/provider/pharm/PACriteria.pdf?  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FT@Data #1Table# WordDocument}SummaryInformation(DocumentSummaryInformation8CompObjyMsoDataStoreTT  !"#$%&'()*+,-./012345678:;<>?@BCD  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. DocumentLibraryFormDocumentLibraryFormDocumentLibraryForm